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Abstract 
 
Human rhinoviruses (HRVs) are the most common causes for symptomatic 
respiratory infections, and have been linked to severe respiratory conditions in 
children, and in immunocompromised and elderly individuals. Currently there are 
no specific treatments or vaccination available for HRV infections and novel antiviral 
therapeutics are urgently required. Cathelicidins are a well-characterized family of 
Host Defence Peptides (HDP) with potent antibacterial, antiviral and 
immunomodulatory functions. This study investigates the antiviral activity of the 
human cathelicidin LL-37 against human rhinovirus together with the capacity of 
the peptide to modulate inflammation and host cell death in rhinovirus infection. 
We demonstrate that LL-37 has significant antiviral activity against HRV1B when the 
virus is exposed to peptide prior to cell infection, and when cells are infected prior 
to LL-37 treatment, indicating that LL-37 exerts its effects by directly targeting the 
virus and/or acting on host cells reducing their susceptibility to infection. 
Cathelicidin-mediated inflammatory pathway modulation was measured via 
quantification of IL-8, IL-6 and CCL5 gene expression and protein release. Our data 
indicates that LL-37 can significantly reduce pro-inflammatory gene expression and 
protein release induced by HRV1B infection in bronchial epithelial cells, when the 
peptide is exposed to HRV prior to infection. However, LL-37 was shown to increase 
HRV-induced inflammatory gene expression and protein release by bronchial 
epithelial cells, when cells were infected prior to LL-37 treatment. This data 
indicates that the cellular microenvironment and the context of cathelicidin 
exposure could determine the direction of cellular response to infection. We further 
demonstrate that LL-37 suppresses induction of apoptotic cell death in HRV-
infected cells, which may represent a novel immunomodulatory role for LL-37 in the 
context of this infection. Taken collectively, these data suggest that cathelicidins 
represent an exciting therapeutic avenue for rhinovirus infections, via targeting of 
virus particles and modulation of host cell responses to infection.  
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Chapter 1. Introduction 
 
1.1. Human Rhinovirus  
Human rhinoviruses (HRVs) were first identified in 1956 by Winston H. Price, and 
since then have been widely reported as the most common organism for causing 
cold-like illnesses in both adults and children. HRV infections occur worldwide 
throughout the year, but tend to peak in autumn and spring seasons (Arruda et al., 
1997; Monto, 2002). For a long period of time, HRVs were thought to cause 
relatively benign upper airway tract illnesses, however, evidence has emerged 
implicating HRV infections with lower respiratory tract illnesses such as 
exacerbations of chronic obstructive pulmonary disease and the development of 
asthma. Recent advances in molecular viral diagnostic techniques, such as PCR-
based assays, have permitted the detection of previously undetectable respiratory 
viruses, and have led to a more complete understanding of the diseases caused by 
HRV infections. Thus HRV have now been linked to severe bronchiolitis in infants 
and children (Papadopoulos et al., 2002; Pitrez et al., 2005), pneumonia (Juvén et 
al., 2000), croup (Rihkanen et al., 2008) and otitis media (Pitkäranta et al., 1998). 
1.1.1. Rhinovirus structure and replication cycle  
Rhinovirus is a non-enveloped, single-stranded, positive-sense RNA (ssRNA) virus of 
approximately 7200 bp from the genus Enterovirus of the family Picornaviridae. The 
genome of HRV comprises a single gene in which the translated protein is cleaved 
by virally encoded proteases to produce 11 proteins (Palmenberg et al., 2010). The 
5’ untranslated region (UTR) of the genome includes structural and sequence 
elements which are required for gene translation (Figure 1). The 5’UTR region is 
followed by an open reading frame (ORF) which codes for the capsid proteins, VP4, 
VP3, VP2 and VP1, and by seven non-structural proteins which are involved in the 
viral genome replication and assembly. The VP1, VP2 and VP3 proteins form the 
major part of the viral capsid and are accountable for virus antigenic diversity, 
whereas VP4 protein lies at the interface between the capsid and the RNA genome, 
anchoring the RNA core to the capsid. The virion presents an icosahedral structure 
formed by the capsid which is composed of 60 copies each of the four capsid 
proteins.  
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Figure 1. Genomic structure of Human rhinovirus.  
The HRV genome consists of a single ORF joined to 5’UTR and a viral priming protein (VPg) 
which is cleaved to form 11 proteins which either form the capsid (VP4-VP1) or are 
necessary for viral replication. RDRP, RNA-dependent RNA polymerase; IRES, internal 
ribosomal entry subunit. [Image adapted from Jacobs et al., (2013)] 
 
Initial research identified more than 100 different HRVs strains which were 
subsequently serotyped and divided into species HRV-A or HRV-B in accordance to 
their phylogeny (Conant and Hamparian, 1968). Currently, there are 77 known 
serotypes of HRV-A and 25 serotypes of HRV-B (Savolainen et al., 2002). With the 
improvement of sequencing technology, a new species has been identified termed 
HRV-C. Recent studies have shown that HRV-C is not a new virus, and that it has 
circulated in human populations for many years (Linder et al., 2013). The delay in 
identifying HRV-C species is attributed to the fact that they are difficult to grow in 
cell culture, and for this reason their discovery took longer than comparable 
pathogens. However, to date there are more than 60 known serotypes of HRV-C 
(Simmonds et al., 2010).  
Human rhinoviruses replicate in epithelial cells of the upper and lower airway tract 
(Arruda et al., 1995; Gern et al., 1997). HRV-B and HRV-A species access the cell 
either via the human intracellular adhesion molecule 1 (ICAM-1) [major group of 
viruses] or via the low-density lipoprotein receptor (LDLR) [minor group of viruses]. 
The human cadherin-related family member 3 (CDHR3), an asthma susceptibility 
gene enconding for a transmembrane protein with unknown biological function 
Non-structural proteins  
Protease  Protease  RDPR 
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(Bønnelykke et al., 2014), has recently been identified has the specific cellular 
receptor used by HRV-C to enter cells (Bochkov et al., 2015).  
Virus uptake is dependent on the receptor type and it may occur via clathrin-
dependent, or independent endocytosis or through micropinocytosis (Fuchs and 
Blaas, 2010). The virus particles undergo conformational change forming 
hydrophobic subviral particles, and this is initiated by ICAM-1 and/or the low pH 
environment in endosomes. The viral RNA is released through an opening formed in 
the viral capsid and crosses the endosome membrane via a pore formed by the viral 
proteins or alternatively through membrane rupture allowing the RNA to enter the 
cytosol. The positive-sense, single stranded RNA once in the cytosol is then 
replicated and translated into a polyprotein by the host cell ribosome (Fuchs and 
Blaas, 2010). The viral replication occurs entirely in the cytosol, where ssRNA forms 
a dsRNA intermediate, which is known as the main form of viral RNA genome inside 
the host cell. The resulting polyprotein (~250 kDA) is then cleaved by viral proteases 
2Apro and 3Cpro into the 11 protein variants (4 structural and 7 non-structural 
proteins) (Knott et al., 1989; Sommergruber et al., 1989). 
 
1.1.2. Transmission of rhinovirus  
The major route of dissemination of HRV includes: airborne transmission of 
aerosolised virus which can enter the body through the airway tract; transmission 
from person to person via direct contact; or fomite transmission (i.e. objects that 
may become contaminated and serve as vehicles in transmission). The most 
common is through the hand-nose-hand route which is followed by self-inoculation 
of intranasal/conjunctival mucosa (Jennings and Dick, 1987). Studies with natural 
rhinovirus infected-adults provided further evidence on the transmission of 
rhinovirus, demonstrating that infected subjects lead to the contamination of 
environmental surfaces with rhinovirus, such as light switches, telephone dials and 
handsets, transferring the virus to the fingers of non-infected individuals (Winther 
et al., 2007). 
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1.1.3. HRV Epidemiology 
In healthy individuals, rhinovirus infections are usually limited within the upper 
respiratory tract with little evidence of lower respiratory tract involvement 
(Message et al., 2008). Epidemiological studies reveal a higher incidence of HRV-
induced infections in children than adults and almost all children by the age of two 
have experienced at least one HRV infection (Blomqvist et al., 2002). HRV is 
responsible for more than 80% of the common colds, with peaks of infection 
between April and May and between September and November which are the high 
prevalence seasons, nonetheless HRV is present all-year round in the community 
and can affect people of all ages (Turner, 1997). The HRV- induced upper airway 
infections include the common cold, acute otitis media and rhinosinusitis. Acute 
otitis media has been linked to HRV infection and complicates one third of the cold-
like illnesses in young children (Winther et al., 2007).  
 
As well as the upper respiratory tract illnesses, human rhinoviruses have been 
associated with lower airway infections (Hayden, 2004). A prospective 4-year study, 
which included adults and children hospitalized with various acute respiratory 
infections, identified rhinovirus infection by virus isolation from nose and throat 
swabs. The frequent diagnoses in young children were bronchiolitis, pneumonia and 
asthma (El-Sahly et al., 2000). Bronchiolitis and pneumonia are the most frequent 
clinical manifestations of rhinovirus in children under five years old and bronchiolitis 
is the most common reason for hospitalization (Jartti and Gern, 2011). HRV-
associated bronchiolitis in infancy is a potential long-term risk factor for recurrent 
wheezing and asthma (Beigelman and Bacharier, 2013). A cohort study with very-
low birth weight infants revealed that the predominant pathogen during 
bronchiolitis episodes was HRV (Miller et al., 2012). Human rhinovirus has been 
established as a common pathogen in children hospitalized with community-
acquired pneumonia (CPA) with a rate of around 26%. Unfortunately, the clinical 
manifestations of CPA can be severe, particularly in children with underlying chronic 
diseases (García-García et al., 2012).  
 
Rhinovirus plays a major role in triggering exacerbations of asthma and chronic 
obstructive pulmonary disease (COPD). A cross-sectional study of children 
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hospitalized with asthma exacerbations revealed that HRV was detected in 85% of 
the cases and the major HRV genogroup associated with this was identified as HRV-
C (Mak et al., 2011). The key mechanisms in the pathogenesis of asthma and 
chronic obstructive pulmonary disease are associated with abnormal repair 
processes of the respiratory epithelium which lead to an anomalous organization 
and integrity of the epithelium followed by perturbations of innate immune 
functions (Folli et al., 2008). A study by Bossios et al. (2005) provided evidence that 
rhinovirus is able to delay wound healing in bronchial epithelial cells contributing to 
asthma exacerbations. Furthermore, children who experience wheezing as a result 
of rhinovirus infection are more prone of subsequently developing asthma (Gavala 
et al., 2011). 
 
Rhinovirus infections represent a serious risk for elderly people, where major 
rhinovirus outbreaks in healthcare facilities have resulted in severe infections, as 
well as deaths, have been reported (Hicks et al., 2006; Louie et al., 2005). Rhinovirus 
infections in hospitalized elderly patients are also associated with a significantly 
higher mortality and longer hospitalization periods when compared to influenza 
virus infection (Hung et al., 2017). A study by Nicholson et al. (1996) revealed that 
HRV infections are the main cause of debility and lower airway infections among 
community-dwelling elderly. 
 
1.1.4. Pathogenesis and host immune responses 
1.1.4.1. Infection of the upper respiratory tract  
HRV is responsible for most of the upper airway tract infections experienced by 
humans (van Kempen et al., 1999). The most common symptoms are nasal 
obstruction and rhinorrhea (aka “runny nose”). These symptoms are related with a 
neutrophilic inflammatory response which stimulates mucus hypersecretion and 
increases vascular permeability. Viral infections of the upper respiratory tract are 
frequently followed by secondary bacterial infections in the form of acute 
rhinosinusitis and studies have demonstrated that rhinovirus increases the 
expression of host cell adhesion molecules, such as, fibronectin, platelet-activating 
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factor receptor, in nasal epithelial cells as a possible mechanism responsible for the 
increase in susceptibility to bacterial infections (Wang et al., 2009).  
 
Other respiratory viruses, such as IAV and RSV, have been shown to cause damage 
of airway epithelial cells (Troy and Bosco, 2016), however rhinovirus is rarely 
associated with cytopathic effects of the upper airway tract. Nasal biopsies from 
patients with natural colds showed that the epithelial cell lining and borders 
remained structurally intact (B. Winther et al., 1984). Nevertheless, rhinovirus was 
shown to disrupt the airway epithelial barrier function by dissociating the zona 
occludens-1, also known as tight junction protein-1, from the tight junction 
complex, thus enabling HRV binding, translocation, as well as facilitating secondary 
bacterial infection (Sajjan et al., 2008). 
 
1.1.4.2. Infection of the lower respiratory tract 
In recent years, there has been increasing evidence that supports the role of HRV as 
a lower airway pathogen(Gern et al., 1997). The symptoms associated with HRV-
driven lower respiratory tract infections are more pronounced in patients who have 
underlying asthma or other chronic lung diseases and include chest tightness, 
wheezing, cough and shortness of breath (Folkerts et al., 1998; Las Heras and 
Swanson, 1983; Papadopoulos et al., 2000). There have been a number of 
controversies regarding the pathogenesis of HRV-induced lower respiratory tract 
infections which centers on the extent to which HRV can directly infect cells of the 
lower respiratory tract as opposed to an indirect influence related to the immune 
response of the upper airway infection. There are, however, various obstacles to 
lung infection by HRV and the temperature sensitivity of viral replication is one of 
them (Killington et al., 1977). Initial experiments implied that viral replication was 
optimal at 33°C and was significantly reduced at 37°C and 39 °C, although a study by 
Papadopoulos et al. (1999) demonstrated that there were minimal differences in 
viral replication capacities between 33°C and 37°C. In a follow-up study, 
Papadopoulos et al. (2000) demonstrated the potential for HRV to infect cells of the 
lower respiratory tract by performing in vitro and in vivo experiments. In the in vitro 
experiment, results showed that rhinovirus infection of primary human bronchial 
epithelial cells (HBECs) resulted in an increased production of IL-6, -8 and -16, and 
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RANTES as well as associated cytotoxicity. In the in vivo experiment, healthy 
volunteers were inoculated with HRV16 and bronchial biopsy samples were 
analysed using in situ hybridization method to localise rhinovirus infection which 
confirmed the presence of rhinovirus in the lower respiratory epithelium. Other 
studies have also demonstrated the presence of HRV in the lower airway tract (Gern 
et al., 1997; Malcolm et al., 2001). The current literature therefore supports the 
concept that HRV can infect cells of the lower respiratory tract and induce a pro-
inflammatory response. 
 
1.1.4.3. Innate immune responses to rhinovirus infection  
In addition to the direct effects on the airway epithelial cells, the host immune 
responses are also implicated in the pathogenesis of HRV infections. Infection of the 
respiratory epithelium by rhinovirus will initially induce an innate immune response. 
Early innate detection of rhinovirus can depend on the ability of the host to identify 
and sense rhinovirus- associated molecular patterns by pathogen sensors, known as 
pattern recognition receptors (PRRs). These pathogen sensors recognise specific 
molecular patterns on the virus and elicit an inflammatory and antiviral response in 
order to clear the viral infection. In the initial stages of viral infection, the viral 
capsid is recognised by TLR2 located on the cell surface, and upon internalisation 
the ssRNA is recognised by TLR7 and 8 located in the endosomes (Triantafilou et al., 
2011). The viral dsRNA produced during viral replication, represents an important 
stimulus of the host innate immune response and is recognised by four pattern 
recognition receptors, known as Toll-like receptor 3 (TLR3), Melanoma 
differentiation-associated gene 5 (MDA-5), Retinoic acid inducible gene I (RIG-I) and 
the cytosolic RNA-binding protein kinase R (PKR). All these receptors have been 
shown to be expressed in airway epithelial cells (Guillot et al., 2005; Liu et al., 2007; 
Sirén et al., 2006).  
 
TLR3 is localised in the endosomal and plasma membranes. It senses dsRNA and 
signals through the adaptor protein toll/interleukin-1 receptor (TIR) domain-
containing adaptor inducing IFN-β (TRIF) (Yamamoto et al., 2003). Poly I:C (synthetic 
dsRNA) upon ligation to TLR3 was shown to induce the activation of NF-kB and the 
production of type I interferon (Alexopoulou et al., 2001). RIG-I and MDA-5 are 
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homologous cytoplasmic helicases containing two N-terminal caspase activation 
and recruitment domains and a C-terminal DExD/H-Box RNA helicase domain (Gee 
et al., 2008; Kang et al., 2004) and both have been identified as intracellular 
receptors for dsRNA in the cytosol. RIG-I was shown to bind to dsRNA and induce 
antiviral responses in the host cells (Liu et al., 2007). The caspase recruitment 
domain found in RIG-I functions to transmit downstream signals which results in the 
activation of the transcription factors NF-B and IRF3 and subsequent induction of 
type I interferon production (Yoneyama et al., 2004). The MDA-5 sensor is thought 
to function to promote IFNβ induced apoptosis and inhibit cell growth (Barral et al., 
2007; Kuo et al., 2013). Both MDA-5 and RIG-I are induced by IFNβ (Kang et al., 
2004). PKR is a serine/threonine kinase member of the alpha subunit of eukaryotic 
initiation factor 2 (eIF-2α)-specific kinase subfamily (de Haro et al., 1996). PKR is 
characterised by two distinct kinase activities: (1) auto-phosphorylation resulting in 
the activation of eIF-2α and (2) phosphorylation of eIF-2α which results in the 
inhibition of host cell protein synthesis (García et al., 2006). In a non-stressed 
environment, PKR is in a monomeric latent state, and can be activated in response 
to dsRNA of cellular, viral or synthetic origin. Binding of two molecules of dsRNA 
results in PKR dimerization into an active state (García et al., 2006), and PKR is also 
able to phosphorylate IBα leading to the activation of NF-kB transcription factor 
(Kumar et al., 1994).  
 
Studies have demonstrated that dsRNA upregulates the expression levels of pro-
inflammatory cytokines and chemokines in BEAS2B cells and primary bronchial 
epithelial cells including RANTES, CXCL-10 and IL-8, through TLR3 signalling 
(Matsukura et al., 2006). Using short interfering RNA (siRNAs) knockdown for TLR3 
in BEAS-2B cells has revealed a significant decrease in the mRNA levels of these pro-
inflammatory mediators, whereas knockdown of PKR, MDA-5 and RIG-I did not 
significantly inhibit the poly I:C–induced cytokine and chemokine response 
(Matsukura et al., 2007). This indicates that TLR3 has an important role in 
promoting a pro-inflammatory response whereas RIG-I, PKR and MDA-5 may 
function, in part, by delivering an antiviral response in infected host cells. In 
16HBE14o- cells, TLR3 was shown to be partially required for HRV39-induced IL-8 
expression (Sajjan, 2006). Nonetheless, in rhinovirus infection of human bronchial 
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epithelial cells, the coordination between TLR3, RIG-I and MDA-5 was essential for 
maximal antiviral and pro-inflammatory cytokine responses. Notably, the HRV-
induced RIG-I and MDA-5 expression was shown to involve TLR3/TRIF signalling 
(Slater et al., 2010). 
 
Rhinovirus infection of airway epithelial cells has been shown to induce a rapid 
production of several pro-inflammatory cytokines, including IL-8, IL-6, GM-CSF and 
CCL5 (Kim et al., 2000; Papadopoulos et al., 2001; Subauste et al., 1995). Increased 
levels of IL-6 (Zhu et al., 1996), IL-8 (Zhu et al., 1997) and IL-1β (Proud et al., 1994) 
were also detected in nasal washings taken from rhinovirus experimentally infected 
subjects. The levels of IL-6 and IL-8 produced during rhinovirus infection were 
shown to be directly linked to the severity of symptoms scores (R. B. Turner et al., 
1998).  
 
In addition to the production of pro-inflammatory chemokines and cytokines in 
response to rhinovirus infection, airway epithelial cells can also respond by 
secreting cationic host defence peptides (Hiemstra et al., 2016; Proud et al., 2004). 
HRV16 infection of primary bronchial epithelial cells was found to increase the 
expression levels of human β defensins-2 and -3 (Duits et al., 2003). Defensins are 
cationic host defence peptides characterised by three intramolecular disulphide 
bonds that determine their sub-classification into α-, or β-defensins. In addition to 
their broad antimicrobial activity, β-defensins have also shown potent antiviral 
activity against both enveloped and non-enveloped viruses (Wilson et al., 2013), 
and immunomodulatory properties, such as mast cell degranulation (Niyonsaba et 
al., 2001), and chemotactic activity for monocytes, DCs and T cells (Yang et al., 
1999).  
 
Airway epithelial cells can also respond to rhinovirus infection by invoking an 
antiviral response. Interferons are cytokines secreted by host cells in response to 
viral infection that function to limit the spread of virus by inducing the expression of 
many IFN-stimulated genes (ISGs) (Katze et al., 2002). The first antiviral agents to be 
characterised and are still regarded as essential to the early antiviral response are 
type I interferons (IFN-α/β). Type I IFNs are expressed by many epithelial cell types. 
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They bind to the type I IFN receptor complex (IFNAR1 and -2) which in turn triggers 
the intracellular IFN signalling pathways, mainly the JAK-STAT pathway, which 
eventually induce the expression hundreds of IFN-stimulated genes (Basler and 
García-Sastre, 2002). The most studied type I IFN-induced gene is PKR. As noted 
above, dsRNA can activate PKR, which can in turn, inhibit virus replication and 
spread. Furthermore, practically all viruses have developed strategies to block the 
function of PKR so that the virus replication is not compromised (Gale and Katze, 
1998). A novel class of antiviral cytokines has been discovered and has been 
classified as type III IFNs: IFN-λ1/IL-29, IFN-λ2/IL-28A and IFN-λ3/IL-28B. Type III 
IFNs have similar biological activities to type I IFNs; however type III IFNs appear to 
be expressed specially by epithelial cells exerting host-protection primarily at 
epithelial surfaces (Ank and Paludan, 2009).  
 
Rhinovirus infection of bronchial epithelial cells has been shown to strongly induce 
IFNβ and IFNλ (Khaitov et al., 2009). However, bronchial epithelial cells obtained 
from asthmatic patients have shown impaired production of IFNβ in response to 
HRV infection (Wark et al., 2005). Later studies subsequently revealed that 
rhinovirus-induced IFNβ and -λ production was not deficient in well-controlled 
asthma (Sykes et al., 2014). A study by Slater et al. (2010) showed that TLR3, RIG-I 
and MDA-5-mediated signalling was required for maximal IFN-β, -λ and pro-
inflammatory cytokine gene expression by bronchial epithelial cells in response to 
rhinovirus infection. 
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Figure 2. Signal transduction pathways activated by rhinovirus infection of airway 
epithelial cells. 
In the endosome ssRNA and dsRNA are recognised by TLR7/8 and TLR3, respectively. 
Binding of dsRNA to TLR3 upregulates the expression of MDA-5 and RIG-I. In addition MDA5 
and RIG-I sense newly synthesised dsRNA in the cytosol. Interaction with TLR3, RIG-I and 
MDA-5 leads to the upregulation of IFN gene expression as well as pro-inflammatory 
cytokines and chemokines, via NF-kB and IRF3 signalling. TLR7/8 and TLR2 signal through a 
MyD88-dependent pathway, leading to the activation of NF-κB and IRF-7. 
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1.1.4.4. Adaptive immune responses to rhinovirus infection  
The mean incubation time after infection by rhinovirus is 2 days and the typical 
symptoms (common cold symptoms: rhinorrhea and nasal congestion) last on 
average 3 days. Viral shedding in nasal secretions can be detected already at 8-10h 
after exposure and reaches maximum levels between 2-7 days and in some cases 
will continue up to 14 days after infection (Butler et al., 1970; Couch et al., 1966). 
The anti-HRV secretory IgA in nasal secretions occur approximately 7 days after 
infection and serum IgA has shown not to increase before 6 weeks after infection. 
This is also the case for anti-HRV IgG response (Butler et al., 1970). The antibody 
response to rhinovirus does not seem to play a role in viral clearance as it appears 
only after the end of the illness. Nevertheless, a study by Alper et al. (1998) 
determined the influence of serotype-specific neutralizing serum antibodies (IgG) 
titers on the rate of infection after exposure of adult volunteers to HRV. Results 
showed that neutralizing antibodies are associated with protection against the 
infection as well as reduced signs and symptoms following experimental HRV 
exposure.  
 
T cells, through the recognition of viral antigens, can contribute to antiviral 
immunity; however, the T-cell response to rhinovirus infection is not well 
understood. CD4+ T-cells, which secrete IFNγ, have been isolated from PBMCs from 
subjects with previous disease (Wimalasundera et al., 1997). Furthermore, Gern et 
al. (1997) demonstrated that HRV-specific T cells, specifically HRV-CD4 T cells, can 
be activated by either serotype specific, or by shared viral epitopes. This increases 
the possibility of a potent T cell response due to the repeated activation of T cells by 
shared viral epitopes in vivo. 
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Figure 3. Antibody response to rhinovirus infection 
Graph representing the relative intensities and time-course of the viral spread and antibody 
response against human rhinovirus. [Figure from Dotzauer and Kraemer (2012)] 
 
 
1.1.5. Treatment options 
There are no current specific effective treatments for HRV infections. Prevention, 
using vaccination, has been shown to be extremely challenging due to the fact that 
there are more than 150 serotypes of HRVs. The therapeutic options available are 
predominantly supportive measures, and include conventional symptomatic 
treatments (e.g. antihistamines) and dietary supplements (e.g. Echinacea, Zinc). 
These supportive measures are only applicable for mild upper respiratory infections 
(i.e. common cold); for serious respiratory infections, there are no efficient 
treatments available.  
 
There has been a significant effort to develop anti-HRV agents to tackle different 
viral aspects, such as capsid binding agents, viral attachment inhibitors, or 
proteolytic enzyme inhibitors. None of these anti-HRV agents has yet been 
approved by the FDA or EMA. The capsid-binding agents bind to the hydrophobic 
pocket of the viral capsid, causing a conformational change which interferes with 
the virus capacity to interact with the host cellular receptors (Thibaut et al., 2012). 
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Examples of capsid-binding agents include: pleconaril which was the first compound 
to be submitted to FDA for regulatory approval, although its license was declined 
due to concerns about safety and resistance (Hayden et al., 2003a, 2002); pirodavir, 
an intranasal agent which demonstrated efficacy in preventing experimental colds 
(Andries et al., 1992); vapendavir, an orally administered drug that binds to the HRV 
VP1 capsid protein and prevents the release of ssRNA into the target cell (Matz, 
2013). Proteolytic enzyme inhibitors are another chemotherapeutic approach. 
Rupintrivir is an intranasal irreversible inhibitor which has shown potent activity 
against all HRV serotypes and is one of the most effective to inhibit 3C protease in 
vitro (Hayden et al., 2003b). 
 
Another approach to tackle HRV infection is to prevent viral attachment by blocking 
the receptors using soluble forms of ICAM-1 (Abraham and Colonno, 1984). The 
HRV major group use ICAM-1 receptor for attachment to host cells. Tremacamra is 
an example of this type of drugs and shows potential in terms of reducing the 
severity of the experimentally-induced infections; although currently no recent 
development has been reported for these agents (Turner et al., 1999). In addition, 
an anti-human ICAM-1 antibody has been developed, using transgenic mice over-
expressing extracellular domain 1 and 2 of human ICAM-1. In vivo topical or 
systemic administration of anti-ICAM-1 prevented the entry of HRV16 and HRV14, 
as well as, a reduction of cellular inflammation, pro-inflammatory cytokine 
production and viral load (Traub et al., 2013). HRV-neutralizing antibodies have also 
been developed against specific epitopes found on VP proteins of the viral capsid. 
These anti-VP antibodies were shown to block the virus-receptor interaction, 
prevent virus uncoating and promote significant conformational changes on the 
capsid triggering the genome release (Che et al., 1998; Dong et al., 2017; Smith et 
al., 1996).  
Due to the fact that currently there is no effective specific treatments or vaccination 
available for rhinovirus infections, there is a pressing need to develop novel 
alternative antiviral therapies.   
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1.2. Cationic Host Defence Peptides  
Cationic host defence peptides (CHDPs; also termed antimicrobial peptides) are key 
components of the innate immune system, with potent microbicidal, antiviral and 
inflammation and immunity modulatory functions (Barlow et al., 2014; Mookherjee 
and Hancock, 2007; Nijnik and Hancock, 2009). CHDPs can be found in a variety of 
life-forms, and some of the first indications of the presence of CHDPs were in fungi 
and bacteria, where they were viewed as unique defence peptides in unicellular 
organisms (Perlman and Bodanszky, 1971). The first isolated and characterized 
cationic antimicrobial peptides were the cecropins from the moth Hyalaphora 
cecropia (Hultmark et al., 1980). The magainins in the skin of Xenopus laevis 
(Zasloff, 1987) were discovered later, followed by the isolation of α-defensins from 
mammalian neutrophils (Rice et al., 1987). To date, more than 1700 CHDPs have 
been described and although there is great sequence diversity, there are structural 
elements that are shared by the majority of CHDPs. They are typically 12-50 amino 
acids in length, cationic in nature (+2 to +9) and amphipathic with 40-50% 
hydrophobic residues. CHDPs present different secondary structures although two 
forms are predominant: β-sheet structures with disulphide bonds (e.g. porcine 
cathelicidin protegrin) and α-helical structures which are adopted by linear peptides 
(e.g. human cathelicidin LL-37). In mammals the two best characterized CHDP are 
defensins and cathelicidins and specifically in humans, the relevant and best 
described CHDPs include cathelicidins, defensins and histatins (De Smet and 
Contreras, 2005). 
 
Relevant properties for the microbicidal activity of CHDPs include the cationic 
charge, which allows for the interaction of these peptides with the negatively 
charged microbial membranes through electrostatic forces which lead to the 
formation of pores and their hydrophobicity which helps the integration into the 
microbial cell membrane (Steinstraesser et al., 2011). It has been demonstrated 
that CHDPs have antimicrobial activity across a spectrum of infections, including 
bacterial, parasitic, and viral organisms (Bowdish et al., 2005b; Haines et al., 2003). 
It is believed that this is mainly through disruption of cell membranes, and that 
CHDP effects differ between microbe and host cell. The mechanism of action of 
CHDPs is best understood for bacterial targets. Bacterial cytoplasmic membranes 
37 
 
have high number of lipids with negatively charged phospholipids located in the 
outer layer of the phospholipid bilayer, whereas eukaryotic cell membranes are 
formed mainly by lipids with no net charge, and most of the lipids with negatively 
charged phospholipids are located in the inner layer which faces the cytoplasm 
(Matsuzaki, 1999). CHDPs preferentially bind to bacterial membranes with 
abundant acidic phospholipids through electrostatic interactions. Mammalian cell 
membranes can have a high abundance of cholesterol which makes them resistant 
to the activity of CHDP; this resistance may be due to interaction between the 
peptides and cholesterol or due to the stabilization of the lipid bilayer due to the 
high content of sterols (Matsuzaki, 1999).  
The Shai-Matsuzaki-Huang (SMH) model attempts to explain the antimicrobial 
activity of most CHDP (Matsuzaki, 1999; Shai, 1999; Yang et al., 2000). The model 
proposes an initial interaction of the peptide with the bacteria membrane, which is 
followed by the shift of lipids and alteration of the membrane structure and in some 
cases the entry of the peptide into the target cell. In addition to this model, several 
other mechanisms of action have been proposed to explain how CHDP can kill 
microbes, and some of these include: (1) permeabilisation of cell membranes 
(Matsuzaki, 1999); (2) Formation of membrane pores (Yang et al., 2000); (3) 
Disruption of free-energy metabolism of bacteria and dissipation of the electric 
potential of their mitochondrial membrane (Westerhoff et al., 1989); (4) Induction 
of hydrolases which degrade cell walls (Bierbaum and Sahl, 1985). 
 
1.2.1. Defensins 
Defensins are small, cysteine–rich, cationic peptides with a β-sheet structure. 
Defensins have a broad antimicrobial activity, including antiviral properties and the 
capacity to modulate the host immune response. Three different subfamilies of 
defensins are known, and include α-, β- and ϴ-defensins. The α- and β- defensins 
consist of a triple-stranded β-sheet with a distinctive fold, and ϴ-defensins possess 
a cyclic structure.  
The α-defensins are also known as human neutrophil peptides (HNP1, HNP2, HNP3, 
and HNP4) as they are primarily expressed by neutrophils (Ganz et al., 1985). These 
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are also found in much lower concentrations in Natural Killer cells, immature 
dendritic cells, monocytes, macrophages and B and γδ T-cells (Rehaume and 
Hancock, 2008). In contrast, human α-defensins 5 and 6 (HD5 and HD6) are 
constitutively expressed in Paneth cells, salivary glands and genital mucosa (Ganz et 
al., 1985). β-defensins are mainly expressed by epithelial cells (HBD1, -2, -3, -4, -5 
and -6) (Yang et al., 2004), where HBD1 is constitutively expressed by epithelial 
cells, whereas HBD2 and HBD3 can be induced by pathogens, and pro-inflammatory 
cytokines (Duits et al., 2003; Proud et al., 2004; Sørensen et al., 2005). The ϴ-
defensins have been identified in leukocytes from rhesus macaques; rhesus ϴ-
defensins 1 (RTD1), RTD2 and RTD3 (Leonova et al., 2001). In humans, an 
homologous gene to rhesus ϴ-defensin has been found in human bone marrow, 
however these transcripts contain a stop codon upstream of the signal sequence 
that completely prevents their translation (Nguyen et al., 2003).  
Defensins provide an important link between innate and adaptive immune 
response, acting as both anti-and pro- inflammatory mediators. For example, 
HNP1-3 released by neutrophils, have been shown to induce the production of 
TNF-α and IFN-γ from macrophages, which in turn stimulates their phagocytotic 
activity enhancing the clearance of opsonised bacteria (Soehnlein et al., 2008). 
hBD3 was shown to activate antigen presenting cells (monocytes, dendritic cells) 
via TLR 1 and 2 stimulating an adaptive immune response (Funderburg et al., 
2007). In addition, defensins have been shown to dampen LPS-induced pro-
inflammatory cytokine response by neutralization of extracellular LPS as well as 
modulation of intracellular signalling pathways (Mookherjee et al., 2006; Scott et 
al., 2002).  
In regards to their direct antiviral activity, defensins have a dual role in antiviral 
host defence. They are able to directly interact with the viral envelopes, possibly 
in a similar way they target bacterial membranes, and in addition they are able to 
interact with the host cell modulating the immune response to infection. The 
defensin-cell interactions are complex and may be mediated by interacting with 
cell-surface glycoproteins and/ or interacting with cell signalling pathways. 
Defensins have shown potent direct antiviral activity against several different 
viruses, including HIV, IAV, HSV, RSV and adenovirus (reviewed in Klotman and 
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Chang, 2006). In addition, and as mentioned previously, viral infections can 
induce the expression of defensins. In normal oral epithelial cells, HIV-1 was 
shown to induce the mRNA expression of HBD2 and HBD3, but not HBD1, and this 
was observed even in the absence of HIV-1 replication (Quiñones-Mateu et al., 
2003). Similarly, rhinovirus infection of bronchial epithelial cells induced HBD2 
and HBD3, but not HBD1 mRNA expression (Duits et al., 2003; Proud et al., 2004). 
In contrast to HIV-induced HBD expression, active replication of rhinovirus was 
required for the induction of HBD expression. Interestingly, an artificial circular 
peptide based on the sequence of θ-defensins has been created, known as 
retrocyclin, and this peptide has shown to have potent antiviral activity in vitro 
(Cole et al., 2002). 
Due to the fact that defensins have shown potent antimicrobial and antiviral 
activity, as well as the ability to modulate the host immune responses to 
infection, this makes these peptides ideal targets for the development of 
potential therapeutics for a range of diseases. In fact, a number of synthetic host 
defence peptides (HDPs) based on defensin structure are currently in clinical 
trials, which not only aim to exploit the direct antimicrobial properties of these 
peptides, but also their ability to modulate the human immune response (Yeung 
et al., 2011).  
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1.2.2. Cathelicidins 
Cathelicidins range in size from 12 to 88 amino acids and are characterized by the 
presence of an N-terminal signal sequence which directs the newly synthesised 
protein towards the secretory pathway, a conserved cathelin-like domain and 
variable C-terminal antimicrobial domain. The cathelin-like domain is highly 
conserved and shares sequence homology with the porcine cysteine protease 
inhibitor – cathelin. The C-terminal domain, which is highly divergent, becomes the 
mature functional peptide upon proteolytic cleavage. Cathelicidins have been 
discovered in lizards, birds, fish as well as a number of mammals and show great 
diversity across species (Kościuczuk et al., 2012).  
 
In humans, only one cathelicidin has been described, which is known as Human 
Cationic Antimicrobial Peptide of 18kDa, or hCAP18. The cathelicidin hCAP18 is 
encoded by the CAMP gene on the chromosome 3p21.3. This CHDP is stored in the 
peroxidase-negative, or specific granules of neutrophils and is produced and 
secreted by macrophages, eosinophils, lymphocytes, mast cells and NK, T and B 
cells, as well as, expressed by epithelial cells of skin and mucosa of the respiratory, 
urogenital and gastrointestinal tracts (Agerberth et al., 2000; De Yang et al., 2000). 
hCAP18 is cleaved extracellularly by proteinase-3, a serine protease from the 
azurophilic granules of neutrophils, to generate LL-37 which is the dominant 
cleavage product (Sørensen et al., 2001). In the skin, hCAP-18 was shown to be 
processed into its active form LL-37 by serine proteases kallikrein 5 and -7 
(Yamasaki et al., 2006).  
 
LL-37 is a linear, 37 amino acids length peptide with two leucine residues at the N-
terminal which adopts an amphipathic α-helical structure. hCAP18/LL-37 can be 
detected in a variety of body fluids, such as saliva, sweat, semen, milk and airway 
surface fluids (Bowdish et al., 2005a). In addition, three other forms of human 
cathelicidin, other than LL-37, have been found in sweat: KR-20, 20-aa derivative, 
RK-31, a 31aa-derivative; and KS-30, a 30 aa derivative. All three processed peptides 
show more potent antimicrobial activity compared to LL-37(Murakami et al., 2004).  
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The expression of LL-37 can be constitutive or inducible in response to infection, 
inflammatory signals, and wounding (Erdag and Morgan, 2002; Frohm et al., 1997; 
Nell et al., 2004; Zanetti, 2005). In addition, recent studies have demonstrated that 
1,25- dihydroxyvitamin D3 induces hCAP18/LL-37 expression through a specific DNA 
binding vitamin D response element (VDRE) consensus located in the CAMP gene 
promoter region (T.-T.Wang et al., 2004). Further data has revealed that 
1,25(OH)2D3 can induce the expression of LL-37 in several cell lines, as well as in 
primary bronchial epithelial cells (Yim et al., 2007), keratinocytes (Weber et al., 
2005), and myeloid cells (Gombart et al., 2005). A study by Hansdottir et al. (2008) 
provided evidence that airway epithelial cells constitutively activate vitamin D due 
to their high baseline levels of activating 1α-hydroxylase and low levels of 
inactivating 24-hydroxylase, and that viral infections lead to an increased activation 
of vitamin D leading to subsequent increases in the expression of cathelicidin 
mRNA. The capacity of 1, 25-dihydroxyvitamin D3 to increase expression of human 
cathelicidins in vivo has yet to be demonstrated. In addition to vitamin D, another 
exogenous approach which can regulate cathelicidin expression is through the use 
of butyrate and its analogues. Butyrate is a short-chain fatty acid produced in the 
colon by bacterial fermentation of diet fibre. A butyrate analogue, 4-phenylbutyrate 
(PBA), which has already been approved as a drug for use in humans, induces 
cathelicidin LL-37 expression in numerous epithelial cells lines, including airway 
epithelial cells (Steinmann et al., 2009). In vivo experiments also revealed the 
potential of PBA to induce hCAP-18 expression in the mucosal epithelial of the 
airway tract of a rabbit model of shigellosis (Sarker et al., 2011). It has also been 
shown that PBA can induce cathelicidin LL-37 expression synergistically with 1, 25-
dihydroxyvitamin D3 in lung epithelial cells (Steinmann et al., 2009). 
 
Mice express the cathelicidin mCRAMP (murine cathelin-related antimicrobial 
peptide) which is encoded by the Camp gene on chromosome 9. mCRAMP 
maintains high sequence identity with hCAP18 and the porcine cathelicidin PR-39 
(Gallo et al., 1997). mCRAMP is proteolytically cleaved generating a 34 amino acid 
length active peptide with a tertiary structure formed by two amphipathic α-helices 
linked by a flexible region (Yu et al., 2002). In similarity with LL-37, the murine 
cathelicidin is stored in the granules of neutrophils and can be expressed by 
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epithelial cells and leukocytes (Chromek et al., 2006; Iimura et al., 2005; Nizet et al., 
2001). It has shown that CRAMP-deficient mice were more susceptible to bacterial 
infections of the airway tract, skin, urinary tract, and gut (Chromek et al., 2006; 
Iimura et al., 2005; Kovach et al., 2012) than healthy mice. 
 
Pigs express a variety of cathelicidins which differ in activity and structural motifs. 
The porcine cathelicidins include five different protegrins (PGs), three α-helical 
peptides (PMAP-23, -36,-37), two prophenins (PF-1,-2) and the PR-39 peptide. 
Protegrins are between 16-18 amino acids in length and are produced and stored by 
porcine neutrophils as inactive propeptides, but can be proteolytically cleaved into 
their active forms by neutrophil elastase in the extracellular environment 
(Panyutich et al., 1997). PGs present a two-stranded β-sheet structure in solution 
which is linked by a β-hairpin loop and, contain two intramolecular disulphide 
bonds which are required for their maximum bioactivity. A study by Wu et al. (2000) 
demonstrated that the expression of protegrins and PR-39 was enhanced by 
bacterial LPS, IL6, retinoic acid and Salmonella infections. It has been reported that 
PG-1 has the broadest spectrum of antimicrobial activity (Yasin et al., 1996) and 
therefore has excellent potential for the development of synthetic antimicrobial 
compounds.  
 
Cathelicidins have been characterized in many other species Figure 4, such as 
sheep, monkeys, rabbits, horses and cows. In sheep, eight cathelin-associated 
peptides have been identified. The cathelicidin SMAP29 (sheep myeloid 
antimicrobial peptide 29) with a α-helical structure, is one of the most potent CHDP 
in the context of direct antimicrobial activity. The in vitro antimicrobial activity of 
SMAP-29 has been tested against a number of gram-positive and gram-negative 
bacteria and fungi. All bacteria strains tested were highly susceptible to SMA-29 
with minimum inhibitory concentrations (MIC) in the 0.12-2 µM range of 
concentration, which suggest that SMAP-29 is a potent peptide with a wide 
spectrum of activity (Skerlavaj Barbara et al., 1999; Tomasinsig and Zanetti, 2005). 
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Figure 4. Phylogenetic relationships of vertebrate animal groups in which 
cathelicidins have been identified. 
Cladogram showing the phylogenetic relationships in a reverse order from homo. The 
cathelicidin sequences have been identified for 133 species of vertebrates, 85 of which are 
mammalian species. ● Symbol indicates that cathelicidins have been identified and, next to 
it in what number of species within that group. ○ Symbol indicates the presence of a 
cathelicidin, that based on the c-terminal of CHDP domain, is a likely orthologue of LL-37. 
[image taken from Xhindoli et al.(2016)]. 
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1.2.2.1. Antibacterial activity of cathelicidins  
Cathelicidins have been shown to have antimicrobial activity against multiple gram-
positive and gram-negative human pathogens. The physiological significance of the 
human cathelicidin LL-37 has been demonstrated in patients suffering from the rare 
condition known as morbus Kostmann disease, where neutrophils lack specific 
granules and are therefore cathelicidin deficient. While these patients also lack 
other granule contents, they display an increased susceptibility to infection, and 
frequently develop chronic periodontal disease (Putsep et al., 2002). Further 
evidence that LL-37 is important in the prevention of bacterial infections can be 
found by assessing hCAP18/LL-37 expression in patients with Shigella infections 
where cathelicidin expression was shown to be reduced, indicating that cathelicidin-
encoding genes can be supressed by pathogens as a part of their mechanism to 
avoid the immune system defenses, potentially resulting in increased virulence 
(Islam et al., 2001). In contrast, Bals et al. (1999) demonstrated that the transfer of 
hCAP18/LL-37 gene into mouse airways resulted in an enhanced clearance of 
pulmonary Pseudomonas aeruginosa infection.  
 
Extensive in vitro studies have shown the ability of low, physiologically relevant 
concentrations LL-37 to inhibit the growth of a variety of gram-negative 
(P.aeruginosa, S. typhimurium, E.coli) and gram-positive bacteria (S.aureus, 
S.epidermis, Listeria monocytogenes and vancomycin-resistant enterococci) (J. 
Turner et al., 1998). However, the antimicrobial activity of LL-37 has been shown to 
be affected by the presence of high salt conditions (≥100mM NaCl). LL-37 was 
shown to be highly effective against gram-positive bacteria under low-salt 
conditions, for instance the MIC of LL-37 against MRSA under low salt conditions 
was 3 µg/ml, whereas under high salt conditions the MIC of LL-37 was above 79 
µg/ml.  
 
In healthy infants and adults, hCAP-18/LL-37 has been detected in bronchoalveolar 
lavage fluid (BALF) at a concentration of approximately 5 μg/ml and 2 μg/ml, 
respectively. In newborns with pulmonary infections, the concentrations of LL-37 
can reach approximately 25μg/ml and in adult patients with cystic fibrosis LL-37 
concentrations reach 15 μg/ml (Chen et al., 2004; Schaller-Bals et al., 2002). The 
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high concentrations of LL-37 (~ 30 µg/ml) detected in BALF samples during viral 
pulmonary infections (Schaller-Bals et al., 2002), and specially in psoriatic skin 
lesions (approximately 304 µM= 1365.8 µg/ml) (Ong et al., 2002) suggest that the 
concentrations of LL-37 that are effective in vitro are compatible with those found 
in vivo. We therefore estimated an in vitro concentration of 10 µg/ml of LL-37 to be 
of relevance to a physiologically normal state, and a concentration of 30 µg/ml to 
be a physiologically inflammatory concentration of LL-37. 
 
Studies using mice deficient in the murine cathelicidin (mCRAMP) have shown mice 
to be more susceptible to bacterial infections when lacking cathelicidin, displaying 
considerably more susceptibility to Pseudomonas aeruginosa infection and keratitis 
in the cornea (Huang et al., 2007) together with delayed clearance of Pseudomonas 
aeruginosa and Klebsiella pneumoniae from the lungs (Kovach et al., 2012). 
Additional studies using this model have shown decreased protection against the 
enteric pathogen Citrobacter rodentium (Iimura et al., 2005), increased 
susceptibility to urinary tract infections caused by E.coli (Chromek et al., 2006), and 
decreased protection against RSV infection (Currie et al., 2016). 
 
1.2.2.2. Immunomodulatory functions of cathelicidins  
In vivo, the mechanisms underlying the antimicrobial and protective role of these 
peptides remain to be fully elucidated, as both direct bacterial killing and the ability 
to modulate the host innate immune response to infection are likely key properties 
in terms of cathelicidins contributing to host defence. For instance, a study by 
Barlow et al. (2010) demonstrated the ability of LL-37 to induce apoptosis of 
pseudomonas aeruginosa –infected airway epithelial cells, suggesting that the 
peptide is able to modulate the hosts innate immune response to infection by 
inducing apoptosis of infected cells and therefore promoting the clearance of the 
respiratory pathogen. 
 
Historically, the primary function of cathelicidins and other host defense peptides 
was first characterized to be through direct antimicrobial activity, despite in some 
cases, variable antimicrobial activities against pathogens (Fjell et al., 2012). 
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Moreover, these antimicrobial activities are frequently lost at high, but 
physiologically relevant, concentrations of salt and in the presence of serum/plasma 
(Ciornei et al., 2005; Johansson et al., 1998). However, in contrast to their 
antimicrobial activity, later studies have characterized the immunomodulatory 
activities of these peptides under physiologically relevant conditions which point 
towards immune modulation as being another primary role of these peptides in the 
host (Bowdish et al., 2006). 
Cathelicidins have multiple functions in immunity and inflammation and their anti-
infective properties have now been largely attributed to their capacity to mediate 
these immunomodulatory functions. The human cathelicidin LL-37 has shown 
chemotactic effects in vitro, promoting selective migration of different immune cells 
such as neutrophils, immature dendritic cells (iDC), monocytes, eosinophils, T cells 
to a site of infection (Agerberth et al., 2000), and the porcine cathelicidin PG-39 
exhibits direct chemotactic effects for iDCs, T cells and neutrophils (J Huang et al., 
1997; Tjabringa et al., 2006). Other studies have revealed that LL-37 was shown 
recruit neutrophils, monocytes and T cells to sites of infection through interactions 
with the formyl peptide receptor-like 1 (FPRL1) (De Yang et al., 2000). 
At low physiologically relevant concentrations (≤1µg/ml), LL-37 is also able to 
promote chemotaxis of immune cells in an indirect manner, by inducing the 
production of chemokines, such as RANTES, MCP-1, IL-8, MIP-1β and -3α, from 
immune and epithelial cells (Bowdish et al., 2006; Montreekachon et al., 2011; 
Mookherjee et al., 2006; Scott et al., 2002). The study by Scott et al. (2002) also 
demonstrated that LL-37 upregulates the surface expression of chemokine 
receptors in macrophages, such as CXCR-4, CCR2, and IL-8RB.  
The human cathelicidin was shown to chemoattract and degranulate murin, rat and 
human mast cells, which results in the release of histamine and prostaglandins, 
subsequently increasing vascular permeability via mast cell activation (Chen et al., 
2006; Niyonsaba et al., 2002, 2001). 
The human cathelicidin, LL-37, has previously shown to have contrasting effects on 
apoptotic cell death pathways in different cells (Barlow et al., 2010, 2006; Lau et al., 
2006; Li et al., 2009; Suzuki et al., 2011). For example, it was shown that LL-37 
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preferentially induced the apoptosis of Pseudomonas aeruginosa-infected bronchial 
epithelial cells, via induction of mitochondrial membrane depolarization, 
cytochrome c release and activation of caspase-9 and -3 (Barlow et al., 2010). In 
addition, although not in the context of infection, LL-37 was shown to induce 
apoptosis in primary epithelial cells possibly involving the activation of P2X7 
receptor, which has been shown to be a partial receptor for LL-37 –host cell 
interaction and signalling (Barlow et al., 2006). In contrast, in keratinocytes, LL-37 
was shown to supress camptothecin-mediated apoptosis via a COX-2/PGE-2 
antiapoptotic pathway (Chamorro et al., 2009). A study by Barlow et al., (2006) 
provided evidence relative to the capacity of LL-37 to suppress neutrophil 
apoptosis, demonstrating the potential of cathelicidins in protecting the host 
against bacterial invasion by prolonging the lifetime of neutrophils. LL-37 supressed 
neutrophil apoptosis, signalling through P2x7 and G-protein-coupled receptors 
other that FPRL1, and by inducing the expression of Mcl-1, an anti-apoptotic 
protein, and inhibiting BID and caspase-3 activity.  
 
At sites of inflammation, the levels of LL-37 are likely to be high (≥30 µg/ml) due to 
the presence of recruited neutrophils and epithelial cells which can release LL-37 
into the microenvironment (Schaller-Bals et al., 2002). High concentrations of LL-37 
(≥30 µg/ml) have been shown to be a potent modifier of dendritic cell (DC) 
differentiation, demonstrating an important link between the innate and adaptive 
immune responses (Davidson et al., 2004). In addition, immature DC exposed to LL-
37 were shown to substantially change their phenotype, which was characterised by 
an increased expression of the antigen-presenting molecule HLA-DR and the co-
stimulatory molecule CD86 (Bandholtz et al., 2006). The murine cathelicidin 
mCRAMP has also been implicated in the regulation of adaptive immune responses, 
as a study by Kin et al. (2011) demonstrated that mCRAMP has the ability to 
differentially regulate T- and B- cell functions.  
 
Cathelicidins are known to influence several other immunomodulatory functions, 
such as promotion of wound healing, angiogenesis (capillary growth) and 
arteriogenesis (pre-existing vessels growth). LL-37 was shown to induce 
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neovascularization in the chorioallantoic membrane and in a rabbit model of hind-
limb ischemia, as well as, increasing the proliferation and formation of vessel-like 
structures in endothelial cells, again via the receptor FPRL1. Angiogenesis was also 
shown to be induced in vivo and in vitro by the porcine cathelicidin PR39, and this 
was achieved through peptide-mediated inhibition of the degradation of hypoxia-
inducible factor 1α (HIF-1α) by the ubiquitin-proteasome system (Li et al., 2000). 
HIF-1α is known to regulate the expression of various angiogenesis-related genes, 
such as VEGF and FLT1 (Gerber et al., 1997). 
 
A number of in vivo models of infection and sepsis have shown that cathelicidins, 
such as LL-37 and the bovine cathelicidin BMAP-28, can modulate the host immune 
responses for the resolution of pathogen-induced inflammation (Cirioni et al., 2006; 
Giacometti et al., 2004). The anti-inflammatory activity of LL-37 has been shown to 
be targeted and specific. LL-37 was shown to selectively modulate inflammatory 
responses in LPS-stimulated THP-1 cell line and human PBMCs. The peptide was 
shown to significantly inhibit the expression of LPS induced-pro-inflammatory 
genes, including TNF-α, NFkB1 (p105/p50) and TNFAIAP2, but was shown not to 
inhibit, to the same extent, the LPS- induced expression of some of the known 
negative regulators of NFkB such as TNFAIP3, TNIP3 and NFkBIA (IkBa) (Mookherjee 
et al., 2006).  
The gram-negative bacterial molecule LPS is a potent TLR4 agonist and engagement 
with this receptor can result in the translocation of the pivotal transcription factor 
NF-kB from the cytoplasm to the nucleus, resulting in the transcription of genes 
encoding for cytokines and chemokines, including TNF-α, IL-1β, IL-6 and IL-8 (Jagielo 
et al., 1996). The mechanism behind LL-37-mediated selective regulation of 
inflammatory genes is thought to be related to its capacity to supress NF-kB 
translocation, which can lead to the dysregulation of TLR-induced transcriptional 
responses (Mookherjee et al., 2006). In addition, LL-37 was shown to modulate the 
LPS-induced pro-inflammatory responses in macrophages both in vivo and in vitro, 
by suppressing LPS-induced TNFα and NO production while preserving important 
macrophage functions, such as ROS production, and the ability to phagocytose and 
kill bacteria (Brown et al., 2011). In similarity, LL-37 was shown to reduce LPS-
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induced IL-8 and MCP-1 production in the A549 human lung epithelial cell line 
(Scott et al., 2002). However, it is notable that the role of the peptide in modulating 
inflammation can be paradoxical and is dependent upon the context in which a cell 
is exposed to both the peptide and LPS, as it has been shown that, in some 
instances, the peptide can modulate a pro-inflammatory response. Studies have 
demonstrated that LL-37 stimulation of LPS-primed monocytes can activate the 
inflammasome and induce the production of IL-1β and IL-18 via P2X7 receptor 
(Elssner et al., 2004; Kahlenberg et al., 2013).  
It is clear that the immunomodulatory activities of cathelicidins involve a complex 
array of factors, and mechanistic studies have proposed the involvement of several 
signalling pathways (i.e. NFkB, p38 and JNK, MAPK, and PI3K) which are activated 
depending on the intracellular uptake, endocytic mobilization and the interaction 
with a number of receptors. Intracellular uptake of LL-37 has been shown to be 
particularly important for the immunomodulatory activity of the peptide. LL-37 was 
shown to be actively taken up by A549 cells and eventually localise to the 
perinuclear region in a microtubules-dependent manner (Lau et al., 2005). 
However, the roles of specific receptors involved in the cellular uptake of LL-37 are 
not yet fully elucidated. Cathelicidins have been shown to interact with multiple 
receptors, and this interaction mediates different events depending on the cell type 
and exogenous stimuli.  
LL-37 has been shown to be a direct chemoattractant for neutrophils, monocytes 
and T cells through formyl peptide receptor like-1, a Gi protein-coupled receptor 
(De Yang et al., 2000). It is thought that the interaction between LL-37 and FPRL1 is 
a low-affinity ligand-receptor interaction. The activation of the chemotactic 
receptor FPRL1 by LL-37 results in a G protein-mediated signalling cascade which 
leads to the chemotaxis of leukocytes, as well as increased adhesion, enhanced 
phagocytosis and increased bacterial killing (Zlotnik et al., 1999). In addition to its 
chemotactic activity through FPRL1, LL-37 was shown to supress neutrophil 
apoptosis via the activation of both FPRL1 and P2X7 (Barlow et al., 2006; Nagaoka et 
al., 2006). Both LL-37 and mCRAMP are reported to act as agonists for the 
purinergic nucleotide receptor P2X7, in monocytes and macrophages, inducing the 
activation of the inflammasome and the subsequent production of IL1β and IL-18 
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(Elssner et al., 2004; Kahlenberg et al., 2013). Of relevance, an intracellular 
receptor, GAPDH, has also been identified as a functional direct binding protein or 
receptor for LL-37, thus potentially contributing to peptide-mediated innate 
responses in monocytes and macrophages (Mookherjee et al., 2009). Furthermore, 
LL-37 activation of P2X7 was shown to enhance COX-2 and PGE2 production via 
activation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase 
(JNK) in human gingival fibroblasts (Chotjumlong et al., 2013).  
LL-37 has also been proposed to transactivate the epidermal growth factor 
receptor, EGFR, in airway epithelial cells and keratinocytes, inducing cytokine 
release and cell migration (Tjabringa et al., 2003; Tokumaru et al., 2005). LL-37-
induced keratinocyte migration involved STAT3 signalling and LL-37-mediated IL-8 
release from airway epithelial cells has been shown to involve MAPK/ERK signalling 
which are both downstream of EGFR transactivation. LL-37 was also shown to be a 
partial agonist for insulin-like growth factor 1 receptor (IGF-1R), a receptor linked to 
cancer development, and this interaction is known to result in phosphorylation and 
ubiquitination of the receptor with downstream activation of MAPK/ERK signalling 
(Girnita et al., 2012). However, other specific host cell receptor interactions, and 
downstream mediation of immune function are not completely understood and 
require further characterisation. 
In addition to their ability to modulate immune responses, dysregulation of LL-37 in 
humans has been associated with the development of pathological conditions. LL-
37 has been implicated in psoriasis pathogenesis, which is a common autoimmune 
disease of the skin. Lande et al. (2007), showed the ability of LL-37 to bind to self-
DNA forming aggregates that could be delivered to endosomes in plasmacytoid 
dendritic cells (pDCs), triggering TLR9 and inducing a potent interferon response. 
pDCs can sense viral and bacterial DNA through TLR9 receptors located in 
endosomes which, in turn, induce a type I response. Importantly, in healthy 
individuals, pDCs do not respond to self-DNA, although this pathway appears to be 
altered in psoriasis patients. More recently, a study by Takahashi et al., (2018) 
provided new insights into the mechanism by which LL-37 drives auto-inflammatory 
responses in the skin, such as psoriasis and rosacea. The inflammatory activity of LL-
37 was shown to be mediated by a cell-surface-dependent interaction, by which LL-
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37 enabled keratinocytes and macrophages to recognise self-non coding U1 RNA, 
released during cell death, by facilitating binding to the cell surface scavenger 
receptors that allow the recognition by nucleic acid pattern recognition receptors 
within the cell.  
1.2.2.3. Antiviral activity of cathelicidins 
 
Cationic host defence peptides have been shown to be expressed in response to 
viral infections, however, little is known about their expression in response to 
rhinovirus infection. Currently the evidence that hCAP-18/LL-37 is expressed in 
response to rhinovirus infection is very little. Nevertheless, a recent cohort study of 
hospitalised infants, which focused upon examining the role of LL-37 in 
bronchiolitis, revealed that infants with higher serum LL-37 levels were less likely to 
have RSV, but more likely to have HRV, indicating that elevated LL-37 levels were 
associated with rhinovirus infection (Mansbach et al., 2017). Other studies have 
demonstrated that HRV infection induces respiratory epithelial cell expression of 
both β-defensin-2 and -3 in vitro and in vivo. However, there is no evidence of their 
direct antiviral activity against rhinovirus. The increase in both β-defensin-2 and -3 
correlates with an increase in IL-8 production; and stimulation of β-defensin-2 and -
3 mRNA levels appear to be dependent on viral replication (Proud et al., 2004).  
 
Cationic host defense peptides have primarily been described as antibacterial 
agents, although as has been highlighted, they have broad immunomodulatory 
properties and, more recently, have been shown to have a potent antiviral activity.  
Cathelicidins have been shown to possess antiviral activity against a substantial 
number of viral pathogens including IAV (Barlow et al., 2011; Tripathi et al., 2015, 
2013), HIV (Bergman et al., 2007; Levinson et al., 2009; Wong et al., 2011), Dengue 
Virus (Alagarasu et al., 2017; Rothan et al., 2012), RSV (Currie et al., 2013; Harcourt 
et al., 2016), Vaccinia virus (Dean et al., 2010; Howell et al., 2004) and Adenovirus 
(Gordon et al., 2005; Smith et al., 2010) (reviewed in Barlow et al., 2014).  
The human cathelicin LL-37 was shown to inhibit the replication of HIV-1 in 
peripheral blood mononuclear cells (Bergman et al., 2007). In IAV studies, the 
pandemic IAV strains have been shown to be more resistant to innate inhibitors of 
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seasonal IAV strains, such as human and murine cathelicidins. A recent study 
compared the antiviral activities of LL-37 and derived fragments against seasonal 
and pandemic strains of IAV and revealed that the central fragment of LL-37 (GI20) 
showed greater activity against the pandemic IAV strain than LL-37 in vitro (Tripathi 
et al., 2015). These findings suggest the possibility of engineering new LL-37 
derivatives with more potent antiviral activity.  
In in vivo studies, murine models receiving LL-37 or mCRAMP treatment showed a 
significant increase in survival following IAV (Barlow et al., 2011) or RSV (Currie et 
al., 2016) infection compared to saline treated mice. In addition, the Camp -/- mice 
were shown to develop a more severe disease that the wild-type mice during RSV 
infection, demonstrating the important role of endogenous cathelicidins in host 
defense against this respiratory pathogen (Currie et al., 2016).  
LL-37 has also been shown to target viral envelop proteins inhibiting virus entry into 
the cells. Molecular docking studies revealed LL-37 binding to the envelop E-protein 
of dengue virus type 2 (Alagarasu et al., 2017). The underlying antiviral mechanism 
of cathelicidin peptides appears to be partly due to direct effects on the virus 
envelope, and this has been demonstrated in a number of detailed in vitro studies. 
Both LL-37 and mCRAMP can damage the viral envelope of vaccinia virus (Dean et 
al., 2010), IAV (Tripathi et al., 2013), and Herpes simplex virus (Gordon et al., 2005).  
Cathelicidins can also inactivate non-enveloped viruses such as adenovirus and 
rhinovirus (Barlow et al., 2014; Gordon et al., 2005; Sousa et al., 2017). In fact, the 
human cathelicidin LL-37 was shown to inhibit human adenovirus replication in 
A549 cells (Barlow et al., 2014). Optimal inhibition of virus replication is 
demonstrated when the virus is pre-incubated with the peptide prior to host cell 
infection, although other studies have shown that host cell pre-treatment or 
delayed treatment with exogenous LL-37 also inhibited RSV (Currie et al., 2013; 
Harcourt et al., 2016), IAV (Tripathi et al., 2013) and Adenovirus (Barlow et al., 
2014) replication to an extent. In vivo studies have further demonstrated the ability 
of LL-37 to modulate inflammatory responses to viral infection by inhibiting 
excessive inflammation in IAV-infected mice (Barlow et al., 2011). This 
demonstrates that the mechanisms underpinning the antiviral activity of 
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cathelicidins are complex and can potentially include direct interaction with the 
virus particles by directly damaging the viral envelope or capsid, or by binding to 
specific proteins present in the envelope blocking viral entry. The interaction with 
host cells modulating inflammatory and innate immune responses to viral infection 
is also likely to be critical.  
As previously mentioned there are no specific effective treatments or vaccination 
available for human rhinovirus infection. We will show here, in agreement with 
other studies, that exogenous and vitamin D-induced LL-37 has potent direct 
antiviral activity against HRV (Schögler et al., 2016; Sousa et al., 2017; Telcian et al., 
2017). We also assess the ability of LL-37 to induce cell death in HRV-infected 
airway epithelial cells in the context of previous studies utilising bacteria (Barlow et 
al., 2010). Determining the impact of cathelicidins on rhinovirus infections may lead 
to the development of therapeutic strategies aimed at the prophylactic modulation 
of endogenous cathelicidin expression and/or the development of cathelicidin-
derived analogues for the treatment of infected individuals. 
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Figure 5. Functions of cathelicidins. 
Cathelicidins protect against infections by directly targeting the pathogen or by modulating 
the host’s immune responses. [Adapted from Mookherjee and Hancock, 2007)] 
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1.3. Aims and hypothesis 
 
Human rhinovirus is associated with increased morbidity and mortality especially 
amongst individuals with underlining respiratory conditions, immunocompromised 
individuals, elderly and young children. Due to the lack of alternative and effective 
treatments or vaccination for HRV infections, novel antiviral approaches are 
urgently required. Cathelicidins, a key component of the innate immune system, 
have shown potent antiviral activity against a number of viruses. Previous work 
(Barlow et al., 2011) together with our initial experiments has established an 
antiviral role for cathelicidins in rhinovirus infection. This study aims to investigate 
the antiviral activity of the human cathelicidins LL-37 against HRV, via 
characterisation of direct antiviral activity, modulation of inflammation and cell 
death. 
 
The hypotheses of this study are as follows: 
 
(1) The antiviral activity of LL-37 against rhinovirus will likely be attributed to 
both direct antiviral and immunomodulatory activity, via inhibition of HRV 
replication, viral lysis, alterations in binding and host cell protection against 
HRV-induced cytopathic effects.  
(2) The human cathelicidin LL-37 will modulate the pro-inflammatory cytokine 
and chemokine response of viral infected respiratory epithelial cells.  
(3) LL-37 will affect cell death pathways of HRV-infected cells via the modulation 
of apoptotic pathways.  
(4) LL-37 will act on several intracellular and cell-surface targets, inducing a 
protective antiviral state in treated airway epithelial cells.  
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Chapter 2. General Materials and Methods  
 
2.1. Reagents  
Dulbecco’s modified Eagle’s medium (DMEM), L-glutamine, Foetal bovine serum 
(FBS), non-essential amino acids (NEAA), Bovine Serum Albumine fraction V (BSA), 
Triton-X-100, Tween®20, Polyinosinic:polycytidylic acid (poly I:C), RNAzol-RT, 
Saponin and DNA damaging agent Camptothecin were all purchased from Sigma-
Aldrich, Irvine, UK. Iscove’s Modified Dubecco’s Medium (IMDM) GlutaMAX™ 
Supplement, 0.05% trypsin-EDTA, Penicillin-Streptomycin (10,000U/ml) and DPBS 
were all purchased from GIBCO™, ThermoFisher Scientific, Loughborough, UK. 
Utroser™ G Serum Substitute was purchased from Pall Corporation, Portsmouth, 
UK. The human fibronectin (1 μg/ml) was purchased from Merck Millpore EMD, 
Watford, UK. The human LDLr APC conjugated antibody, LDLr isotype control 
(mouse IgG 1 APC-conjugated antibody) and Cultrex Mouse Collagen IV (0.5 μg/ml) 
were purchased from R&D, Abingdon, UK. The human CD54 PE conjugated antibody 
and ICAM-1 isotype control (PE mouseIgG1, k isotype control FC antibody) were 
purchased from BioLegend, London, UK. The human vLDLr FITC conjugated antibody 
was purchased from LSbio, Nottingham, UK. The antibodies pan enterovirus 
monoclonal antibody (Mouse/IgG2a, L66J), goat anti-mouse IgG, Alexa Fluor® 488 
and F (ab')2 anti-Mouse IgG PE (A10543) were all purchased from ThermoFisher 
Scientific, Loughborough, UK. The anti-cleaved caspase 3 antibody was purchased 
from Cell signalling Technology, Hitchin, UK. The goat BV421-anti-rabbit was 
purchased from BD Horizon™, BD Biosciences, UK. Vectashield Hardset mounting 
medium with 49, 6-diamidino- 2-phenylindole (DAPI) was supplied by Vector 
Laboratories, Peterborough, UK. RT-PCR primers were ordered from Eurofins 
(Ebersberg, Germany) unless otherwise stated. The RNeasy mini kit was supplied by 
Quiagen, Manchester, UK. CytoTox 96 Non-Radioactive Cytotoxicity Assay (LDH) was 
supplied by Promega, Southampton, UK. FITC Annexin V Apoptosis Detection 
Kit I was purchased from BD Pharmingen™, Oxford, UK. ). ELISA kits were 
purchased from R&D (Abingdon, UK), unless otherwise stated. Reconstituted 
peptide masses were characterised by MALDI-TOF analysis (Proteomics Facility 
Moredun Research Institute, UK). 
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2.2. Peptide synthesis 
The peptides were assembled using the Fmoc/tBu solid-phase peptide synthesis 
approach (Zughaier et al., 2010) using either model 433A (Applied Biosystems, CA, 
USA) or model Liberty (CEM Corporation, NC, USA) automated peptide synthesizers 
followed by cleavage in the trifluoroacetic acid 
(TFA)/phenol/thioanisole/ethanedithiol/water (10:0.75:0.5:0.25:0.5, w/w) mixture 
at 25 C for 90 minutes followed by precipitation with cold diethyl ether. The crude 
peptides were purified by preparative reversed-phase high-pressure liquid 
chromatography (RP-HPLC). The peptide purity (>98%) was confirmed by analytical 
RP-HPLC, and the masses were confirmed by mass spectrometry. Following 
lyophilization, the purified peptides were obtained in the form of their TFA salts; 
namely: LL-37 (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES), LL-37 analog having 
“scrambled” sequence (RSLEGTDRFPFVRLKNSRKLEFKDIKGIKREQFVKIL), termed sLL-
37 (control peptide). All peptides were dissolved in endotoxin-free ultrapure water 
(Sigma-Aldrich, Irvine, UK) and stored at −80 C until use. 
 
2.3. Respiratory epithelial cell culture 
A549 (adenocarcinoma human alveolar basal epithelial cells) and HeLa 
(adenocarcinoma human cervix epithelial cells) were sourced from the European 
Collection of Authenticated Cell Cultures (Public Health England, Salisbury, UK). The 
16HBE14o- transformed human bronchial epithelial cell line was a kind gift from 
former Professor Dieter Gruenert (University of California, San Francisco, USA). 
A549 and HeLa cells were cultured in Dulbecco’s modified eagle medium high 
glucose (DMEM, 4.5 g/L glucose), supplemented with 1% Penicillin-Streptomycin, 
and 10% fetal bovine serum (FBS). 16HBE14o- cells were cultured in Iscove’s 
modified Dulbecco’s medium (IMDM), GlutaMAX™ supplemented with 1% 
streptomycin-penicillin and 10% FBS. For 16HBE14o- cell culture, flasks were coated 
with a basement layer of Cultrex mouse collagen IV (0.5 μg/ml), human fibronectin 
(1 μg/ml) and bovine serum albumin fraction V (100 μg/ml), before seeding cells, for 
cell adhesion, in order to allow the formation of tight junctions in this cell line. All 
cell lines were grown at 37oC in a humidified incubator with 5% CO2. Cells were 
detached with 0.05% Trypsin-EDTA and seeded at 5x104cells/ml (16HBE14o- cells) or 
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1x105cells/ml (A549 cells) for 12-well plate and allowed to grow for 24h prior to 
experiments. The passage number was controlled and all experiments were 
performed with low passage number. 
 
2.4. Viral propagation and infection 
HRV1B viral stocks (Public Health England Virus Collection, Salisbury, UK) were 
propagated in HeLa cells grown at 33oC/ 5% CO2. HeLa cells were previously tested 
for LDLr and ICAM-1 surface expression by flow cytometry and exhibited high basal 
levels of these receptors. Briefly, HRV1B stocks were exposed to confluent 
monolayers of HeLa cells in serum free DMEM for 2h at 33oC. Cells were then 
washed and left in DMEM supplemented with 5%FBS. After 5 days, HRV infected or 
non-infected cells (HeLa lysates control) were subjected to three freeze-thaw cycles, 
harvested and spun to remove cellular debris (3000xg for 0.5h at 4oC), and then 
aliquoted and frozen at -80oC. 
2.5. RNA isolation 
Total RNA was extracted using RNAzol® RT (Sigma-Aldrich, Irvine, UK) or RNeasy 
mini kit (Quiagen, Manchester, UK) according to manufacturer’s protocol. RNA 
concentrations were determined using a NanoDrop 1000 spectrophotometer 
(Thermo Fisher Scientific, Loughborough, UK). RNA integrity was determined using 
an Agilent Bioanalyser (Agilent, Craven Arms, UK), where RIN≥8 was used as a 
quality filter for further downstream analyses. 
2.6. qPCR  
Total RNA (0.5-1μg) was transcribed to cDNA using Precision RT all-in-one mix kit 
(PrimerDesign Ltd, Camberley UK) as per manufacturer’s instructions. qPCR 
reactions included cDNA (25 ng), 250 nM specific primers and SYBR green 
mastermix (PrimerDesign Ltd, Camberley UK) in total volume of 20µl. qPCR was 
performed using the StepOnePlus instrument (Applied Biosystems, Warrington, UK). 
A panel of six human reference genes were evaluated using a geNorm kit 
(Primerdesign Camberley,UK) and qbase+ (Biogazelle Zwijnaarde, Belgium) software. 
The geometric means of ACTB and GAPDH genes were selected as the most stable 
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combination for normalization in 16HBE14o- cells. The 2ΔΔCt method was used and 
data is represented as fold changes over untreated cells (Pfaffl MW, 2004).  
 
ΔΔCT= (CT(TARGET, UNTREATED - CT(REF, UNTREATED))-(CT(TARGET, TREATED)-
CT(REF, TREATED)) 
2.7. ELISAs 
Supernatants from experiments were analysed for the release of IL-8, IL-6, CCL5 and 
IFN1β by ELISA, as per the manufacturer’s instructions. The human IL-8 DuoSet 
ELISA DY208-05, Human IL-6 Duoset ELISA DY206-05 and Human CCL5/RANTES 
DuoSet ELISA DY278-05 were purchased from R&D, Abingdon, UK and the human 
IFN β ELISA kit was purchased pbl Assay Science, (Piscataway Township, USA).  
 
2.8. Statistical analysis 
Statistical analysis was performed using GraphPad Prism Version 6.0. (GraphPad Inc, 
San Diego, CA, USA). Data are presented as means ± SEM. Data were analysed using 
the appropriate statistical test and post-test as stated in the figure legends. A p-
value ≤0.05 was considered statistically significant.  
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 Chapter 3. Characterisation of airway epithelial cell models 
of rhinovirus infection 
 
3.1. Introduction 
3.1.1. Rhinovirus Infection of the airway epithelium  
Human rhinoviruses replicate in epithelial cells of the upper and lower airway tract. 
HRV-B and HRV-A species access the cell either via ICAM-1, known as the major 
group of viruses (Greve et al., 1989) or via LDLr or vLDLr, known as the minor group 
of viruses (Hofer et al., 1994; Nicodemou et al., 2005). The minor group of virus do 
not access airway cells via ICAM-1, although studies have provided evidence on 
their ability to upregulate surface ICAM-1 expression in airway cells indicating that 
the induction of ICAM-1 is not receptor- or serotype restricted (Papi and Johnston, 
1999; Terajima et al., 1997). The minor group of virus bind to LDLr or vLDLr, which 
are typically endocytic-recycling receptors and endocytosis of the virus is thought to 
occur in a clathrin-dependent manner (Snyers et al., 2003), although some virus can 
enter cells in clathrin-independent mediated endocytosis. The virus-receptor 
complex is delivered to early endosomes and later progresses to late endosomes 
and lysosomes (Schober et al., 1998). The low pH leads to the uncoating of the virus 
and release of viral RNA into the cytoplasm. In the cytoplasm, the positive RNA 
stand is used for viral replication and viral protein synthesis. The virus particles are 
assembled and new, infectious virions are released to infect other neighbouring 
cells (Figure 6).   
The virus is able to reside and replicate within the airway epithelial cell without 
compromising the host cell viability, as shown by their inability to alter the 
morphology or integrity of the airway epithelium (Birgit Winther et al., 1984). 
Instead, the epithelial cells respond to rhinovirus infection by inducing an antiviral 
and pro-inflammatory response, which contributes to the recruitment of and 
activation of inflammatory cells, such as neutrophils, eosinophils and T cells 
(Sanders et al., 1998; Subauste et al., 1995; Wang et al., 1996). HRV infection of 
airway epithelial cells has been shown to induce a rapid production of several pro-
inflammatory cytokines, including IL-8, IL-6, GM-CSF and CCL5 (Kim et al., 2000; 
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Papadopoulos et al., 2001; Subauste et al., 1995). Increased levels of IL-6 (Zhu et al., 
1996), IL-8 (Zhu et al., 1997) and IL-1β (Proud et al., 1994) were also detected in 
nasal washings taken from rhinovirus experimentally infected subjects. In addition 
to the production of pro-inflammatory mediators, airway epithelial cells also 
respond to HRV infection by activating an antiviral signalling pathway. Interferons 
are an important component of the innate immune response, being able to directly 
interfere with viral replication thereby limiting the spread of infection (Parronchi et 
al., 1992). Rhinovirus infection of primary human bronchial epithelial cells has been 
shown to induce IFN1β and IFN-λ production (Wark et al., 2005).  
An important factor which until recently has been neglected are strain specific 
effects, current in vivo and in vitro studies have provided an insight on the 
importance of strain differences for HRV pathogenesis. A study by Rajan et al. 
(2013), using a co-culture system with airway epithelial cells and PBMCs, 
demonstrated that both differences in the HRV strains and the source of PBMCs 
contributed to changes in the expression of several cytokines and chemokines. 
Interestingly, clinical studies have linked minor group of HRVs to increase rates of 
asthma exacerbations (Denlinger et al., 2011). In vitro studies of airway cell 
response to rhinovirus infection have been extensively studied; however, the focus 
of the studies was mainly on HRV-A species (Y. Chen et al., 2006; Proud et al., 2008; 
Subauste et al., 1995).  
In this chapter, we investigated the ability of minor group HRV1B to replicate in 
alveolar and bronchial epithelial cell lines as well as characterising the antiviral and 
pro-inflammatory response of these cell models to viral infection. We assessed the 
direct airway epithelial cell response to HVR infection by investigating the gene 
expression of pro-inflammatory mediators, IL-8, IL-6 and CCL5, as well as antiviral 
mediators, IFN1β, induced at different stages of rhinovirus 1B infection in alveolar 
and bronchial epithelial cells.  
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Figure 6. Rhinovirus replication in airway epithelial cells. 
HRV bind to ICAM-1 or LDLr, and enter cells by clarthin dependent or independent 
endocytosis, the virus-receptor complex are delivered to early endosomes and later move 
to late endosomes and lysosomes. The acidic pH leads to the dissociation from the 
receptors and to the uncoating of the virus. Viral RNA is released into the cytoplasma and 
used for viral replication and translation of viral proteins. Image adapted from Swiss 
Institute of bioinformatics.  
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3.2. Materials and Methods 
 
3.2.1. Cell culture 
A549 (adenocarcinoma human alveolar basal epithelial cells) and HeLa 
(adenocarcinoma human cervix epithelial cells) were sourced from the European 
Collection of Authenticated Cell Cultures (Public Health England, Salisbury, UK). The 
16HBE14o- transformed human bronchial epithelial cell line was a kind gift from 
former Professor Dieter Gruenert (University of California, San Francisco, USA). 
A549 and HeLa cells were cultured in Dulbecco’s modified eagle medium high 
glucose (DMEM, 4.5 g/L glucose), supplemented with 1% Penicillin-Streptomycin, 
and 10% fetal bovine serum (FBS). 16HBE14o- cells were cultured in Iscove’s 
modified Dulbecco’s medium (IMDM), GlutaMAX™ supplemented with 1% 
streptomycin-penicillin and 10% FBS. For 16HBE14o- cell culture, flasks were coated 
with a basement layer of Cultrex Mouse Collagen IV (0.5 μg/ml), human fibronectin 
(1 μg/ml) and Bovine Serum Albumine fraction V (100 μg/ml), before seeding cells. 
All cell lines were grown at 37oC in a humidified incubator with 5% CO2. Cells were 
detached with 0.05% Trypsin-EDTA and seeded at 5x104cells/ml (16HBE14o- cells) or 
1x105cells/ml (A549 cells) for 12-well plate and allowed to grow for 24h prior to 
experiments.  
 
3.2.2. Viral propagation and infection 
HRV1B viral stocks (Public Health England Virus Collection, Salisbury, UK) were 
propagated in HeLa cells grown at 33oC/ 5% CO2. HeLa cells were previously tested 
for LDLr and ICAM-1 surface expression by flow cytometry and exhibited high basal 
levels of these receptors. Briefly, HRV1B stocks were exposed to confluent 
monolayers of HeLa cells in serum free DMEM for 2h at 33oC. Cells were then 
washed and left in DMEM supplemented with 5%FBS. After 5 days, HRV infected or 
non-infected cells (HeLa lysates control) were subjected to three freeze-thaw cycles, 
harvested and spun to remove cellular debris (3000xg for 0.5h at 4oC), and then 
aliquoted and frozen at -80oC. 
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3.2.3. RNA isolation and qPCR 
Total RNA was extracted using RNAzol® RT (Sigma-Aldrich, Irvine, UK) according to 
manufacturer’s protocol. Briefly, A549 cells or 16HBE14o- cells were seeded at 1x105 
or 5x104 cells/well in a 12-well plate, respectively, and incubated at 37oC overnight. 
The following day, different doses of HRV1B (MOI 0.1, 1, 5) were used to infect cells 
for 2h at 33oC in serum-free IMDM media. Cells were then washed and re-immersed 
in fresh media supplemented with 5% FBS for different time-points (ranging from 2h 
up to 72h). After each time-point, cell supernatants were aspirated and stored at -
80oC until further use, and ice-cold 500µl RNAzol® RT was added to each well. Cells 
were scrapped of the surface of the plate with a cell-scrapper. Cell lysates were 
stored at -80oC until extraction. Total RNA was isolated using RNAzol® RT according 
to manufacturer’s protocol. RNA concentrations were determined using a 
NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, Loughborough, UK). 
RNA integrity was determined using an Agilent Bioanalyser (Agilent, UK), where 
RIN≥8 was used as a quality filter for further downstream analyses. 
For the molecular quantification of viral infectivity, viral RNA copies isolated from 
cell lysates or cell supernatants were determined using the Genesig Human 
Rhinovirus (all subtypes) qPCR kit (PrimerDesign, Camberley, UK) according to 
manufacturer’s protocols. 
For the determination of IL-8, IL-6, CCL5 and IFN1β gene expression, total RNA (0.5-
1μg) was transcribed to cDNA using Precision RT all-in-one mix kit (PrimerDesign 
Ltd, Camberley, UK) as per manufacturer’s instructions. qPCR reactions included 
cDNA (25 ng), 250 nM specific primers (Table 1) and SYBR green mastermix 
(PrimerDesign Ltd, Camberley, UK) in total volume of 20µl. qPCR was performed 
using the StepOnePlus instrument (Applied Biosystems). A panel of six human 
reference genes were evaluated using a geNorm kit (Primerdesign) and qbase+ 
(Biogazelle) software. The geometric means of ACTB and GAPDH genes were 
selected as the most stable combination for normalization in both 16HBE and A549 
cell lines. The 2ΔΔCt method was used and data is represented as fold changes over 
untreated cells.  
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Table 1. qPCR primer sequences 
Target Forward Reverse Reference 
GAPD
H  
AAGCTCATTTCCTGGTATGAC
A 
TCTTACTCCTTGGAGGCCAT
GT 
(Wang et al., 
2012) 
ACTB GGACTTCGAGCAAGAGATGG AGGAAGGAAGGCTGGAAGA
G 
(Tarrats et al., 
2011) 
IL-8 ACTGAGAGTGATTGAGAGTG
GAC 
AACCCTCTGCACCCAGTTTT
C 
(Tsai et al., 
2009) 
IL-6 GGTACATCCTCGACGGCATC
T 
GTGCCTCTTTGCTGCTTTCA
C 
(Keller et al., 
2003) 
CCL5 CAGTCGTCTTTGTCACCCGA CGGGTGGGGTAGGATAGTG
A 
Designed 
IFN1β TCTGGCACAACAGGTAGTAGGC GAGAAGCACAACAGGAGAGCA
A 
 
(Warnking et 
al., 2015) 
 
3.2.4. IL-8 ELISA 
Supernatants from the different infection time points of 16HBE14o- and A549 cells 
were analysed by ELISA for IL-8 release, as per the manufacturer’s instructions 
(human IL-8 DuoSet ELISA DY208-05, R&D, UK). 
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3.3. Results 
3.3.1. Assessment of rhinovirus replication in airway epithelial cell models 
 
In order to determine the ability of HRV1B to replicate in alveolar epithelial cells, 
the number of viral RNA copies was determined in samples collected from A549 cell 
lysates at indicated time points. As shown in Figure 7 a higher multiplicity of 
infection used to infected cells corresponded to a greater viral load. The viral RNA 
copy number is substantial increased by 2h post infection indicating that the virus is 
rapidly up-taken by A549 cells. Peak viral loads were observed at 18h post-infection 
and maintained up to 48h after infection followed by a steady decrease at 72h post 
infection. This pattern was seen for a MOI 1 and 5, a MOI 0.1 used to infect cells 
was too low to generate a high viral copy number. 
 
 
 
 
 
 
 
 
 
 
Figure 7.Rhinovirus 1B rapidly enters and actively replicates in A549 cell model of 
infection. 
A549 cells were infected with different MOIs of HRV1B (0.1, 1 and 5) for 2h in serum-free 
media and washed prior to re-immersing cells in fresh DMEM supplemented with 5% FBS 
for 2, 6, 18, 24, 48 or 72h at 33oC. Total RNA was isolated from cell lysates and viral RNA 
copies were determined by qPCR at indicated time points.  
 
To ensure that the observed increases in intracellular viral RNA isolated from A549 
cell lysates were associated with an active intracellular replication and adequate 
assembly of viral replicative units and release into the supernatants, we determined 
the viral RNA copies in A549 cell supernatants at indicated time points. Figure 8 
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shows the viral RNA copy number in A549 cell lysates (A) and in A549 cell 
supernatants (B) from the same experiment. Results show that at 2h post-infection 
the viral RNA copy number in A549 cell supernatants was 2.4 times higher 
compared to intracellular viral RNA copy number. No viral RNA copies were 
detected intracellularly at 6h post-viral infection (Figure 8A). No infective virus was 
detectable in cell supernatants within 6h and 18h post inoculation (Figure 8B). In cell 
lysates peak titers were observed within 48h and declined by 72h after infection 
(Figure 8A), whereas in cell supernatants viral RNA copies increased from 24 to 72h 
post-infection (Figure 8B).  
 
 
 
 
 
 
 
 
 
Figure 8.Rhinovirus 1B actively replicates in A549 cell model. 
A549 cells were infected with different MOI of HRV1B (0.1, 1 and 5) for 2h in serum- free 
media and washed prior to re-immersing cells in fresh DMEM supplemented with 5% FBS 
for 2, 6, 18, 24, 48 or 72h at 33oC. Total RNA was isolated from cell lysates and supernatants 
and viral RNA copies were determined by qPCR at indicated time points.  
 
In order to determine the ability of HRV1B to replicate in bronchial epithelial cells, 
the number of viral RNA copies was determined in samples collected from 
16HBE14o- cell lysates at indicated time points. As shown in Figure 9 a higher 
multiplicity of infection corresponds to a greater viral load. A marked increase in 
viral RNA copies in HRV1B- infected 16HBE14o-  cell lysates was observed within 18 
and 24h followed by a steady decrease at 48-72h. All multiplicity of infection used 
to infect 16HBE14o- cells followed the same pattern of replication. 
B. A. 
Cell Lysates 
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Figure 9. Rhinovirus 1B replicates in bronchial epithelial cells 
Bronchial epithelial cells (16HBE14o-) were infected with different MOI of HRV1B (0.1, 1 and 
5) for 2h in serum- free media and washed prior to re-immersing cells in fresh IMDM 
supplemented with 5% FBS for 4, 16, 22, 46 or 70h at 33oC. Total RNA was isolated from cell 
lysates and supernatants and viral RNA copies were determined by qPCR at indicated time 
points.  
 
3.3.2. Determination of basal levels of host cell-surface receptors used by HRV to 
access airway epithelial cells  
 
ICAM-1, LDLr and vLRDL are known to be found in the cell surface of airway 
epithelial cells and are important receptors in rhinovirus binding, uptake and signal 
transduction processes. The transcriptional and translational basal levels of ICAM-1, 
vLDLr and LDLr were investigated in alveolar and bronchial epithelial cells and 
compared to levels expressed on HeLa cells. Results indicated that 16HBE14o- cells 
expressed high levels of surface ICAM-1 and LDLr proteins, displaying 95.1% positive 
cells for both ICAM-1 and LDLR staining. HeLa cells displayed 99.3% positive cells for 
both ICAM-1 and LDLr staining. A549 cells exhibited 28.4% positive cells for both 
ICAM-1 and LDLr staining and 71.3% positive cells for LDLr staining (Figure 10A). 
mRNA levels indicated that all cells lines highly expressed LDLr and vLDLR genes, 
whereas the ICAM-1 gene was highly expressed in 16HBE14o-and HeLa cells, but not 
in the A549 cell line (Figure 10 B).  
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Figure 10. Alveolar and bronchial epithelial cells express high levels of HRV-target 
host cell receptors. 
(A) Surface ICAM-1 and LDLr were measured by flow cytometry on HeLa, A549 and 16HBE 
cells. All cells were stained for ICAM-1 and LDLr using conjugated antibodies and unstained 
cells were used as a control to set the negative population. Representative flow cytometric 
histogram indicates surface expression of ICAM-1 and LDLR in HeLa, A549 and 16HBE14o- 
cells. (B) ICAM-1, LDLr and vLDLR gene expression were determined in HeLa, A549 and 
16HBE cells by qPCR. Relative expression of ICAM-1, LDLr and vLDLr was normalised to 
GAPDH. Results represent one independent experiment. Results kindly provided by Dr 
Victor Casanova. 
  
A. 
B. 
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3.3.3. Characterisation of HRV-mediated pro-inflammatory and antiviral response 
in alveolar and bronchial epithelial cells  
In order to determine the antiviral and pro-inflammatory responses of airway 
epithelial cells to rhinovirus 1B infection, we assessed IFN1β, IL-8, IL-6 and CCL5 
gene expression changes as well as IL-8 protein release across different time points 
in alveolar and bronchial epithelial cell models of infection.  
As shown in Figure 11 a greater upregulation of IL-8, IL-6, CCL5 and IFN1β gene 
expression corresponds with a higher MOI, indicating that a higher viral titer is 
associated with an increase antiviral and pro-inflammatory response in A549 cells. 
HRV infection markedly induced IL-8 mRNA expression in a MOI and time-
dependent manner (Figure 11A). HRV induced a greater increase in IL-8 mRNA 
expression at later stages of infection (5.9-fold at 72h, MOI 1 and 7.4–fold at 48h, 
MOI 5). IL-6 mRNA levels were markedly induced at later stages of infection (i.e. 
72h), in which a higher MOI resulted in a 5.6-fold increase in comparison to 
uninfected A549 cells (Figure 11 B). Early stages (i.e. 6-24h) of HRV infection of A549 
cells did not strongly upregulate CCL5 mRNA expression. The maximum 
upregulation of CCL5 mRNA expression was seen with a MOI 1 at later stages of 
infection – 72h- reaching 3.77-fold increase in comparison to uninfected cells (Figure 
11C). We also observed increased levels of mRNA encoding for IFN1β at later stages 
of infection, reaching 5.4-fold increase compared to uninfected cells at 48h with a 
MOI 5 (Figure 11 D). Since the virus inoculum was a crude preparation, we used HeLa 
lysates as a control, and observed, using a threshold of 2, no upregulation of IL-8, 
and IL-6, CCL5 or IFN1β expression at any of the indicated time points and doses 
(Appendix 12).  
In addition to determining mRNA fold-changes we assessed the viral copy numbers 
for the indicated time-points and doses of HRV used for infection. We previously 
reported this data although the viral load was determined at 2, 6, 18, 24, 48 and 72 
post-infection, whereas in this case the viral load is determined at 4, 16, 22, 46 and 
70h post-infection (Figure 11E). As shown in Figure 11 a marked increase in viral RNA 
copies was seen at 18h of infection and was relatively maintained up to 72h of 
infection. A greater viral load was directly associated with the dose of HRV used to 
infect cells.  
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Figure 11.HRV1B infection upregulates IL-8, IL-6, CCL5 and IFNβ gene expression in 
a MOI and time-dependent manner in A549 cell model. 
A549 cells were infected with different MOIs of HRV1B (0.1, 1 and 5) for 2h in serum- free 
media and washed prior to re-immersing cells in fresh DMEM supplemented with 5% FBS 
for 4, 16, 22, 46 or 70h at 33oC. Total RNA was extracted from A549 cell lysates and qPCR 
E. 
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was performed to determine viral RNA copies as well as the relative expression of IL-8 (A), 
IL-6 (B), CCL5 (C) and IFN1β (D). The GAPDH and actin genes were used as reference genes. 
Results represent one independent experiment. 
 
To confirm changes in mRNA transcript level were translated to changes at the 
protein level, we assessed cell supernatants for IL-8 protein release at indicated 
time-points (Figure 12). In agreement with the mRNA transcript levels, HRV infection 
of A549 cells induced IL-8 secretion in a time-dependent manner. We observed no 
apparent differences in IL-8 concentration using different MOI to infect cells (i.e. 
MOI1 and 5). Lower MOI 0.1 did not induce a marked IL-8 release above uninfected 
cells at any of the time-points indicated. Early stages of infection (i.e. 6-18h – MOI 1 
and 5) did not result in a marked increase in IL-8 release compared to uninfected 
cells. Later stages of HRV infection induced a marked increase in IL-8 secretion 
compared to uninfected cells (109.2 pg/ml MOI 1 and 107.7 pg/ml MOI 5 compared 
to 54.2 pg/ml for uninfected at 48h time point and 177.2 pg/ml for MOI 1 and 162.3 
pg/ml MOI 5 compared to 96.4 pg/ml for uninfected cells at 72h time point). Poly 
I:C was used as a positive control and as expected strongly induced IL-8 release in a 
time-dependent manner.  
 
 
 
 
 
 
 
 
Figure 12.HRV infection induces IL-8 secretion in A549 cell model. 
A549 cells were infected with different MOIs of HRV1B (0.1, 1 and 5) for 2h in serum- free 
media and washed prior to re-immersing cells in fresh DMEM supplemented with 5% FBS 
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for 4, 16, 22, 46 or 70h at 33oC. A549 cells were exposed to poly I:C (10 µg/ml) for 6, 18, 24, 
48 or 72h in DMEM supplemented with 5%FBS. IL-8 protein levels released into cell 
supernatants were assessed by ELISA at the indicated time points. Results represent one 
independent experiment. 
 
We determined the antiviral and pro-inflammatory response to HRV infection in 
bronchial epithelial cells, where 16HBE14o- cells were infected with different 
multiplicity of infection of HRV and IL-8, IL-6, CCL5 and IFN1β gene expression and 
IL-8 release were determined at indicated time points (Figure 13).  
As shown in Figure 13, mRNA transcript levels of IL-8, IL-6, CCL5 and IFN1β genes 
follow a similar pattern, where a time-dependent induction occurs at early stages of 
infection peaking between 18-24h and a steady decrease is observed at later stages 
of infection, between 48-72h. Infection with HRV induced a marked increase in IL-8 
mRNA in a non-MOI and time-dependent manner, in which the highest upregulation 
was seen at 48h (15.1-fold MOI 0.1, 14.8-fold at MOI 1 and 14.3-fold MOI 5 over 
uninfected) [Figure 13 A]. IL-6 gene expression was strongly induced at 18 and 24h of 
infection exhibiting greater changes at MOI 5 (7.4-fold at 18h and 5-fold at 24h over 
uninfected) [Figure 13 B]. Infection with HRV strongly induced CCL5 mRNA levels. 
Highest induction of CCL5 mRNA was observed at 24h of infection (33-fold MOI 0.1, 
23.7-fold MOI 1 and 67.8-fold MOI 5 over uninfected cells) [Figure 13C]. A similar 
pattern was seen for IFN1β mRNA, where highest induction was observed after 24h 
of infection (3653.3-fold MOI 0.1, 2941.6-fold MOI 1 and 8807.8-fold MOI 5 over 
uninfected), followed by a steady decrease at 48h and at 72h [Figure 13 D]. Since the 
virus inoculum was a crude preparation, we used HeLa lysates as a control, and 
observed, using a threshold of 2, no upregulation of IL-8, and IL-6, CCL5 or IFN1β 
expression at any of the indicated time points and doses (Appendix 13). 
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Figure 13. HRV1B infection strongly induces IL-8, IL-6, CCL5 and IFNβ gene 
expression in 16HBE14o- cell model. 
16HBE14o- cells were infected with differing MOI of HRV1B (0.1, 1 and 5) for 2h in serum- 
free media and washed prior to re-immersing cells in fresh IMDM supplemented with 5% 
FBS for 4, 16, 22, 46 or 70h at 33oC. Total RNA was extracted from 16HBE cell lysates and 
qPCR was performed to determine the relative expression of IL-8 (A), IL-6 (B), CCL5 (C) and 
IFN1β (D). The GAPDH and β-actin genes were used as reference genes. Results represent 
one independent experiment. 
 
To confirm changes in mRNA transcript level were translated to changes at the 
protein level, we assessed cell supernatants for IL-8 protein release at the indicated 
time-points (Figure 14). In contrast to mRNA transcript data, induction of IL-8 release 
was only observed at later stages of HRV infection where concentrations of IL-8 
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were dramatically increased compared to uninfected cells (2103.7pg/ml MOI 0.1, 
1969.7pg/ml MOI 1 and 2054.9pg/ml MOI 5 compared to 244.5pg/ml for uninfected 
cells at 72h). In agreement with IL-8 mRNA expression data, induction of IL-8 release 
was not dependent on the MOI utilised to infect 16HBE cells. Poly I:C was used as a 
positive control and as expected strongly induced IL-8 release in a time-dependent 
manner. 
 
 
 
 
 
 
 
 
Figure 14. HRV infection induces IL-8 secretion in 16HBE14o- cell model. 
16HBE14o- cells were infected with different MOIs of HRV1B (0.1, 1 and 5) for 2h in serum- 
free media and washed prior to re-immersing cells in fresh IMDM supplemented with 5% 
FBS for 4, 16, 22, 46 or 70h at 33oC. 16HBE cells were exposed to poly I:C (10 µg/ml) for 6, 
18, 24, 48 or 72h in IMDM supplemented with 5%FBS. IL-8 protein levels released into cell 
supernatants were assessed by ELISA at the indicated time points. 
  
78 
 
3.3. Discussion 
 
The data in this supplementary chapter provides an analysis of rhinovirus 1B 
replication cycle and host cell response to viral infection based on a time course 
using two different cell models of the lower respiratory tract; adenocarcinoma 
human alveolar epithelial cells (A549 cells) and SV40-immortalized human bronchial 
epithelial cells (16HBE14o- cells). The respiratory epithelium is the primary site of 
rhinovirus infection and replication (Arruda et al., 1995). With the development of 
novel diagnostic techniques, such as PCR based assays, rhinovirus was shown to 
infect cells of the lower airway tract (Gern et al., 1997; Mosser et al., 2002). Several 
in vitro (Bochkov et al., 2010; Y. Chen et al., 2006) and in vivo (Proud et al., 2008) 
studies have provided a comprehensive notion of the host response to HRV 
infection, focusing on the gene expression patterns induced by rhinovirus infection 
of the lower respiratory tract. However, majority of the studies focused on a single 
species of HRV-A. Therefore, in this chapter we aimed to characterise HRV 1B 
infection in both alveolar and bronchial epithelial cell lines.   
Several different cell lines have been utilised to investigate rhinovirus, including 
HeLa cells (Amineva et al., 2011), A549 cells (Jang, 2006), 16HBE14o- cells (Xatzipsalti 
and Papadopoulos, 2007) and BEAS-2B (Hudy et al., 2010). However much of what 
is known about rhinovirus live cycle was generated in HeLa cell models. A study by 
Amineva et al. (2011) compared rhinovirus infection in human primary epithelial 
cells and HeLa cells and revealed that the replication patterns in both cell models 
were remarkably similar. These cells are also commonly used to propagate 
sufficient quantities of virus (Lee et al., 2015). Although, of notice, HeLa cells are not 
airway cells making them a poor cell model of HRV infection. For the purpose of this 
thesis, HeLa cells were only used to propagate HRV1B.  
A549 and 16HBE14o-cell models both originated from airway epithelium, where A549 
cell line was initiated from lung carcinomatous tissue (Giard et al., 1973) and 
16HBE14o-cell line was isolated from normal human bronchial epithelium and then 
transformed with the recombinant retrovirus LXSN16E6E7 containing the human 
HPV E6E7 gene and cloned (Tsao et al., 1996). 16HBE14o- cells maintain many of the 
characteristics of differentiated primary cells, such as the presence of tight 
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junctions and cilia (Cozens et al., 1994). Both A549 and 16HBE14o- cell models can 
therefore be determined to be adequate for the detailed investigation of 
respiratory virus-epithelial cell interactions.  
In order to investigate the ability of HRV1B to replicate in A549 and 16HBE14o- cells, 
HRV1B was exposed to airway cells for 2h at 33oC in serum-free medium. The two-
hour incubation period was required for the virus to attach to, and enter, epithelial 
cells. Cells were washed with saline to remove any unattached virus and re-
immersed in fresh media supplemented with 5% FBS. Viral RNA copies were 
determined in samples collected from A549 and 16HBE14o- cell lysates and cell 
supernatants at the indicated time points.   
HRV infection of alveolar epithelial cells resulted in a MOI and time-dependent 
increase in viral RNA copies isolated from A549 cell lysates, with a peak viral load at 
18h and at 24h post-infection, followed by a steady decrease at 48h and 72h post-
infection. Although, when the highest MOI used to infect cells, peak viral load was 
observed at 48h post-infection. To ensure that the increases in viral RNA copies 
extracted from lysates of A549 cell pellets were due to the ability of rhinovirus to 
assemble functional virus capable of infecting neighbouring cells, we investigated 
the viral RNA copies in A549 cells supernatants. Results showed that at 2h post-viral 
inoculation the viral RNA copies were detectable both intracellularly and in cell 
supernatants, where the number of viral RNA copies was 2.4x higher in cell 
supernatants compared to cell lysates. This initial quantification of copies of viral 
RNA collected from cell lysates may be in fact the detection of viral RNA from the 
inoculum most likely without active intracellular replication yet, indicating that 
rhinovirus 1B is rapidly taken-up by A549 cells. In the cell supernatants, the 
presence of such a high number of viral RNA copies may be in fact be attributed to 
detection of copies from the inoculum used to initially infect cells, which was not 
completely removed during the wash steps. At 6h after infection, no viral RNA was 
detectable intracellularly or in the extracellular environment. HRV at this stage has 
normally initiated replication but would not have completed a full replicative cycle 
not yet being released into cell supernatants. During viral replication there are two 
detectable RNA strands, the genomic positive RNA strand and the replicative 
negative RNA strand (Johnston et al., 1998). It is possible that at 6h post-virus 
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inoculation, rhinovirus has initiated replication and there is an abundance of one of 
the strands, most likely the replicative negative RNA strand. For the quantification 
of viral RNA copies, we utilised a specific kit from Primerdesign®, which provides 
HRV specific primers. The nucleotide sequence of these primers is unknown due to 
commercial reasons. Therefore, a possible explanation for the lack of intracellular 
viral RNA copies at 6h post-viral inoculation may be that these primers target the 
genomic positive RNA strand. Viral RNA copies were detected both intracellularly 
and in cell supernatants up to 72h post-viral inoculation. According to the data 
acquired from experiments analysing both intracellular and extracellular viral RNA 
copies, it is apparent that HRV1B achieved higher viral loads approximately at 48h 
post infection.  Viral RNA copies were also determined at 4, 16, 22, 46 and 70h post-
infection, and followed a similar replication pattern, although a striking difference 
was the greater number in viral RNA copies compared to the previous time-points 
utilised. This discrepancy may be due to the differences in viral stocks used.   
HRV1B infection of 16HBE14o- cells was found to occur most easily when the virus 
was exposed to sub-confluent monolayers of cells. The reasons behind this are 
unclear. 16HBE14o- cells maintain many of the characteristics of differentiated cells, 
such as the presence of tight junctions (Wan et al., 2000). Confluent monolayers of 
16HBE14o- cells can form tight junctions, which can act as a barrier to virus entry 
and spread throughout the airway monolayer (Vareille et al., 2011). Differentiated 
human airway epithelial cells were shown to be more resistant to rhinovirus 
infection compared to poorly differentiated cells (Lopez-Souza et al., 2004). 
Although 16HBE14o- cells are relatively undifferentiated, they form tight junctions in 
confluent monolayers, which could explain the decreased susceptibility to 
rhinovirus infection. This aligns with other work, as A549 cells, which fail to form a 
tight epithelial barrier, exhibit increased susceptibility to rhinovirus infection when 
the virus is exposed to a confluent monolayer of cells (Grek et al., 2009).   
HRV infection of bronchial epithelial cells resulted in a MOI and time-dependent 
increase in intracellular viral RNA copies, with a peak viral load at 16h and at 22h, 
followed by a steady decrease at 46h and 70h post-infection. In accordance with 
our data, both A549 and 16HBE cell lines are permissive to HRV1B. The replication 
cycle of HRV is similar in both alveolar and bronchial epithelial cells, where viral 
81 
 
replication occurs rapidly and viral synthesis peaks within 48h and declines by 72h 
after infection.  
To further characterise alveolar and bronchial epithelial cells as relevant cell models 
for HRV1B infection, we analysed the mRNA levels and surface receptor expression 
of ICAM-1, LDLr and vLDLr on these cell lines. The cellular receptors for HRV1B are 
LDLr and vLDLr, and although HRV1B does not require ICAM-1 to enter airway cells, 
this cellular receptor has been shown to be induced during minor group HRV 
infection, which indicates that induction of ICAM-1 is not receptor- or serotype 
restricted. IL-8, TNFα and IL1β, cytokines known to be released following rhinovirus 
infection, were shown to increase ICAM-1 expression on uninfected cells (Sethi et 
al., 1997). ICAM-1 is therefore indirectly induced by the minor group of viruses 
possibly through inflammatory mediators produced after viral infection (Matsukura 
et al., 1996). 
 
These receptors, found in cell surface of epithelial cells, are important for rhinovirus 
binding, uptake and signal transduction processes (Kim and Schleimer, 2009). 
Results indicated that ICAM-1 and LDLr gene and protein basal levels were highly 
expressed in 16HBE14o- cells, similar to basal levels observed on HeLa cells. A549 
cells highly expressed LDLr mRNA and surface protein levels; however, ICAM-1 
expression was considerably lower compared to 16HBE14o- and HeLa cells. vLDLr 
basal mRNA levels were high in all cell lines investigated. A study by Suzuki et al. 
(2001) showed that using an antibody against LDL receptor inhibited the RV2 (minor 
group) infection without affecting RV14 (major group) infection. This suggests that 
LDL receptor is specific for minor group of rhinoviruses. LDL receptor is shown to be 
highly expressed in A549 and 16HBE14o- cells, which makes these cells highly 
permissive to HRV1B infection, and relevant cell models of infection for the minor 
group of rhinovirus.  
 
To assess the HRV-induced pro-inflammatory and antiviral responses by alveolar 
and bronchial epithelial cells we determined the gene expression induced at 
different stages of rhinovirus infection by qPCR analysis. In addition, we assessed 
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cell supernatants for IL-8 protein release at the different time-points during HRV 
infection.  
Human rhinovirus infection can stimulate airway epithelial cell pro-inflammatory 
chemokines and cytokine production. We assessed IL-8, IL-6 and CCL5 gene 
expression induced at different stages of rhinovirus infection, as these pro-
inflammatory mediators have been shown to be rapidly and strongly induced during 
rhinovirus infection in vitro (Subauste et al., 1995) and in vivo (Zhu et al., 1997, 
1996). These inflammatory mediators have been extensively studied and associated 
with pathogenesis of rhinovirus infection (Chun et al., 2013; Grünberg et al., 1997).  
HRV1B infection of alveolar A549 epithelial cells induced IL-8 mRNA within 24h after 
infection (MOI 5) with marked accumulation of IL-8 in supernatants within 48-72h 
after infection. This is agreement with previous earlier studies demonstrating that 
infection of epithelial cells with rhinovirus (Proud et al., 2008; Subauste et al., 1995) 
also induce IL-8 production within this time-frame. IL-8 mRNA levels tended to 
decrease at subsequent time points; however IL-8 secretion increased with later 
time points. This is in agreement with a study by Chun et al. (2013) demonstrating 
an increase IL-8 release from A549 cells in a time-dependent manner. Although at 
later time point after infection (48-72h), it is difficult to distinguish between 
changes induced by direct viral induction compared to those induced by feedback 
action of other cellular products induced by viral signalling. IL-6 and CCL5 gene 
expression induction was seen within 48h and increased at subsequent time points. 
This was also reported in RSV studies, in which increased levels of IL-6 in 
supernatants were only detected at later time points (Noah and Becker, 1993). Of 
interest, HRV infection induced IL-8, IL-6 and CCL5 mRNA expression in a dose-
dependent manner, which is indicative of a direct correlation between the viral load 
and pro-inflammatory induction. Previous studies have demonstrated a direct 
correlation between virus titer and occurrence, along with severity of infection 
(Douglas et al., 1966).  
HRV1B infection strongly induced IL-8, IL-6 and CCL5 mRNA expression in bronchial 
epithelial cells. IL-8, IL-6 and CCL5 genes followed a similar pattern of expression, 
where enhanced mRNA expression was seen within 18h of infection followed by a 
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decrease at 48h and 72h of infection; this coincided with an increase viral titer seen 
at 18h and at 24h followed by a drop at later stages of the infection. Previous 
studies have reported HRV ability to induce mRNA expression of several different 
genes at early stages of infection, revealing a significant difference between HRV-
infected and uninfected alveolar epithelial cells at 6h post-infection (Reza Etemadi 
et al., 2017) although this contrasts with other studies which have reported no 
upregulation of differentially expressed genes at early stages of infection and were 
in agreement with our study showing increased upregulation within 24h of infection 
(Y. Chen et al., 2006; Chun et al., 2013). Cell supernatants were assessed for IL-8 
release and results indicated a marked increase in IL-8 release at 48h and at 72h of 
infection.  
IL-8, IL-6 and CCL5 mRNA expression were highly expressed by bronchial epithelial 
cells compared to alveolar epithelial cells following rhinovirus infection. A549 and 
16HBE cells are both permissive to HRV1B and relatively similar viral loads were 
observed in these two cell lines. It is unclear why rhinovirus infection induces a 
much higher pro-inflammatory response in 16HBE14o-cell line compared to A549 
cell line.  ICAM-1 expression was shown to be enhanced by both major and minor 
group of viruses (Papi and Johnston, 1999). Pro-inflammatory mediators produced 
following viral infection can lead to an increase in ICAM-1 expression (Papi and 
Johnston, 1999; Sethi et al., 1997). We compared basal ICAM-1 expression on 
alveolar epithelial cells and bronchial epithelial cells and observed a marked 
difference in expression. The basal expression of ICAM-1 on A549 cells is much 
lower compared to 16HBE14o- cells. ICAM-1 mediates not only viral entry but also 
the activation of signalling pathways that lead to an enhanced inflammatory 
response to rhinovirus infection by airway epithelial cells. Syk, an important 
immunoregulatory protein tyrosine kinase, has been shown to be downstream of 
ICAM-1 mediating the inflammatory response of the airway epithelium via 
activation of p38 MAPK pathway. However, syk-mediated inflammatory response 
occurs as a result of ICAM-1 engagement with HRV rather than viral replication 
(Wang et al., 2006). This signals that viral replication of the minor group of virus 
would not suffice for an ICAM-1-enhanced inflammatory response, as HRV1B does 
not directly engage with ICAM-1. Nevertheless, ICAM-1 was shown to initiate NF-kB 
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activation upon viral entry in bronchial epithelial cells exposed to influenza virus 
(Othumpangat et al., 2016). NF-kB pathway plays an essential role in the regulation 
of inflammatory responses (Ghosh et al., 1998) and in airway epithelial cells, HRV-
induced IL-8 and IL-6 production is mediated, in great extent, by an NFkB-
dependent transcription activation process (Zhu et al., 1996 and Zhu et al., 1997). 
Therefore, it is possible that HRV1B replication upregulates ICAM-1 which in turn 
activates NF-kB signalling pathway leading to an enhanced inflammatory response. 
Due to the fact that A549 cells do not express high basal levels of ICAM-1, this could 
indeed explain the defective pro-inflammatory response to HRV1B infection 
compared with infection of 16HBE14o- cells.  
Induction of type I interferon is a common phenomenon in HRV infection of airway 
epithelial cells. Rhinovirus infection of tracheobronchial and bronchial epithelial 
cells has been shown to result in a significant induction of IFNβ (Y. Chen et al., 2006; 
Wark et al., 2005). In this chapter, we showed that HRV1B infection of alveolar 
epithelial cells did not result in a significant induction of IFN 1β mRNA expression. 
IFN1β mRNA expression was induced at later stages- 72h of infection- at the highest 
dose of HRV used to infect cells. Similar studies have reported that HRV14 and 
HRV72 infection failed to induce high levels of IFN1β mRNA in A549 cells (Kotla et 
al., 2008; Reza Etemadi et al., 2017). Kotla et al. (2008) revealed that the low levels 
of IFN1β could be explained by the impaired activation of IRF3 in the presence of 
the activated NF-kB and ATF-2. IRF-3 is essential for the activation of the type I 
interferon response following viral infection (Hiscott, 2007). In contrast, IFN 1β 
mRNA expression was strongly induced in 16HBE14o- cells, with the highest fold-
changes occurring at 24h post infection. Similar results were observed by Chen et al. 
(2006) using tracheobronchial cells.  
This chapter shows a detail analysis of HRV1B-epitheial cell interaction using 
alveolar and bronchial epithelial cells with the aim of determining the most suited 
cell model for rhinovirus 1B infection in order to study the modulatory effects of the 
human cathelicidin, LL-37, on the host response to viral infection. The findings 
based on these models led us to conclude that the most relevant cell model is 
16HBE14o- cells derived from normal human bronchial epithelium. 16HBE14o- cells 
were permissive to HRV1B exhibiting high basal levels of surface LDLr, vLDLr and 
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ICAM-1, as well as, responding to infection with a strong and rapid production of 
antiviral and inflammatory mediators. Additionally, 16HBE14o- cells maintain many 
of the characteristics of primary differentiated cells, such as the presence of tight 
junctions (Cozens et al., 1994), better mimicking the differentiated airway 
epithelium in comparison to A549 cell line. Furthermore, 16HBE14o- cells are easily 
maintained, and avoid several of the difficulties including high cost and 
reproducibility associated with primary cell culture methods (Ehrhardt et al., 2002).  
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Chapter 4. Investigating the antiviral activity of LL-37 against 
rhinovirus 
 
4.1. Introduction 
 
The underpinning mechanism for cathelicidin-mediated antiviral activity remains 
largely indeterminate. The capacity of LL-37 to reduce viral infection has been 
associated with the ability of the peptide to directly target the virus particles 
(Alagarasu et al., 2017; Barlow et al., 2011; Currie et al., 2013; Harcourt et al., 2016), 
as well as targeting the host cell (Currie et al., 2013; Harcourt et al., 2016).  
In this chapter we aim to characterise the antiviral activity of LL-37 against 
rhinovirus 1B in alveolar and bronchial epithelial cells in the context of a number of 
LL-37 concentrations and exposure regimens. 
 
4.1.1. Rhinovirus targeted- airway epithelial cell receptors 
 
Human rhinoviruses are one of the most common causes for airway infections and 
exacerbations of COPD and bronchial asthma. Around 90% of HRV serotypes use 
ICAM-1 to infect target cells, and these serotypes are known as the major group of 
rhinovirus (Greve et al., 1989). The remaining serotypes, known as the minor group 
of virus, can enter host cells via the LDL receptor family (Uncapher et al., 1991). 
ICAM-1 (CD54) is a cell surface glycoprotein that belongs to the immunoglobulin 
superfamily, and contains a cytoplasmic tail, a transmembrane region and five 
extracellular domains for binding to leukocytes (Simmons et al., 1988). ICAM-1 has 
been proposed to be ligand for both lymphocyte function-associated antigen-1 
(LFA-1) [Rothlein et al., 1986] and Mac-1 (CD11a/CD18) [Diamond et al., 1990], 
which are members of the β2 subfamily of integrins. The interactions between 
ICAM-1 expressed in epithelial and endothelial cells, and the β2-integrins expressed 
in leukocytes are essential for the complex cascade of adhesive events, which 
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include leukocyte rolling, adhesion and trans-(endo)epithelium migration to the 
sites of inflammation (Springer, 1990).  
ICAM-1 has been shown to modulate eosinophil and lymphocyte infiltration. There 
is substantial evidence that ICAM-1 plays an important role in the activation of 
these inflammatory cells contributing to the pathogenesis of asthma (Manolitsas et 
al., 1994). Epithelial ICAM-1 expression is increased by allergen challenge (Ciprandi 
et al., 1994), upon stimulation with TNF-α and IFNγ (Chang et al., 2002; Krunkosky 
et al., 2000), or other stimuli, such as LPS (Fakler et al., 2000; Madjdpour et al., 
2000), and exposure to pathogens (Avadhanula et al., 2006; Papi and Johnston, 
1999). Notably, while ICAM-1 acts as the cellular receptor for the major group of 
rhinovirus, it has been demonstrated that rhinovirus can induce a marked increase 
in ICAM-1 expression, in both primary bronchial epithelial cells and in A549 cell line 
(Papi and Johnston, 1999). HRV infection of airway epithelial cells mediates 
increased surface ICAM-1 expression via NF-B-mediated transcriptional 
upregulation. The minor group of rhinovirus is also able to upregulate surface ICAM-
1 expression in airway cells, which indicates that the induction of ICAM-1 is not 
receptor- or serotype restricted (Papi and Johnston, 1999; Terajima et al., 1997). 
Therefore, rhinovirus infection may cause both a direct increase in ICAM-1 in upper 
and lower respiratory tract epithelial sites, but also an indirect increase via other 
factors that are produced as a result of the viral infection.  
LDL receptors are important in lipid metabolism through facilitating the transport of 
cholesterol into cells via receptor-mediated endocytosis. It is known that these 
receptors are expressed by airway epithelial cells and can be used by the minor 
group of rhinoviruses to access and infect these cells. In the airway epithelium, LDLr 
has been shown to negatively regulate house dust mite (HDM) - induced airway 
hyper-responsiveness (AHR) by binding to apolipoprotein E. Thus, the activation of 
the apolipoprotein E-low-density lipoprotein receptor pathway may be a novel 
target for asthma therapy (Yao et al., 2010). The LDLr, VLDLr and LDLR-related 
protein (LRP) are known to bind to, and internalise, apolipoprotein E, which is 
expressed by lung macrophages, functionally attenuating airway inflammation. The 
vLDLr is a multi-ligand receptor, which is known to mediate pleiotropic biological 
processes (Fredriksson et al., 2014). However, there is a relative paucity of 
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information on the involvement of vLDLr in inflammatory or immune responses. 
Interestingly, a study by Baitsch et al. (2011) revealed that the apolipoprotein E-
very-low-density lipoprotein receptor pathway promoted the conversion of a pro-
inflammatory M1 macrophage phenotype to the anti-inflammatory M2 macrophage 
phenotype. A recent study has also identified a novel role for the vLDLr receptor in 
which they supress DC-mediated Th2 adaptive immune responses in response to 
HDM- induced airway hyperresponsiveness (Fredriksson et al., 2014). Taken 
together, these studies point towards the involvement of LDL receptor family 
members in limiting excessive HDM-induced airway inflammation by binding to 
apolipoprotein-E, and this may represent a novel target for the development of 
treatment approaches for asthma.   
The minor group HRV2 is known to infect primary airway cells via binding to the LDL 
receptor expressed on these cells. It has been demonstrated that HRV2 infection 
can result in an increased production of IL-1β, IL-8, IL-6 and TNF-α and upregulation 
of cell surface LDL receptor expression and mRNA expression in human tracheal 
epithelial cells. It is thought that increased LDL receptor expression by HRV2 
infection may be mediated through the activation the transcriptional factor SP-1, 
which was shown to be upregulated by HRV2 infection in human tracheal epithelial 
cells. It was also shown that both minor and major groups induced LDL receptor 
expression in human airway cells. An interesting finding showed that blocking LDLr 
inhibited HRV2 infection and the production of cytokines in response to viral 
infection, but had no effect on HRV14 infection (Suzuki et al., 2001).  
The modulation of cell surface receptors has been proposed as a possible HDP-
mediated antiviral mechanism targeting the host cell. The β-defensins HBD2 and 
HBD3, but not HBD1, were shown to reduce cell surface expression of CXCR4, but 
not CCR5, during HIV-1 infection (Feng et al., 2006; Quiñones-Mateu et al., 2003). 
The chemokine receptors CXCR4 and CCR5 function as co-receptors for HIV-1 entry 
into CD4+ T cells and peripheral blood mononuclear cells (PBMCs) (Bleul et al., 
1997). Studies further confirmed that CXCR4 was down-modulated in PBMCs by 
HBD2 and HNP1 (Seidel et al., 2010). As previously noted, HRV enters respiratory 
epithelia cells only via ICAM-1 (major group) or LDLr (minor group). We propose 
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that LL-37 may modulate the HRV-targeted receptor expression on bronchial 
epithelial cells as a mechanism to prevent virus entry and dissemination.  
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4.2. Materials and Methods 
 
4.2.1. Virus purification 
HRV1B virus stock was transferred into Vivaspin protein concentrator spin columns 
(100.00MW filter size column, GE Healthcare Life Sciences, Chalfont Saint Giles, UK) 
and centrifuged at 775 RCF (Eppendorf centrifuge 5804 series rotor S-4-72, 
Stevenage, UK) for 2h at 4oC to concentrate the virus. A 30% sucrose gradient was 
prepared in DPBS (30% sucrose w/v, pH 71.-7.2). Using a syringe, sucrose was 
transferred into an ultracentrifuge tube (Quick-Seal®, Polypropylene, 8 mL, 
Beckman coulter, High Wycombe, UK) and the concentrated virus was gently 
layered on top of the sucrose gradient. The sucrose gradient with layered virus was 
then ultracentrifuged at 76 790 RCF for 3h at 16oC in a SW32.1Ti Swinging Bucket 
Rotor (Beckman coulter, High Wycombe ,UK). The sucrose was discarded and the 
pellet was gently washed with PBS and re-suspended in fresh PBS. The concentrated 
virus was aliquoted and was stored at -80oC. 
 
4.2.2. Virus purification for transmission electron microscopy analysis 
HeLa cells were grown at 37oC/5% CO2 in T175 flasks and infected with HRV1B when 
they had reached a confluency of 60-70%. HRV1B was propagated in HeLa cells by 
infecting cells in serum-free DMEM for 2h at 33oC with an MOI 10. The inoculum 
was then removed and cells were incubated for 2-3 days in low serum media (5% 
FBS supplemented DMEM). Cells were then subjected to three cycles of 
freeze/thaw before harvesting the supernatant containing released virus. The 
supernatant was collected and stored at -80oC in BD Falcon tubes. The virus stock 
was thawed at room temperature and centrifuged at 3500 RCF for 30 minutes at 
4oC. The supernatant was recovered and cell pellet was disposed. An 8% PEG 
solution was added to supernatants and left overnight at 4oC in order to precipitate 
the virus. The supernatant was centrifuged at 3500 RFC for 0.5h at 4oC in order to 
pellet the virus. The supernatant was then discarded and the pellet was re-
suspended in HEPES buffer (50mM Hepes, 200 mM NaCl, pH=8). The solution was 
centrifuged at 3500 RCF for 0.5h at 4oC and the supernatant was transferred to an 
ultra-clear™ centrifuge tube (Beckman Coulter, High Wycombe UK). A solution of 
92 
 
30% sucrose in HEPES buffer (2ml) was added to the bottom of the tube to create a 
gradient allowing the virus to be positioned above the sucrose. Tubes were 
centrifuged at 77,140 RCF for 3h at 4oC (SW41 rotor, Beckman Coulter, High 
Wycombe, UK). After centrifugation, the supernatants were discarded and 500µl of 
HEPES buffer was added to the pellet and left overnight at 4oC. The pellet was 
carefully re-suspended in the buffer and centrifuged at 3500xg for 1h at 4oC. 
Supernatant was recovered and kept on ice; HEPES buffer (200µl) was added to the 
pellet and centrifuged at 3,500 RCF for 1h at 4oC. A sucrose gradient (15-45%) was 
constructed with the help of a gradient master (Biocomp, York, UK). The 
supernatant was placed on top of the gradient and ultracentrifuged at 77,140 RCF 
for 3h at 4oC (SW42 rotor, Beckman coulter, High Wycombe UK). Using a white light 
under the ultraclear tube, the blue band corresponding to the virus and other 
cellular components was visualised. Desalting columns (Thermo Scientific™ Zeba 
Spin 7K MWCO Desalting Columns, Loughborough, UK) were subsequently used to 
remove sucrose. The virus fractions were added to desalting columns and 
centrifuged for 2 minutes at 1000 RCF. The virus was collected and transferred into 
Vivaspin Protein concentrator spin columns (100.00MW filter size column, GE 
Healthcare Life Sciences, Chalfont Saint Giles, UK) and centrifuged at 3,500 RCF for 
10 minutes. Concentrated virus was stored at -80oC until further use.  
4.2.3. SDS-PAGE 
Each fraction obtained from the ultracentrifuged sucrose gradient was mixed with 
loading buffer (NuPAGE™ LDS sample buffer 4x, Thermo Fisher Scientific, Paisley, 
UK) and heated in a heating block for 2 minutes at 95oC. The samples and protein 
ladder (PageRuler™ prestained protein ladder, 10 to 180kDA, Thermo Fisher 
Scientific, Loughborough, UK) were loaded into the wells of a precast 
polyacrylamide gel (4-20% Mini-PROTEAN® TGX ™ Precast protein gel, Bio-Rad, 
Watford, UK). The gel was run for 1h at 120V and the proteins were detected by 
staining the gel with InstantBlue™ (Expedeon, Cambridge, UK) for 15mins.  
4.2.4. Transmission Electron Microscopy  
For negative stain transmission electron microscopy a concentration of 73 µg/ml of 
purified rhinovirus 1B was exposed to 50µM of LL-37 or endotoxin-free water and 
incubated for 2h on ice. A volume of 1µl of sample was applied to carbon coated 
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copper grids (agar scientific, Stansted, UK). The stained layer was dried and imaged 
by TEM Technai T12 operated at 120kEV.  
For cryo-transmission electron microscopy a concentration of 136 µg/ml of purified 
rhinovirus 1B was exposed to 50µM of LL-37 or endotoxin-free water and incubated 
for 5 minutes on ice. A volume of 1µl of sample was applied to cryoEM C-flat™ holey 
carbon and copper grids CF-2/1-2C (Protochips, USA) and vitrified with a FEI 
Vitrobot IV (FEI, Hillsboro, OR). Electron micrographs were collected on a FEI 
Technai Polara microscope operated at 300kEV with the grids at liquid nitrogen 
temperature. Micrographs were semi-automatically acquired with EM-tools (TVIPS 
software). The absolute magnification of the digital micrographs collected on a 
Gatan ultrascan 4000 UHS CCD camera was 37,037x corresponding to a pixel size of 
1.35 Å on a molecular scale.  
 
4.2.5. Molecular quantification of viral infectivity 
To determine rhinovirus infectivity, A549 and 16HBE14o- cells were used as in vitro 
models of respiratory infection and a number of treatment approaches were 
employed. Briefly, A549 or 16HBE14o- cells were seeded in a 12-well plate and 
incubated in a heated humidified incubator at 37oC/5% CO2, and were subsequently 
subjected to two different treatment approaches. For the “virus-peptide” approach, 
HRV1B was exposed to varying concentrations of LL-37 for 2h at 33oC in serum-free 
media. Cells were exposed to the mixture for 1h, washed and re-immersed in low-
serum (5% FBS) supplemented media (DMEM or IMDM) for 23h at 33oC (Figure 15). 
 
Figure 15. “Virus-peptide” experimental regimen. 
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HRV1B was exposed to varying concentrations of LL-37 (10 µg/ml, 30 µg/ml or scramble LL-
37 30 µg/ml) for 2h at 33oC in serum-free media. Cells (A549 or 16HBE14o-) were exposed to 
the mixture for 1h, washed and re-immersed in low-serum (5% FBS) supplemented media 
(DMEM or IMDM) for 23h at 33oC.  
 
For the “cell-peptide” approach, A549 or 16HBE14o- cells were infected with HRV1B 
for 2h at 33oC in serum-free media, washed with saline and exposed to LL-37 for 
22h at 33oC in DMEM or IMDM supplemented with 1% (v/v) Ultroser G (Figure 16).  
 
Figure 16.”Cell-peptide” experimental regimen. 
Airway epithelial cells (A549 or 16HBE14o- cells) were infected with HRV1B for 2h at 33oC in 
serum-free media, washed and exposed to LL-37 37 (10 µg/ml, 30 µg/ml or scramble LL-37 
30 µg/ml) for 22h at 33oC in DMEM or IMDM supplemented with 1% (v/v) Ultroser G. 
 
A549 and 16HBE14o- cells were pre-treated with LL-37 prior to HRV infection using 
different LL-37 exposure times. In brief, for the “2h treatment” A549 or 16HBE14o- 
cells were exposed to LL-37 (0-30µg/ml) for 2h at 33oC in DMEM or IMDM 
supplemented with 1% (v/v) Ultroser G. Cells were washed and infected with HRV1B 
for 2h in serum-free media, followed by washing and re-immersing cells in 5% FBS 
supplemented media for 20h at 33oC (Figure 17).  
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Figure 17. The 2h treatment” experimental regimen. 
Airway epithelial cells (A549 or 16HBE14o- cells) were exposed to LL-37 (10 µg/ml, 30 µg/ml 
or scramble LL-37 30 µg/ml) for 2h at 33oC in DMEM or IMDM supplemented with 1% (v/v) 
Ultroser G. Cells were washed and infected with HRV1B for 2h in serum-free media, 
followed by washing and re-immersing cells in 5% FBS supplemented media for 20h at 33oC. 
 
For the “24h treatment” regimen, A549 cells were exposed to LL-37 (0-30 µg/ml) for 
24h at 33oC in DMEM supplemented with 1% (v/v) Ultroser G. Cells were washed 
and exposed to HRV1B for 2h in serum-free media, followed by washing cells with 
saline and re-immersing them in 5% FBS supplemented DMEM for 20h at 33oC 
(Figure 18).  
 
Figure 18. The “24h treatment” experimental regimen. 
A549 cells were exposed to LL-37 (10 µg/ml, 30 µg/ml or scramble LL-37 30 µg/ml) for 24h 
at 33oC in DMEM supplemented with 1% (v/v) Ultroser G. Cells were washed and exposed 
to HRV1B for 2h in serum-free media, followed by washing cells with saline and re-
immersing them in 5% FBS supplemented DMEM for 20h at 33oC.  
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For the “24h + wash treatment” regimen, A549 cells were exposed to LL-37 for 2h in 
DMEM supplemented with 1% (v/v) Ultroser G, washed and left in contact with 5% 
FBS supplemented DMEM for 22h at 33oC prior to HRV1B infection for 2h in serum-
free DMEM. A549 cells were washed and re-immersed in 5% FBS supplemented 
DMEM for 20h at 33oC (Figure 19).  
 
Figure 19. The “24h + wash treatment” experimental regimen. 
A549 cells were exposed to LL-37 (10 µg/ml, 30 µg/ml or scramble LL-37 30 µg/ml) for 2h in 
DMEM supplemented with 1% (v/v) Ultroser G, washed and left in contact with 5% FBS 
supplemented DMEM for 22h at 33oC prior to HRV1B infection for 2h in serum-free DMEM. 
A549 cells were washed and re-immersed in 5% FBS supplemented DMEM for 20h at 33oC.  
 
After each treatment, media was aspirated and 300µl RLT buffer from RNeasy®mini 
kits (Qiagen, Crawley, UK) was added to each well and cells were scrapped of the 
surface of the plate with a cell-scrapper. Cell lysates were stored at -80oC until 
extraction. Total RNA isolation was performed using the RNeasy® mini kit system 
following manufacturer’s protocols. RNA integrity was determined using an Agilent 
Bioanalyser (Agilent, UK), where RIN≥8 was used as a quality filter for further 
downstream analyses. Viral RNA was quantified using the Genesig Human 
Rhinovirus (all subtypes) qPCR kit (PrimerDesign, Camberley, UK) according to 
manufacturer’s protocols. 
 
4.2.6. qPCR to determine mRNA  levels of IFN1β, PKR and IL-8 
Total RNA (0.5-1μg) was transcribed to cDNA using Precision RT all-in-one mix kit 
(PrimerDesign Ltd, Camberley, UK) as per manufacturer’s instructions. qPCR 
reactions included cDNA (25 ng), 250 nM specific primers (Table 2) and SYBR green 
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mastermix (PrimerDesign LTtd, Camberley,UK) in total volume of 20µl. qPCR was 
performed using the StepOnePlus instrument (Applied Biosystems,Thermo Fisher 
Scientific, Loughborough, UK). A panel of six human reference genes were 
evaluated using a geNorm kit (Primerdesign, Camberley, UK) and qbase+ (Biogazelle, 
Zwijnaarde, Belgium) software. The geometric means of ACTB and GAPDH genes 
were selected as the most stable combination for normalization in both 16HBE and 
A549 cell lines. The 2ΔΔCt method was used and data is represented as fold change 
over untreated cells (Pfaffl MW, 2004). Statistical analysis was performed on the Δct 
values, unless otherwise stated in figure legend. We applied a threshold of two-fold 
above unstimulated control to consider upregulation of the expression of the genes 
of interest.  
 
Table 2. qPCR primer sequences 
Target Forward Reverse Reference 
GAPD
H  
AAGCTCATTTCCTGGTATGAC
A 
TCTTACTCCTTGGAGGCCAT
GT 
(Wang et 
al., 2012) 
ACTB GGACTTCGAGCAAGAGATGG AGGAAGGAAGGCTGGAAGA
G 
(Tarrats et 
al., 2011) 
IL-8 ACTGAGAGTGATTGAGAGTG
GAC 
AACCCTCTGCACCCAGTTTT
C 
(Tsai et al., 
2009) 
IFN1β TCTGGCACAACAGGTAGTAGGC GAGAAGCACAACAGGAGAGCA
A 
 
(Warnking 
et al., 2015) 
PKR CAGTTTGCCTTCCTGGATTTGTA CTTCCCGTATCCTGGTTGGAA Designed 
 
4.2.7. Quantification of IFN1β release by 16HBE14o- cells  
Briefly, HRV1B was exposed to varying concentrations of LL-37 for 2h at 33oC in 
serum-free IMDM media. 16HBE14o- cells were exposed to the mixture for 1h, 
washed and re-immersed in low-serum (5% FBS) supplemented media IMDM for 
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23h at 33oC. Supernatants from each well were collected and stored at -80oC until 
further use. Supernatants were analysed for the release of IFN1β by ELISA, as per 
the manufacturer’s instructions (Human IFN beta ELISA kit, pbl Assay Science, 
Piscataway Township, USA).  
 
4.2.8. Viral titer assessment (TCID50/ml) 
The infectious titer of rhinovirus was determined by TCID50 assay. For experimental 
assessment of the antiviral effects of LL-37, WI-38 cells were seeded at 2x104 per 
well in a 96-well plate and cultured at 37oC/5% CO2 overnight. Supernatants from 
experiments in which HRV1B (MOI 5) was exposed LL-37 prior to cell infection 
(“virus-peptide”) or 16HBE14o- cells which were first infected with HRV 1B (MOI5) 
prior to LL-37 treatment (“cell-peptide”) were collected and used for TCID50 assay. 
Briefly, these supernatants were 10-fold diluted in serum-free media and 
subsequently added to WI-38 cells, which were then incubated for 1h at 33oC. 
Following incubation, the inoculum was removed and cells were cultured in 5% FBS 
supplemented DMEM for a period of 5 days before assessment of cytopathic 
effects. TCID50 assay was determined using the Reed-Muench method (Reed and 
Muench, 1938).  
 
4.2.9. Flow cytometric analysis 
16HBE14o- cells were seeded at 1x105 per well in a 12-well plate and cultured 
overnight at 37oC / 5% CO2. HRV1B (MOI 5) was exposed to varying concentrations 
of LL-37 (0-30µg/ml) for 2h at 33oC in serum-free IMDM. 16HBE cells were exposed 
to HRV+LL-37 mixture for 1h and then washed and exposed to 5% FBS 
supplemented IMDM for a further 23h or 47h according to treatment regimen. Cell 
media was aspirated and stored for further analysis and cells were washed with 
saline before incubation with 2x Trypsin/EDTA solution for 5 minutes to detach cells 
from the surface of the plate. Complete culture media was added to neutralise 
trypsin and cells were transferred into BD Falcon 5 ml polystyrene tubes and 
centrifuged at 230×g for 5minutes. Supernatant was discarded and cells were 
washed with 10% FBS in PBS and centrifuged at 230×g for 5 minutes. Supernatant 
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was discarded leaving approximately 200µl of 10% FBS in PBS in contact with cells 
for 20 minutes at room temperature for further blocking. Without removal of the 
blocking solution, 2.5µl of each antibody was added to each tube (human LDLr APC 
conjugated antibody, R&D Abingdon, UK; human CD54 PE conjugated antibody, 
BioLegend, London, UK; human vLDLr FITC conjugated antibody, LSbio Nottingham, 
UK). Isotype controls for ICAM-1 (PE mouse IgG1, k isotype control FC antibody, 
Biolegend, London, UK) and LDLr (mouse IgG 1 APC-conjugated antibody, R&D 
Abingdon, UK) were also added to respective tubes. Unstained cells were retained 
as a negative control. Cells were incubated with antibodies for 25 minutes in the 
dark at 4oC and subsequently washed twice with 2 ml of PBS. Cells were then re-
suspended in 200µl of PBS before analysis by flow cytometry (FACS Calibur, BD 
biosciences, Heidelberg, Germany).  
 
4.2.10. Confocal microscopy  
16HBE14o- cells were seeded at 2.5x104 per well in an 8-well chamber slide (Thermo 
Scientific™, Loughborough, UK) and cultured overnight in a heated humidified 
incubator at 37oC / 5%CO2. A purified stock of HRV1B (MOI 5) was exposed to 
varying concentrations of LL-37 (0-30µg/ml) for 2h at 33oC in serum-free IMDM. 
16HBE14o- cells were exposed to the HRV+LL-37 mixture for 1h and then washed 
and exposed to 5% FBS supplemented IMDM for further 23h. Supernatants were 
removed and cells were washed with warm PBS. Cells were fixed for 20 minutes at 
room temperature using 4% paraformaldehyde. Cells were washed 3x times with 
PBS and permeabilised with 0.1% Triton-X in PBS for 5 minutes. Cells were washed 
with PBS to remove Triton-X and subsequently blocked with 5% goat serum in PBS 
for 1h at room temperature. The blocking solution was removed and cells were 
incubated with a pan enterovirus monoclonal antibody (mouse IgG2a, 
L66J,Invitrogen, ThermoFisher Scientific, Loughborough, UK) diluted in 5% goat 
serum in PBS (1:200) overnight at 4oC. The primary antibody was removed and cells 
were washed 4 times with 0.05% Tween20 in PBS. Goat anti-mouse IgG, Alexa 
Fluor® 488 (ThermoFisher Scientific, Loughborough, UK) was diluted in 5% goat 
serum in PBS (1:1000) and incubated with cells for 1h, in the dark, at room 
temperature. Cells were washed 3 times with 0.05% Tween20 in PBS followed by 2 
100 
 
more washes with PBS. DAPI (1mg/ml) was diluted 1:1000 in PBS and incubated 
with cells for 10 minutes. Cells were washed 3 times with PBS before adding 
mounting media (Vectashield, Vector Laboratories, Peterborough, UK) and 
removing the plastic structure. Slide was covered with a glass coverslip and edges 
were sealed with nail polish. Slides were kept in the fridge protected from direct 
light. Stained cells were assessed using a Zeiss LSM 880 AxioObserver Z1 Confocal 
fluorescent microscope (wavelengths: 405 nm, 488 nm, 594 nm, and laser power set 
at 2%).  
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4.3. Results 
 
4.3.1. Assessment of the antiviral activity of LL-37 against rhinovirus  
 
In order to assess the antiviral potential of the human cathelicidin, LL-37, against 
human rhinovirus, the A549 airway epithelial cell line was used as cell model of 
infection. To mimic interactions that could occur in vivo between LL-37 and HRV in 
the airway surface liquid before infection of airway cells, the virus was incubated 
with LL-37 prior to A549 cell infection and the number of viral RNA copies were 
assessed by qPCR after 24hours. The incubation of HRV1B with LL-37 peptide 
resulted in a significant reduction in viral RNA copies (****p<0.0001) compared to 
virus alone (Figure 20A). A scrambled LL-37 peptide exhibited no antiviral effects 
against HRV1B (Figure 20B). In addition, infection of A549 cells for 2h prior to LL-37 
treatment also resulted in a significant reduction of detectable viral RNA copies 
(***p<0.001) compared to virus alone (Figure 20A). The scrambled LL-37 control 
showed no antiviral activity (Figure 20B). 
 
 
 
  
 
 
 
 
 
 
  
A. 
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Figure 20. LL-37 displays direct and cell based antiviral activity against rhinovirus 
in an A549 cell model 
(A) Human rhinovirus was incubated with LL-37 for 2h prior to cell infection (“virus-
peptide”) or A549 cells were infected with HRV1B (MOI 1) for 2h prior to LL-37 treatment 
(“cell-peptide”). (B) Human rhinovirus was incubated with a scrambled LL-37 peptide for 2 h 
prior to cell infection (“virus-peptide”) or A549 cells were infected with HRV1B (MOI 1) for 
2h prior to scrambled LL-37 treatment(“cell-peptide”). All treatments were then incubated 
for either 22h (“cell-peptide”) or 23h (“virus-peptide”) at 33oC. Total RNA was extracted 
from cell lysates and qPCR was performed to determine the number of viral RNA copies. 
Figures represent at least five independent experiments showing mean values ± SEM. The 
percentage data was converted into arcsin values and statistical analysis was performed on 
these values using an unpaired t-test to compare virus only (control) to peptide treatment 
(30µg/ml) (*** p< 0.001; ****p<0.0001).  
 
 
The antiviral effects of LL-37 against HRV1B were also investigated in the 16HBE14o- 
bronchial epithelial cells and assessed by TCID50 assay and qPCR for quantification of 
viral RNA. The pre-incubation of HRV1B with LL-37 peptide resulted in a significant 
reduction in viral RNA copies at ≥10 µg/ml of LL-37 (****p<0.0001) compared to 
virus alone (Figure 21A) and this was reflected in a reduction in the measurable 
virus titer determined by TCID50 assay (p>0.05), although, there was a trend no 
statistical significance was found (Figure 21C). Interestingly, LL-37 did not elicit a 
reduction in detectable viral RNA copy number when 16HBE cells were infected for 
2h prior to LL-37 treatment (Figure 21A). However, infective titer assessment by 
TCID50/ml assay revealed a statistically significant reduction of virus titer at both 
B. Scrambled LL-37 
103 
 
doses of LL-37 (*p<0.05 at 10 µg/ml and 30 µg/ml) compared to virus alone (Figure 
21C). The scrambled LL-37 peptide did not induce a reduction in measureable viral 
RNA copy number (Figure 21B) or a reduction in the infective virus titer compared 
to virus alone (Figure 21D) with either treatment regimen.  
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 21. LL-37 displays direct and cell based antiviral activity against rhinovirus 
in a 16HBE14o- cell model 
Human rhinovirus was incubated with LL-37 (A&C) or Scrambled LL-37 (B&D) for 2h prior to 
cell infection or 16HBE14o- cells were infected with HRV1B (MOI 5) for 2h prior to LL-37 
(A&C) or Scrambled LL-37 (B&D) treatment for 22h. Total RNA was extracted from cell 
lysates and qPCR was performed to determine the number of viral RNA copies (A&B) and 
TCID50 assay was performed to assess infective virus titer in cell supernatants 4 days after 
infection (C&D). Figure represents at least 4 independent experiments and displays mean 
values ± SEM. The percentage data was converted into arcsin values and statistical analysis 
was performed on these values using one-way ANOVA with Tukey´s multiple comparisons 
post-test to compare virus only (control) to LL-37 treatment (*p<0.5 **** p<0.0001). 
A. C. 
B. 
D. 
Viral RNA copies  Virus titer 
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4.3.2. Assessment of the potential for LL-37 to enhance host cell resistance to 
rhinovirus infection 
We sought to investigate the antiviral potential of LL-37 against rhinovirus when 
epithelial cells were briefly exposed to the peptide prior to infection. To assess this, 
A549 cells were treated with LL-37 for 2h prior to HRV infection and assessment of 
viral RNA copy number was performed 24h after infection (“2h treatment”). 
Exposure of A549 cells for 2h prior to infection did not result in a reduction viral 
copy number in comparison to untreated control (Figure 22A). We further assessed 
the effects of a 24h LL-37 treatment prior to HRV infection (“24h treatment”). Our 
results indicated that there was a reduction of viral RNA copies when 10µg/ml of LL-
37 was utilised, however this reduction was not statistically significant there was a 
trend observed. No reduction in viral RNA copies was observed at 30 µg/ml of LL-37 
(Figure 22A).  
In contrast, we observed treatment of A549 cells with LL-37 for 2h followed by a 
wash step and the addition of fresh maintenance media for up to 24h prior to HRV 
infection (“24h + wash treatment”), resulted in a loss of the antiviral activity of the 
peptide (Figure 22A). No antiviral effects were observed using a scrambled LL-37 
under the same experimental conditions (Figure 22B).  
In order to establish if LL-37 was internalised by A549 cells, cells were exposed to 
DANSYL-labelled LL-37 for 30 minutes, washed and then imaged by confocal 
microscopy. The DANSYL-labelled LL-37 peptide was observed to be associated with 
A549 cells (Figure 22C). The intracellular localization of the peptide was relatively 
diffuse throughout the cell. A z-stack analysis further confirmed that the localization 
of LL-37 was intracellular (Appendix 1).  
 
 
  
 
 
A. 
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Figure 22. Prolonged LL-37 treatment can enhance host cell resistance to 
rhinovirus infection 
A549 cells were treated with LL-37 (A) or scrLL-37 (B) for 2h (“2h treatment), or 24h (“24h 
continuous treatment”) or 2h followed by wash step and 22h in contact with 5%FBS in 
DMEM (“24h wash+treatment”). After each corresponding treatment A549 cells were 
washed and infected with HRV1B (MOI 1) for 2h in serum-free media, washed and left in 
contact with 5% FBS in DMEM for 20h at 33oC. Total RNA was extracted from cell lysates to 
determine the number of viral RNA copies (A&B). Figure represents at least 4 independent 
experiments and shows mean values ± SEM. The percentage data was converted into arcsin 
values and statistical analysis was performed on these values using one-way ANOVA with 
Tukey´s multiple comparison post-test to compare virus only (control) to LL-37 treatment 
(p>0.05). (C) A549 cells were exposed to DANSYL-labelled LL-37 for 30 minutes, washed, 
fixed and mounted with DAPI prior to confocal microscopic analysis (63 x magnification). 
This representative image combines the wavelength of DANSYL-tagged LL-37 in green 
(cadaverin 488/516 nm) and nuclei in blue (DAPI 405/454 nm).  
A549 cells 
C. 
B. 
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We subsequently investigated the antiviral protective effects of LL-37 in bronchial 
epithelial cells, whereby 16HBE14o- cells were treated with LL-37 for 2h prior to 
HRV1B infection. The number of viral RNA copies was determined by qPCR after a 
period of 24h. Results showed a moderate reduction in RNA viral copies at 30 µg/ml 
of LL-37 (p>0.05) compared to virus alone (Figure 23A), however there was a trend 
no statistical significance was found. Scrambled LL-37 did not alter the host cell 
response (Figure 23 B). To confirm the internalization and retention of LL-37 by 
16HBE14o- cells, cells were exposed to DANSYL-labelled LL-37 for 30 minutes, 
washed and then imaged by confocal microscopy (Figure 23 I). As with A549 cells, 
DANSYL-labelled LL-37 was observed to be associated with 16HBE14o- cells (Figure 
23 I), localizing around the perinuclear region. A confocal z-stack analysis indicated 
that the LL-37 was predominantly intracellular (Appendix 2).  
Using this cell model, we investigated the ability of LL-37 to enhance the host cell 
antiviral response by modulating the expression of type I interferon and the viral 
sensor PKR as well as pro-inflammatory mediator IL-8 in healthy and infected 
16HBE14o- cells. Our data indicated that LL-37 did not upregulate IFN1β (Figure 
23C), PKR (Figure 23 D), or IL-8 (Figure 23 E) gene expression in comparison to 
control in healthy non-infected cells. In addition, in 16HBE14o- cells treated with LL-
37 prior to HRV1B infection, our data also indicated that there was no statistically 
significant difference in IFN1β (Figure 23 F,) PKR (Figure 23 G) and IL-8 (Figure 23 H) 
gene expression between LL-37 treatment and virus alone. Control cell (HeLa) 
lysates also had no effect. 
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Figure 23. LL-37 can rapidly enter 16HBE14o- cells but does not alter the type I 
interferon, PKR or IL-8 response of the host cell during rhinovirus infection. 
16HBE14o- cells were treated with LL-37 for 2h, washed and infected with HRV1B (MOI 5) 
for 2h. Cells were washed and left in contact with 5%FBS in IMDM for 20h at 33oC. (A-B) 
Total RNA was extracted from 16HBE14o- cell lysates and qPCR was performed to determine 
viral RNA copy number. Each figure represents three independent experiments and shows 
mean values ± SEM. Statistical analysis was performed using one-way ANOVA with Tukey’s 
multiple comparisons post-test to compare virus only (control) to LL-37 treatment. (C-H) 
qPCR was performed to determine IFN1β gene expression in healthy (C) and infected cells 
(F) treated with LL-37, PKR gene expression in healthy (D) and infected cells (G) treated with 
LL-37, and IL-8 gene expression in healthy (E) and infected cells (H) treated with LL-37. The 
GAPDH and β-actin genes were used as reference genes and each figure represents three 
independent experiments (mean values ± SEM).). (I) 16HBE14o- cells were exposed to 
DANSYL-labelled LL-37 peptide for 30 minutes. Cells were subsequently washed, fixed and 
mounted with DAPI prior to confocal microscopic analysis (63 x magnifications). The image 
combines the wavelength of DANSYL-tagged LL-37 in green (Cadaverin 488/516 nm) and 
nuclei in blue (DAPI 405/454 nm). 
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3.3.3. Assessment of HRV and LL-37 mediated alteration of HRV-targeted receptor 
expression on host cells 
 
In order to establish if LL-37 was able to modulate the expression of cell surface 
receptors utilised by rhinovirus for infection, we first assessed the ability of 
rhinovirus 1B to induce ICAM-1, LDLr and vLDLR cell surface protein expression in 
16HBE14o- cells during replication. Cell surface expression of ICAM-1, LDLr and 
vLDLR were determined by flow cytometry at 18, 24, 48 and 72h post-HRV1B 
infection. Our data indicated that rhinovirus infection increased surface ICAM-1 
expression after 24h (Figure 24D) and that the increase in expression was enhanced 
at 48h post infection (Figure 24G) and 72h (Figure 24J). LDLr surface protein was 
considerably increased at 48h (Figure 24H) and 72h (Figure 24K) post infection. 
vLDLr surface protein was expressed at an extremely low level in 16HBE14o-  cells, 
and HRV1B infection did not appear to alter expression of this receptor in 
comparison to unstimulated cells (Figure 24 C, F, I, L).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18 h time point  
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Figure 24. Time course of rhinovirus-induced ICAM-1 and LDLr surface expression 
on 16HBE epithelial cells. 
Surface LDLr, vLDLr and ICAM-1 were measured by flow cytometry on healthy or RV1B-
infected 16HBE cells (MOI 5; 2h). Cells were washed and incubated in maintenance media 
for 18, 24, 48 and 72h. All cells were stained for ICAM-1, LDLr and vLDLR using conjugated 
antibodies with unstained cells as a control for background autofluorescence to set the 
negative population. Representative flow cytometric histograms for each time point 
indicating surface expression of ICAM-1, LDLr and vLDLr in HRV1B –infected and uninfected 
16HBE cells are displayed. Geometric mean values are shown for infected, non-infected and 
unstained cells for each fluorescence channel. 
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We assessed the ability of LL-37 to modulate HRV-target receptors. Rhinovirus was 
incubated with LL-37 prior to infection of 16HBE14o- cells and cell surface 
expression of ICAM-1 and LDLr were determined by flow cytometry at 24 and 48h.  
At 24h, HRV replication was shown to induce the expression of ICAM-1 and at 48h, 
HRV greatly increased the expression of ICAM-1 as well as LDLr. Therefore these 
two time points were selected to further study the modulatory properties of LL-37 
on HRV-target receptors. In addition several other parameters were measured at 
these time points throughout this project, such as viral RNA copies, cytokine and 
chemokine expression and production, which together can help to fully characterise 
the peptides antiviral properties. The percentage of positive events for both ICAM-1 
and LDLr surface expression was determined for each condition at 24 and 48h. Our 
data indicated that at 24h, rhinovirus infection alone did not increase expression of 
cells positive for both ICAM-1 and LDLr compared to untreated cells, and at this 
timepoint LL-37 did also not alter ICAM-1 and LDLr surface expression in both 
infected and uninfected 16HBE cells (Figure 25B).  
However, while rhinovirus infection significantly increased the percentage of ICAM-
1 and LDLr positive cells compared to uninfected cells (*p<0.05) at 48h, LL-37 
treatment inhibited the HRV-mediated increase in receptor expression (Figure 25D). 
The scrambled control peptide treatment of both infected and uninfected cells, 
together with LL-37 treatment of healthy cells, did not induce any changes in 
surface receptor expression (Figure 25D).   
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Figure 25. LL-37 modulates ICAM-1 and LDLr cell surface expression in response to 
rhinovirus infection. 
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Purified rhinovirus 1B (MOI 5) was incubated with LL-37 in serum-free media for 2h at 33oC 
prior to 16HBE14o- cell infection. Cells were subsequently incubated for a total of 24h (A&B) 
or 48h (C&D). Cell surface ICAM-1 and LDLr were measured by flow cytometry and data 
shown are representative scatter dot plots showing the percentage of positive events for 
both ICAM-1 and LDLr surface protein expression at 24h (A) and 48h (C). Graphical 
representation (mean values ± SEM) of percentage of positive events for both ICAM-1 and 
LDLr surface proteins are shown at 24h (B) and 48h (D). Figures represent at least four 
independent experiments. Statistical analysis was performed using one-way ANOVA with 
Tukey´s multiple comparisons post-test to compare infected and un-infected cells treated 
with LL-37 to untreated cells(* p<0.05; **p< 0.01). 
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4.3.4. Characterisation of LL-37 mediated alterations in HRV infectivity 
 
Our data has shown that incubating rhinovirus with LL-37 prior to 16HBE14o- cell 
infection led to a significant reduction in viral RNA copies compared to virus alone 
(Figure 21). For additional characterisation of this observation and to assess the 
effects of LL-37 on viral infectivity, a pan-enterovirus monoclonal antibody was used 
to detect rhinovirus by confocal microscopic analysis. Quantification of the 
fluorescence detected shows a dose-dependent decrease in viral infectivity in 
airway cells infected with HRV exposed to LL-37 prior to infection (Figure 26 A and 
B). Scrambled LL-37 did not induce a reduction in the number of infected cells 
compared to virus alone (Figure 26 A and B).  
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Figure 26. LL-37 exposure affects rhinovirus infectivity. 
Human rhinovirus 1B (purified stock) was incubated with LL-37 for 2h at 33oC prior to 
16HBE14o- cell infection (MOI 1). 16HBE14o- cells, previously seeded in chamber slides, were 
exposed to peptide/virus mixture for 1h, washed and cultured for further 23h in 
maintenance media at 33oC. Cells were washed, fixed and permeabilised with 0.1% Triton-
X. A pan-enterovirus monoclonal antibody (raised in mouse) was used to detect rhinovirus 
VP3 and imaged by confocal microscopy. (A) A goat anti-mouse IgG (Alexa Fluor 488) was 
used as a secondary antibody for primary pan-enterovirus antibody; Virus appear in green 
and nuclei were stained with DAPI and appear blue. Images taken at 63x objective. (B) 
Representative graph of the % infected cells counted from at least 3 fields of view with 
more than 40 cells per field of view. Images taken at 40x objective.  
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To further determine if LL-37 binding to HRV resulted in destabilization of the viral 
particle structure, we assessed viral capsid integrity by transmission electron 
microscopy in the presence and absence of LL-37. In order to visualise the HRV 
virions, a number of purification steps were undertaken to ensure high purity prior 
to imaging. A sucrose gradient ultracentrifugation was performed to 
concentrate/purify the virus particles according to their density, thereby separating 
them from other cellular material. SDS-PAGE was performed to identify the 
presence of viral proteins (VP1-VP3 ~ 20-30 kDA) [Appendix 4]. We exposed HRV1B 
to LL-37 for 2h at 4oC before imaging by negative staining in transmission electron 
microscopy (Figure 27). Imaging data showed a dramatic reduction in the number of 
HRV1B virions when exposed to LL-37, compared to untreated, purified HRV1B 
(Figure 27). A second sucrose gradient ultracentrifugation of HRV1B samples was 
conducted to obtain virus preparations of a higher concentration and purity to 
image with cryotransmission electron microscopy. Following analysis by SDS-PAGE, 
the second gradient purification resolved in a clear band indicating that the sample 
was highly pure (Appendix 5). We subsequently exposed the purified HRV1B to 50 
µM LL-37 for 5 minutes at 4oC, or endotoxin-free water as a negative control, before 
imaging of the samples by cryoEM. In accordance with the negative staining 
obtained through transmission electron microscopy imaging (Figure 27), the cryoEM 
micrographs also revealed a dramatic reduction in virions in LL-37 exposed HRV1B 
compared to control HRV1B (Figure 27). However, in both untreated and LL-37-
exposed HRV1B samples, the virions demonstrated similar morphology and 
appearance, indicating no perceptible alterations on the viral capsid and no free 
capsid content. 
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Figure 27. LL-37 reduces viable rhinovirus concentrations but does not appear to 
alter virus ultrastructure. 
Negative staining electron microscopy and cryo-transmission electron microscopy 
micrographs of control HRV and HRV exposed to LL-37. HRV1B was exposed to LL-37 or 
endotoxin-free water for 2h (TEM) or 5 minutes (cryoEM) on ice. For negative stain, 
samples were added to carbon coated copper grids. The stained layer was dried and 
imaged by TEM Technai T12 running at 120keV. For cryoEM, samples were added to C-flat™ 
holey carbon coated copper grid and vitrified with a FEI Vitrobot IV. Electron micrographs 
were collected on a FEI Technai Polara microscope operated at 300 keV. The absolute 
magnification was 37,037x corresponding to a pixel size of 1.35 Å on a molecular scale. 
Micrographs represent observations from a minimum of two grids analysed per condition. 
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4.3.5. Assessment of the impact of LL-37 on the bronchial epithelial cell response 
to HRV infection  
 
We previously showed that treating HRV with LL-37 prior to cell infection leads to a 
reduction in viral infectivity (Figure 21) and cryoEM studies further revealed the 
ability of the peptide to directly target the virus reducing the number of virions 
(Figure 27). To then assess the impact of LL-37 on bronchial epithelial cell response 
to HRV infection, we investigated the mRNA transcript levels of type I interferon 
genes-IFN1β and interferon inducible gene PKR as well as IFN1β protein levels.  
 
HRV infection strongly induced IFN1β transcription (301-fold above unstimulated 
cells) and only mildly induced PKR transcription (3.4-fold above unstimulated cells) 
although in LL-37 treated cells transcription levels were significantly lower (Figure 
28A&B). Addition of LL-37 reduced virus induced IFN1β gene expression to 54.7-fold 
at 10 µg/ml (*p<0.05) and 44.8-fold at 30 µg/ml (p<0.05) [Figure 28A], and PKR 
gene expression to 1.8-fold at 10µg/ml and 1.6-fold at 30 µg/ml (Figure 28b). 
Scramble LL-37 did not alter IFB1β and PKR mRNA expression in comparison to 
infected cells (Figure 28 A&B). LL-37 exposure to uninfected cells did not induce 
IFN1β or PKR gene expression above uninfected cells (Figure 28 A&B). 
 
 To confirm that the mRNA transcript levels were translated to changes at the 
protein level, we assessed cell supernatants for IFN1β protein release. In 
accordance to the gene expression data, HRV infection induced an increase in IFN1β 
secretion (42.9 pg/ml) and the addition of LL-37 lead to a significant dose 
dependent decrease in IFN1β secretion (13.89 pg/ml for 10µg/ml and 10.63 pg/ml 
at 30µg/ml, *p<0.05) [C]. The IFN1β protein concentration in uninfected control was 
too low to detect. Scramble LL-37 did not alter IFN1β secretion compared to HRV-
infected cells (Figure 28C). 
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Figure 28. LL-37 treatment reduces the antiviral response associated with HRV1B 
infection. 
HRV1B (MOI 5) was pre-incubated with LL-37 in serum-free media for 2h prior to cell 
infection. 16HBE14o- cells were exposed to mixture for 1h, washed and cultured for further 
23h in maintenance media at 33oC. Total RNA was extracted from 16HBE14o- cell lysates 
and qPCR was performed to determine levels of IFN1β (A) and PKR (B) mRNA transcripts. 
Values represent fold-changes over uninfected cells. The GAPDH and β-Actin genes were 
used as reference genes. IFN1β protein levels released into the supernatants were 
determined by IFNβ ELISA (C). Each figure represents three independent experiments. 
Figures show mean values ± SEM. Statistical analysis was performed using one-way ANOVA 
with Dunnett's multiple comparisons post-test to compare virus only to LL-37 treatment (* 
p<0.05). 
A. B. 
C. 
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4.4. Discussion 
 
The sole human cathelicidin, LL-37, has been shown to possess antiviral activity 
against a number of viruses (reviewed in Barlow et al., 2014). hCAP18/LL-37 is 
produced primarily by neutrophils and airway epithelial cells and can be 
upregulated in response to infection and inflammation in the airway environment. 
In this study, we aimed to characterise the antiviral activity of LL-37 against 
rhinovirus in the context of a number of concentrations and exposure regimens.    
 
In healthy infants and adults, hCAP-18/LL-37 has been detected in bronchoalveolar 
lavage fluid (BALF) at a concentration of approximately 5μg/ml and 2μg/ml, 
respectively (Schaller-Bals et al., 2002). Higher concentrations of the peptide have 
been detected during infection. In newborns with pulmonary infections, 
concentrations of LL-37 can reach approximately ~25 μg/ml in the lungs, and in 
adult patients with cystic fibrosis, LL-37 concentrations are estimated to be 
~15μg/ml (Chen et al., 2004; Schaller-Bals et al., 2002). In the literature, and in this 
current study, an in vitro concentration of 10 µg/ml of LL-37 has been considered to 
be of relevance to a physiologically normal state, and a concentration of 30 µg/ml 
to be a physiologically inflammatory level of LL-37. Furthermore, LL-37 has been 
shown to be significantly inhibited by the presence of human serum (Ciornei et al., 
2005) and Wang et al. (1998) reported that apolipoprotein A-I (apoA-I) present in 
human plasma can bind and scavenge LL-37, thus inhibiting its activity. Thus, to 
appropriately represent the serum-free environment of the lung, all treatments 
were conducted either in serum-free media or in the presence of ultroSer™ G 
synthetic serum substitute.  
 
In this chapter we show that the human cathelicidin, LL-37, has potent antiviral 
activity against HRV1B in vitro. The antiviral effects of LL-37 were assessed in 
relevant pulmonary cell models of rhinovirus infection, A549 and 16HBE14o- cells. In 
A549 cells, we determined that the antiviral effects were most visible when the 
virus was exposed to peptide prior to infection, as well as when cells were infected 
with virus prior to peptide treatment. 
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In 16HBE14o- cells, LL-37 showed potent antiviral activity at both physiologically 
normal (10µg/ml) and physiologically inflammatory (30µg/ml) concentrations, 
decreasing the measurable viral RNA copies in infected cells by approximately 50-
70%, when the virus was exposed to the peptide prior to cell infection 
(****p≤0.0001). This was confirmed by TCID50 assay, which indicated that LL-37 led 
to a dose-dependent decrease in virus titer compared to virus alone when HRV is 
treated with LL-37 prior to cell infection (“virus-peptide”, p>0.05), however this 
reduction was not statistically significant a trend was observed. In contrast to data 
obtained using A549 cells, treating infected 16HBE14o- cells with LL-37 did not lead 
to a reduction in viral RNA copy number. However, analysis by TCID50 assay revealed 
that LL-37 did lead to a statistically significant reduction of virus titer in this cell 
model. Previous studies have reported similar findings investigating the antiviral 
effects of LL-37 against viral airway pathogens. Currie et al., (2013) assessed the 
effects of LL-37 against respiratory syncytial virus (RSV) revealing that LL-37 has the 
potential to directly target RSV and/or host airway epithelial cells, and a maximal 
antiviral effect was achieved when exposing RSV to the peptide prior to cell 
infection. Similar results have also been reported in studies using Influenza A virus 
(Barlow et al., 2011; Tripathi et al., 2013). In the context of this study, a lack of 
reduction in viral RNA copies, but a measurable decrease in virus titer measured by 
TCID50 assay may indicate that LL-37 directly affects the virus extracellularly, or 
indeed alters the host cell response, inhibiting virus entry or exit, in turn inhibiting 
infection of neighboring cells. Indeed, in the context of other HDP, HBD2 was shown 
to block viral cellular entry of RSV through its ability to destabilize the RSV viral 
envelope (Kota et al., 2008). In the non-enveloped adenovirus, HBD5 was shown to 
induce AdV aggregation (Gounder et al., 2012), which could impact viral infectivity 
by impeding cell binding.  
 
Alternatively, we hypothesised that LL-37 could target the host cell by directly 
modulating host cell surface receptors important for HRV entry. Support for this 
hypothesis came from studies that have shown that HBD2 and HBD3 were able to 
suppress the expression of CXCR4 in PBMC and T cell lines during HIV-1 infection, 
thereby reducing HIV infectivity of these cells (Quiñones-Mateu et al., 2003). In 
addition, an important factor to consider in this experimental context is the 
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prolonged exposure of 16HBE14o- cells to LL-37. Studies have shown that LL-37 can 
exhibit cytotoxicity activity toward eukaryotic cells (Johansson et al., 1998); the 
peptide was shown to cause cell death in human nasal epithelial cells through the 
pro-inflammatory necrotic and/or pyroptotic pathways rather than apoptosis 
(Thomas et al., 2017). Thus, in Chapter 5 we explored the relationship between 
decreased viral infectivity induced by inflammatory concentrations of LL-37 in 
tandem with cytotoxicity, as a potential mechanism of action.  
 
To determine if the antiviral effects of LL-37 were sequence specific, we tested the 
antiviral activity of a scrambled LL-37 peptide with identical amino-acid sequence at 
inflammatory concentrations (30µg/ml). Our data indicated that the control 
scrambled LL-37 peptide did not exhibit any anti-HRV activity. This is consistent with 
previous studies investigating the antiviral activity of LL-37 against IAV (Barlow et 
al., 2011), RSV (Harcourt et al., 2016; Tripathi et al., 2013) and dengue virus 
(Alagarasu et al., 2017).  
 
Human rhinoviruses infect the lower respiratory tract (LRT), with a major site of 
infection occurring in bronchial epithelial cells (Papadopoulos et al., 2000). Several 
studies have provided evidence of rhinovirus ability to replicate and infect alveolar 
epithelial cells, further supporting the implication of the virus in lower respiratory 
tract infections (Johnston et al., 1998; Kennedy et al., 2012; Reza Etemadi et al., 
2017). Due to the fact that HRV has showed the ability to replicate in different 
locations of the lower respiratory tract, we have chosen two different cell models 
representing the bronchial (16HBE14o-) and alveolar epithelium (A549), which we 
previously shown in chapter 3 to be relevant cells models of HRV infection.  
A549 cells are derived from a human alveolar carcinoma cells with properties of 
type II alveolar epithelial cells. Type II cells secrete pulmonary surfactant and their 
morphology is granular and roughly cuboidal (French, 2009). 16HBE14o- are a 
human bronchial epithelial cell line isolated from a 1 year old male patient and 
immortalised with the origin of replication (ORF-) defective SV40 plasmid (pSVori-). 
This cell line maintains the characteristic features of normal differentiated bronchial 
epithelial cells such as the cobblestone morphology, cytokeratin expression, the 
ability to form tight junctions and directional ion transport (Cozens et al., 1994; 
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Wan et al., 2000). To fully elucidate the ability of the virus to infect the LRT and to 
investigate the ability of LL-37 to inhibit HRV replication, studies were carried out in 
both bronchial and alveolar cell line, which possess different functions and 
morphologies in the LRT.  
 
Our data showed that physiologically normal concentrations of LL-37 (10µg/ml) 
significantly reduced the ability of A549 cells to be permissive to HRV infection 
when cells were pre-treated with peptide for 24h and washed before HRV infection. 
We also found that exposing A549 cells to LL-37 for 2h prior to HVR infection did 
not result in a reduction of viral infectivity, and indeed, similar results were seen 
when cells were treated with LL-37 for 2h, washed and left in maintenance media 
for up to 24h prior to infection with the virus. This suggests that a prolonged 
exposure to LL-37 may be required for an anti-HRV effect on the host epithelial cell. 
Other studies have reported similar results, in which cells were pre-treated with LL-
37 and washed prior to viral infection, observing reductions in RSV viral load (Currie 
et al., 2013) and IAV infectivity (Tripathi et al., 2013). The human cathelicidin LL-37 
inhibits influenza A viruses through a mechanism distinct from that of surfactant 
protein D or defensins (Tripathi et al., 2013). We propose that rhinovirus may 
interact with cell-associated LL-37 which was not removed during the wash step or 
that LL-37 is internalised by host cells and modulates the host response to HRV 
infection. However, given that we did not see a substantial loss of measureable 
virus with this treatment regimen, it is likely that other factors are involved.  
 
We investigated the internalisation of LL-37 by airway epithelial cells by exposing 
A549 and 16HBE14o- cells to DANSYL-labelled LL-37 and imaging by confocal 
microscopy. Our data demonstrated that LL-37 treatment prior to viral infection 
resulted in rapid peptide internalisation and retention. Using fluorescent LL-37, we 
also assessed LL-37 degradation over time after cell internalization and found no 
alteration in mean DANSYL intensity values after a period of 16h (Appendix 3). 
However, this does not exclude the possibility of peptide degradation, as the 
fluorochrome attached to LL-37 may remain intact even after peptide degradation. 
Previous studies have demonstrated that LL-37 can interact with epithelial cells, 
being actively taken-up by A549 epithelial cells and trafficked to the perinuclear 
124 
 
region in a microtubule-dependent manner (Lau et al., 2005), but fully 
characterising intracellular peptide stability requires further study.  
 
Viral infections are known to induce a rapid and strong type I interferon response 
which has a potent ability to alter viral replication. Previous studies have 
investigated the ability of LL-37 to modulate a type I interferon response in 
different systems, inducing IFN-1β expression in plasmacytoid dendritic cells (pDC) 
and in normal epidermal keratinocytes via TLR9 or TLR3, respectively (Lande et al., 
2007; Takiguchi et al., 2014). We therefore investigated whether the internalised 
peptide could induce an antiviral response which would protect cells from 
subsequent infection. Our data suggested that, in 16HBE14o- cells, LL-37 did not 
induce IFN-1β or PKR gene expression in healthy cells, and in HRV-infected cells 
there was no enhancement of IFN 1β or PKR gene expression above that observed 
in infected cells. This data indicated that internalised LL-37 could mediate 
moderate protection against HRV infection in A549 and 16HBE cells, although the 
mechanism behind the activity of the peptide did not appear to involve the 
modulation of type I interferon production. 
 
Human rhinoviruses replicate efficiently in epithelial cells of the upper and lower 
airway tract. The major group of this virus accesses airway cells via the ICAM-1 
receptor (Greve et al., 1989) and the minor group of the virus accesses airway cells 
via LDLr or vLDLr (Hofer et al., 1994; Nicodemou et al., 2005). Our initial studies 
demonstrated that rhinovirus 1B infection of 16HBE14o- cells increased the cell 
surface expression of ICAM-1 and LDLr protein. ICAM-1 expression was induced at 
24h post-infection and expression increased throughout time peaking at 72h. LDLr 
expression was induced after 48h and remained elevated above unstimulated cells 
for up to 72h post-infection. Similar results have also been shown in A549 cells 
during HRV16 infection, a major group of virus, although peak expression of surface 
ICAM-1 was seen at 8h post-infection. ICAM-1 expression was still significantly 
increased compared to unstimulated cells at 72h p.i (Papi and Johnston, 1999). The 
minor group of virus, HRV2, was also shown to upregulate ICAM-1 expression at 8h 
p.i in A549 cells. In human tracheal epithelial cells, HRV2 (minor group) was shown 
to induce surface expression of LDLr three days after infection and HRV14 (major 
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group) was shown to induce LDLr surface expression five days after infection. An 
antibody against LDLr inhibited HRV2 infection and cytokine production in response 
to infection but had no effect on HRV14 infection or cytokine production (Suzuki et 
al., 2001). This indicates that rhinovirus-induction of ICAM-1 and LDLr is not virus-
strain specific. This further signifies that both ICAM-1 and LDLr cell receptors can be 
upregulated in an indirect form due to viral infection. Rhinovirus-induced ICAM-1 
expression is dependent upon upregulation of NFkB, and LDLr expression is 
dependent in the upregulation of SP-1 transcriptional factor, both of which have 
been shown to be upregulated by both minor and major group of virus during 
infection of airway cells (Papi and Johnston, 1999; Suzuki et al., 2001). 
 
Having found that HRV1B enhanced ICAM-1 and LDLr surface expression in 
16HBE14o- cells, we sought to investigate the ability of LL-37 to modulate the 
expression of these receptors during HRV infection. 16HBE14o- cells were infected 
with HRV1B that had been pre-treated with LL-37, and receptor expression was 
assessed after 24 and 48h by flow cytometry. Results indicated that rhinovirus 
infection did not increase the expression of either ICAM-1 or LDLr in 16HBE14o- cells 
above untreated cells after a period of 24h. LL-37 did also not alter the expression 
of both receptors in infected cells and healthy cells. At 48 h, HRV infection 
significantly increased the expression of both receptors on 16HBE14o- cells above 
unstimulated cells, and this was also seen in 16HBE14o- cells infected with HRV pre-
treated with scrambled LL-37. However we did observe that at this time-point, in 
16HBE14o- cells infected with HRV pre-treated with LL-37, there was not a 
significant increase in the expression of ICAM-1 and LDLr compared to unstimulated 
16HBE cells, indicating that the peptide appeared to suppress virus mediated 
expression of these receptors. These results suggest that LL-37 can down-modulate 
rhinovirus target receptor expression in bronchial epithelial cells either through a 
direct effect on the virus or on the host cell. For example, the modulatory effects of 
LL-37 on HRV-target receptors may be in fact due to the direct effects of the 
peptide on the virus, inhibiting viral replication and consequently resulting in a 
lower expression ICAM-1 and LDLr surface proteins.  
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In similarity to our own results, HBD2 and HBD3 have shown the ability to 
downregulate CXCR4 expression in PBMCs, which is a chemokine receptor that 
functions as a co-receptor for HRV-1 entry into CD4 positive cells, blocking HIV-1 
replication (Quiñones-Mateu et al., 2003). Consequently our results suggest that LL-
37 could inhibit HRV1B replication both via direct interaction with the virion, and 
potentially through the down-modulation of ICAM-1 and LDLr receptor expression 
in bronchial epithelial cells. However, further investigation will be required to 
elucidate the exact mechanism of action, and whether any effect is likely to be 
temporal or cell type specific. 
 
A number of studies have attempted to provide insights on the direct mechanism of 
action of LL-37 against a number of viruses. Currie et al., (2016) demonstrated that 
LL-37 mediates an antiviral effect on RSV by directly damaging the viral envelope, 
disrupting viral particles and reducing virus binding to, and infection of, human 
airway epithelial cells. This was also observed in IAV, in which LL-37 was found to 
cause disruption in viral membranes (Tripathi et al., 2013). LL-37 has also been 
shown to target DENV-2, by binding to the E protein inhibiting virus cell entry 
(Alagarasu et al., 2017). However, the mechanism of action of LL-37 against non-
enveloped virus, such as HRV, is not yet well understood. A study by Smith et al. 
(2010) did investigate the mechanism of HD5-mediated neutralization of 
adenovirus, with CryoEM structural studies demonstrating critical sites on the 
adenovirus capsid which HD5 binds to prevent subsequent steps of the virus 
uncoating. We suggest that this would be a valuable way forward in the context of 
this study. 
 
Our confocal microscopy analysis revealed a dose-dependent reduction of infection 
in cells infected with HRV pre-treated with LL-37. Utilising this method, we observed 
a substantial reduction in infection at inflammatory concentrations of LL-37. Our 
initial data obtained by electron microscopy also showed a substantial reduction in 
the number of virions in LL-37-treated HRV sample in comparison to control HRV, 
but with no obvious alteration of the viral capsid structure, and no increase in the 
number of empty capsids in LL-37-treated samples. This data in combination with 
our results showing a reduction in infectivity when HRV is pre-treated with LL-37, 
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further confirms the ability of LL-37 to target HRV potentially disrupting or 
preventing viral replication.  
 
The immunomodulatory properties of LL-37 involve the capacity to alter pattern 
recognition receptor signalling, in which the peptide was shown to facilitate the 
recognition of dsRNA in a TLR3 dependent manner in rhinovirus infected bronchial 
epithelial and promote cytokine release (Lai et al. 2011) as well as the capacity to 
induce IFN1β in keratinocytes in the presence of poly I: C (Takiguchi et al., 2014). 
The pattern recognition receptor, TLR3, directly contributes to the immune 
response of airway cells to rhinovirus infection and Poly I:C (Lai et al., 2011; 
Matsukura et al., 2007). The activation of TLR3 leads to the upregulation of 
inflammatory cytokines and chemokines in airway cells including RANTES, IL-8, IL-6 
as well as activating an antiviral response upregulating IFN1β (Guillot et al., 2005). It 
is thought that MDA5 and TLR3 are each necessary for maximal HRV-induced IFN 
responses (Q. Wang et al., 2009). In addition, studies have reported dsRNA-PKR 
pathway as a major signalling pathway induced by rhinovirus infection responsible 
for the activation of IFN production (Y. Chen et al., 2006). We generated the 
hypothesis that treating rhinovirus with LL-37 prior to cell infection could facilitate 
the recognition of the viral infection through this system resulting in an enhanced 
antiviral type I interferon response. In contrast to our initial hypothesis, our data 
demonstrated that treating HRV1B with LL-37 prior to 16HBE cell infection led to a 
significantly lower production of type I interferon as well as PKR gene expression by 
bronchial epithelial cells in vitro. Together with the gene transcription data IFN1β 
protein levels were also reduced in the presence of LL-37.  
 
Taken together, we now propose that direct exposure of rhinovirus to LL-37, but 
not scrambled LL-37, prior to epithelial cell infection, results in a reduction of 
infectivity that is most likely due to direct interaction with the viral capsid. This 
interaction subsequently inhibits replication, and consequently, reduces the host 
cell response to the viral infection. 
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Chapter 5. Investigating the role of LL-37 on the host 
inflammatory response to rhinovirus infection 
 
5.1. Introduction 
5.1.1. Pro-inflammatory responses of bronchial epithelial cells to rhinovirus 
infection 
The airway epithelium is intimately involved in the front line of defence against 
invading microorganisms, and expresses a variety of pattern-recognition receptors 
(PRRs), that allow cells to sense and respond to pathogens. Respiratory epithelial 
cells can produce and secrete the cytokines and chemokines responsible for 
initiating and tightly regulating lung inflammation and immune responses. 
Rhinovirus infection of the airway epithelium can initially lead to the induction of an 
innate immune response, which will include the production of pro-inflammatory 
chemokines and cytokines. Some of the most important determinants of the clinical 
outcome of HRV infection comprise growth factors, such as GM-CSF (Subauste et 
al., 1995), chemokines, such as IL-8 (Grünberg et al., 1997), RANTES (Schroth et al., 
1999), CXCL10 (Spurrell et al., 2005), and cytokines, such as IL-6 (Zhu et al., 1996), 
IL-11 (Einarsson et al., 1996) and IL-1β (Terajima et al., 1997). 
IL-8, a potent neutrophil chemoattractant and activator, was shown to be increased 
in nasal secretions from rhinovirus experimentally infected symptomatic subjects 
compared to those infected asymptomatic or sham-challenged subjects, and the 
severity of symptoms coincided with the change of IL-8 concentrations from 
baseline (Turner at al 1998). These findings therefore implicate IL-8 in the 
pathogenesis of rhinovirus infections. Furthermore, IL-6 was shown to be present in 
exaggerated quantities in nasal washings of rhinovirus experimentally infected 
symptomatic subjects (Zhu et al. 1996) and this correlates with previous studies in 
naturally occurring URTI in children (Noah et al 1995). IL-6 is a cytokine responsible 
for the production of acute phase proteins, B- cell differentiation, T –cell activation, 
as well as changing the nature of the leukocyte infiltrate (Gaby et al. 2006). The 
increased presence of IL-6 in rhinovirus infection is therefore thought to correlate 
with severity of infection and possibly reflective of an acute-phase inflammatory 
response. The T-cell and eosinophil-attracting chemokine CCL5, also known as 
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RANTES, has also been shown to be upregulated in primary bronchial epithelial cells 
upon rhinovirus infection (Schroth et al. 1999) and to be increased in nasal 
secretions of children with natural virus-induced asthma exacerbations (Teran et al. 
1999). CCL5 is not only a potent chemoattractant for eosinophils and is capable 
inducing eosinophil degranulation, but it is also a potent chemoattractant for 
monocytes and T cells, acting via receptors CCR1, CCR3 and CCR5 (Schall et al., 
1990). 
In addition to the production of pro-inflammatory mediators in response to 
rhinovirus infection, airway epithelial cells also respond by secreting cationic host 
defense peptides (Hiemstra et al., 2016; Proud et al., 2004). The sole human 
cathelicidin, LL-37, is known to be produced by airway epithelial cells and secreted 
into the airway surfactant (Bals et al., 1998). LL-37 has been shown to modulate 
chemokine and cytokine responses to pathogen-associated stimuli, eliciting the 
production of several chemokines and cytokines, particularly IL-8 and IL-6, in 
response to poly I:C (Filewod et al., 2009; Lai et al., 2011), LPS (Filewod et al., 2009; 
Pistolic et al., 2009), flagellin (Pistolic et al., 2009), and HRV infection (Lai et al., 
2011), as well as enhancing responses to IL-1β (Filewod et al., 2009; Pistolic et al., 
2009; Yu et al., 2007). In contrast, LL-37 has been shown to significantly inhibit the 
pro-inflammatory cytokine responses to LPS (Mookherjee et al., 2006; Scott et al., 
2002), mycobacterium tuberculosis infection (Torres-Juarez et al., 2015), IAV 
infection (Barlow et al., 2011) and RSV infection (Harcourt et al., 2016). Various 
factors have shown to be involved in LL-37 capacity to enhance or inhibit pro-
inflammatory stimuli, such as the timing and context within cells that are exposed 
to peptide and stimuli, as well as, the cell type and the microenvironment (Lai et al., 
2011; Scott et al., 2002).  
As IL-8, IL-6 and RANTES have been shown to be critical in the pathogenesis of 
rhinovirus infection; in this chapter we present our findings in relation to the 
characterisation of the ability of LL-37 to modulate these inflammatory cytokine and 
chemokine responses to rhinovirus infection in bronchial epithelial cells.   
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Figure 29. The numerous immunomodulatory functions of LL-37. 
This diagram by Kahlenberg and Kaplan, (2013) fully depicts the numerous 
immunomodulatory fuctions of LL-37 which are dependent on the environment and the 
cellular context. The exposure to LL-37 results in the recruitment of inflammatory cells, 
induction of M1 macrophages, and stimulation of inflammatory responses such as type I 
IFN production and inflammasome activation. Nevertheless, LL-37 has also been shown to 
have a strong anti-inflammatory activity, including the the ability to neutralise TLR4 
activation by LPS, downregulation of pro-inflammatory cytokine responses, and preventing 
invasion and inflammatory responses to pathogenic bacteria. 
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5.2. Materials and Methods 
5.2.1. Reagents 
Polyinosinic:polycytidylic acid, low molecular weight (LMW poly I:C) was purchased 
from Sigma Aldrich (Irvine, UK) and supplied in lyophilized powder form. The 
product was dissolved in ultrapure water to a stock concentration of 10mg/ml and 
aliquots (10µl) were prepared and stored at -20oC until further use.  
5.2.3. UV inactivation of HRV  
HRV1B virus stock (1ml) was exposed to UV light for 15 minutes at 100mJ/cm2 using 
a UV crosslinker linker XL-1000 Series (Spectrolinker™ Series, Burton, USA) 
[Chattoraj et al. 2011]. A TCID50 assay was used to confirm that the procedure 
disrupted the ability of rhinovirus to replicate (Appendix 6).  
5.2.2. RNA isolation 
Total RNA was extracted using RNeasy mini kit (Quiagen, Crawley, UK) or RNAzol® 
RT (Sigma Aldiritch, Irvine UK) according to manufacturer’s protocol. Briefly, 
16HBE14o- cells were seeded at 5x104 cell/well in a 12-well plate and incubated at 
37oC overnight. The following day, HRV1B (MOI 5) was exposed to varying 
concentrations of LL-37 (10 and 30µg/ml) for 2h at 33oC in serum-free IMDM media. 
16HBE14o- cells were exposed to the mixture for 1h, washed and re-immersed in 
low-serum (5% FBS) supplemented IMDM media for 23h at 33oC (Figure 30).  
 
 
 
 
 
 
Figure 30. "Prophylactic treatment" experimental regimen. 
HRV1B was exposed to varying concentrations of LL-37 (10µg/ml, 30µg/ml or scramble LL-
37 30µg/ml) for 2h at 33oC in serum-free media. 16HBE14o- cells were exposed to the 
mixture for 1h, washed and re-immersed in low-serum (5% FBS) supplemented media 
(IMDM) for 23h at 33oC.  
IMDM 
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After each treatment, media was aspirated and stored at -80oC until further use, 
and 300µl RLT buffer from RNeasy® mini kits (Qiagen, Crawley, UK) was added to 
each well. Cells were scraped from the surface of the plate with a sterile cell-
scraper. Cell lysates were stored at -80oC until extraction. Total RNA isolation was 
performed using the RNeasy® mini kit system following manufacturer’s protocols. 
For the following experiments, RNAzol RT was used to isolate RNA. Briefly, 
16HBE14o- cells were seeded at 5x104cells/well in a 12-well plate and incubated at 
37oC overnight and subsequently subjected to different treatment approaches. (1) 
Cells were exposed to purified stock of HRV1B (MOI 5) or UV-inactivated (MOI 5) or 
Poly I:C (10µg/ml) for 2h in serum-free IMDM, washed with saline, and incubated 
with LL-37 (10 and 30µg/ml) for 4h (poly I:C) or 22h in IMDM supplemented with 1% 
(v/v) Ultroser G (Figure 31); 
 
Figure 31. "Therapeutic treatment" experimental regimen. 
Bronchial 16HBE14o- cells were exposed to HRV1B (MOI 5) or UV-inactivated (MOI 5) or Poly 
I:C (10µg/ml) for 2h in serum-free IMDM, washed with saline, and incubated with LL-37 (10 
and 30µg/ml) for 22h or (poly I:C) or 4h in IMDM supplemented with 1% (v/v) Ultroser G. 
 
(2) 16HBE cells were infected with HRV1B (MOI1) for 2h, washed and re-immersed 
in 5% FBS supplemented IMDM media for 22h at 33oC. After 24h, cells were washed 
and exposed to LL-37 (10 and 30µg/ml) for 2h in IMDM supplemented with 1% (v/v)  
Ultraser G, followed by a wash step and re-immersion in 5% FBS supplemented 
IMDM for 22h at 33oC (Figure 32).  
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Figure 32. The "24h post-infection treatment" experimental regimen 
Bronchial 16HBE14o- cells were infected with HRV1B (MOI1) for 2h, washed and re-
immersed in 5% FBS supplemented IMDM media for 22h at 33oC. After 24h, cells were 
washed and exposed to LL-37 (10 and 30µg/ml) for 2h in IMDM supplemented with 1% 
(v/v) ultraser G, followed by a wash step and re-immersion in 5% FBS supplemented IMDM 
for 22h at 33oC 
 
(3) 16HBE14o- cells were infected with purified stock HRV1B (MOI 1) for 2h, washed 
and re-immersed in 5% FBS supplemented IMDM media for 22h at 33oC. After 24h, 
cells were washed and exposed to LL-37 (1 and 10µg/ml) for 24h in IMDM 
supplemented with 1% (v/v) Ultroser G at 33oC (Figure 33).  
 
Figure 33. The “24h post-infection treatment with lower and physiological 
concentrations of LL-37” experimental regimen. 
Bronchial 16HBE14o- cells were infected with purified stock HRV1B (MOI 1) for 2h, washed 
and re-immersed in 5% FBS supplemented IMDM media for 22h at 33oC. After 24h, cells 
were washed and exposed to LL-37 (1 and 10µg/ml) for 24h in IMDM supplemented with 
1% (v/v) Ultroser G at 33oC.  
 
After each treatment, media was aspirated and stored at -80oC until further use, 
and ice-cold 500µl RNAzol® RT was added to each well. Cells were scraped from the 
surface of the plate with a cell-scrapper. Cell lysates were stored at -80oC until 
extraction. Total RNA isolation was performed using RNAzol® RT according to 
manufacturer’s protocol. RNA concentrations were determined using a NanoDrop 
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1000 spectrophotometer (Thermo Fisher Scientific, Loughborough, UK). RNA 
integrity was determined using an Agilent Bioanalyser (Agilent, UK), where RIN≥8 
was used as a quality filter for further downstream analyses. 
 
5.2.4. qPCR to determine mRNA levels of IL-8, IL-6 and CCL5 
Total RNA (0.5-1μg) was transcribed to cDNA using a Precision RT all-in-one mix kit 
(PrimerDesign Ltd, UK) as per manufacturer’s instructions. qPCR reactions included 
cDNA (25 ng), 250 nM specific primers (Table 3) and SYBR green mastermix 
(PrimerDesign Ltd, UK) in total volume of 20µl. qPCR was performed using the 
StepOnePlus instrument (Applied Biosystems). A panel of six human reference 
genes were evaluated using a geNorm kit (Primerdesign) and qbase+ (Biogazelle) 
software. The geometric means of ACTB and GAPDH genes were selected as the 
most stable combination for normalization in 16HBE14o- cells. The 2ΔΔCt method was 
used and data is represented as fold changes over untreated cells (Pfaffl MW, 
2004). We applied a threshold of two-fold above unstimulated control to consider 
upregulation of the expression of the genes of interest.  
 
Table 3. qPCR primer sequences 
Target Forward Reverse Reference 
GAPDH  AAGCTCATTTCCTGGTATGAC
A 
TCTTACTCCTTGGAGGCCA
TGT 
(Wang et 
al., 2012) 
ACTB GGACTTCGAGCAAGAGATGG AGGAAGGAAGGCTGGAAG
AG 
(Tarrats et 
al., 2011) 
IL-8 ACTGAGAGTGATTGAGAGTGG
AC 
AACCCTCTGCACCCAGTTT
TC 
(Tsai et al., 
2009) 
IL-6 GGTACATCCTCGACGGCATCT GTGCCTCTTTGCTGCTTTC
AC 
(Keller et 
al., 2003) 
CCL5 CAGTCGTCTTTGTCACCCGA CGGGTGGGGTAGGATAGT
GA 
Designed 
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5.2.5. Quantification of cytokine/chemokine release by 16HBE14o- cells 
Supernatants from experiments described in section 4.2.2 were analysed for the 
presence of IL-8, IL-6 and CCL5 by ELISA, as per the manufacturer’s instructions 
(human IL-8 DuoSet ELISA DY208-05, R&D; Human IL-6 DuoSet ELISA DY206-05, 
R&D; Human CCL5/RANTES DuoSet ELISA DY278-05, R&D, Abingdon, UK).  
 
5.2.6. Statistical analysis 
Statistical analysis was performed using GraphPad Prism Version 6.0. (GraphPad Inc, 
San Diego, CA, USA). Data are presented as means ± SEM. Data were analysed using 
the appropriate statistical test and post-test as stated in the figure legends. A p-
value ≤0.05 was considered statistically significant. For the statistical analysis of the 
qPCR data the Δct values were utilised to determine statistical significance, unless 
otherwise stated in figure legend.  
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5.3. Results 
5.3.1. Assessment of the capacity of LL-37 to alter HRV-induced inflammatory 
cytokine expression in bronchial epithelial cells 
Rhinovirus infection of airway epithelial cells induces the release of inflammatory 
cytokines and chemokines. We sought to investigate the ability of LL-37 to 
modulate HRV-induced pro-inflammatory cytokine responses using a lung epithelial 
cell model of infection (Figure 34 & Figure 35). Bronchial epithelial cells (16HBE14o-) 
were infected with HRV that had been previously exposed to LL-37 and mRNA 
expression of IL-8 (Figure 34A), IL-6 (Figure 34B), and CCL5 (Figure 34C) was 
determined by qPCR after a period of 24h. Infection with HRV1B that had not been 
treated with peptide increased IL-8 (4.2- fold above uninfected cells), IL-6 (3.49- fold 
above uninfected cells) and CCL5 (7.8-fold above uninfected cells) mRNA levels. 
Notably the addition of LL-37 to virus prior to infection reduced HRV-induced mRNA 
expression of IL-8 (to 1.6 –fold at 10µg/ml of LL-37 and 2.2-fold at 30µg/ml of LL-
37), IL-6 (to 1.4-fold at 10µg/ml of LL-37, **p <0.01,  and 1.5-fold at 30 µg/ml of LL-
37, **p<0.01), and CCL5 (to 2.8-fold at 10 µg/ml of LL-37 and 4.1-fold at 30 µg/ml of 
LL-37). A scrambled LL-37 peptide did not alter HRV-induced pro-inflammatory 
cytokine expression (Figure 34 A, B and C). LL-37 treatment of uninfected cells did 
not induce IL-8, IL-6 or CCL5 mRNA expression above unstimulated cells (Figure 34 
D, E and F). However, higher concentrations of LL-37 (30µg/ml) induced the 
expression of CCL5 in untreated cells (Figure 34 F). HeLa lysates control did not 
upregulate IL-8, IL-6, or CCL5 gene expression above unstimulated cells (Figure 34 D, 
E and F).  
 
 
 
 
 
 
A. B. 
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Figure 34. LL-37 treatment of HRV reduces viral mediated inflammatory cytokine 
gene expression in bronchial epithelial cells. 
HRV1B (MOI 5) was incubated with LL-37 in serum-free media for 2h prior to cell infection. 
16HBE14o- cells were exposed to the mixture for 1h, washed and cultured for further 23h in 
maintenance media at 33oC. qPCR was performed to determine levels of IL-8 (A), IL-6 (B) 
and CCL5 (C) mRNA transcripts. Values represent fold-change over uninfected cells. The 
GAPDH and β-Actin genes were used as reference genes Results are represented as the 
means +/- SEM from three independent experiments. Statistical analysis was performed on 
ΔΔct values using one-way ANOVA with Tukey’s multiple comparisons post-test (**p<0.01). 
  
C. 
F. D. F. E. 
139 
 
To confirm that the mRNA transcript levels were translated to changes at the 
protein level, we assessed cell supernatants for IL-8 (Figure 35A) and CCL5 (Figure 
35B) protein release by ELISA. Rhinovirus infection induced a strong IL-8 response in 
the host cells compared to untreated cells and in accordance with the mRNA 
expression data, the addition of LL-37 to the virus prior to infection resulted in 
lower IL-8 secretion (Figure 35A). A similar trend was observed for CCL5 secretion, 
as infection with rhinovirus induced a strong CCL5 response in the host cells 
compared to untreated cells and the addition of LL-37 to the virus prior to infection 
resulted in a statistically significant reduction in CCL5 release at both concentrations 
used (10µg/ml of LL-37, **p<0.01 and 30µg/ml of LL-37, ****p<0.0001). Scrambled 
LL-37 exposure did not alter the ability of HRV to induce IL-8 and CCL5 secretion 
(Figure 35A&B). Notably, exposure of uninfected cells to physiologically 
inflammatory concentrations of LL-37 (30µg/ml) did result in increased IL-8 
secretion from 194.9pg/ml in untreated cells to 436.8pg/ml (Figure 35A) and CCL5 
secretion from 7.23 pg/ml in untreated cells to 12.24pg/ml (Figure 35B) although 
this effect was not statistically significant.  
 
 
 
 
 
 
 
 
Figure 35. LL-37 reduces pro-inflammatory cytokine release induced by HRV1B 
infection in bronchial epithelial cells. 
Purified HRV1B viral particles (MOI 5) were pre-incubated with LL-37 in serum-free media 
for 2h prior to cell infection. 16HBE14o- cells were incubated with the peptide/virus mixture 
for 1h, washed and incubated for further 23h in maintenance media at 33oC. IL-8 (A) and 
CCL5 (B) protein concentrations released into cell supernatants were quantified by ELISA. 
Results are represented as the means +/- SEM from four independent experiments. 
A. B. 
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Statistical analysis was performed using a one-way ANOVA with Tukey’s multiple 
comparisons post-test to compare virus only to LL-37 treatment (** p<0.01, ****p<0.0001). 
 
 
5.3.2. Assessment of the effects of host cell exposure to LL-37 on the 
inflammatory cytokine response during HRV- infection 
To determine the ability of LL-37 to modulate the pro-inflammatory response in 
rhinovirus-infected bronchial epithelial cells, 16HBE14o- cells were infected with 
HRV for 2h prior to LL-37 treatment for 22h at 33oC. IL-8 (Figure 36A), IL-6 (Figure 
36B) and CCL5 (Figure 36C) and mRNA transcript levels were assessed by qPCR after 
a period of 24h. Rhinovirus infection induced a strong IL-8 (24.3-fold above 
uninfected cells), IL-6 (16.4-fold above uninfected cells) and CCL5 (49.3 fold above 
uninfected cells) response in the context of gene expression. Addition of LL-37 did 
not significantly alter HRV-induced IL-8 (to 17.9-fold at 10µg/ml of LL-37 and 11.7-
fold at 30µg/ml of LL-37), IL-6 (to 10.1-fold at 30µg/ml of LL-37) and CCL5 (to 23-
fold at 30µg/ml of LL-37) gene expression. LL-37 (10 µg/ml) did not reduce the 
expression of IL-6 or CCL5 genes in comparison to HRV alone, although unusually, 
scrambled LL-37 reduced cytokine gene expression (Figure 36A, B and C). LL-37 
treatment of uninfected cells, together with the Hela lysate control did not 
upregulate IL-8, IL-6 or CCL5 gene expression above that of untreated cells (Figure 
36 A, B and C).  
 
 
 
 
 
 
 
 
 
 
B. A. 
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Figure 36. LL-37 treatment does not alter the pro-inflammatory cytokine gene 
expression in response to HRV infection in bronchial epithelial cells. 
16HBE14o- cells were left unstimulated (control) or were exposed to purified stock of HRV 
(MOI 5) for 2 hours at 33oC in serum-free media, washed with saline before incubating with 
LL-37 at concentrations indicated for 22 hours at 33 o C. qPCR was performed to determine 
mRNA expression levels of IL-8 (A), IL-6 (B) and CCL5 (C). The GAPDH gene was used as a 
reference gene. Results are represented as the means +/- SEM from four independent 
experiments. Statistical analysis was performed using one-way ANOVA with Tukey’s 
multiple comparisons post-test. 
 
 
C. 
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5.3.3. LL-37 enhances Poly I:C mediated pro-inflammatory cytokine release 
The capacity for LL-37 to modulate the expression of pro-inflammatory cytokines 
during rhinovirus infection can be, in part, through direct antiviral effects but also 
through peptide-mediated effects on host cells. In order to further understand the 
effects of the peptide on bronchial epithelial cells during host cell response to 
infection, we exposed cells to the TLR3 ligand poly I:C, which is a synthetic analog of 
double-stranded RNA that mimics viral infection, and to UV-inactivated HRV, which 
has previously been shown to be taken up by cells but lacks the ability to replicate 
(Newcomb et al., 2008) [Figure 37 and Figure 38]. 
Bronchial epithelial cells (16HBE14o-) were exposed to poly I:C for 2h and washed 
prior to LL-37 treatment for 4h. IL-8 (Figure 37 A), IL-6 (Figure 37 B), and CCL5 
(Figure 37 C) mRNA expression was determined by qPCR after a total period of 6h. 
Poly I:C stimulation increased mRNA transcript levels of IL-8, IL-6 and CCL5. Addition 
of LL-37 was shown to enhance poly I:C induced cytokine gene expression. 
Scrambled LL-37 did not alter poly I:C-induced IL-8, IL-6 or CCL5 mRNA expression 
when compared to poly I:C alone (Figure 37 A, B and C). LL-37 exposure of 
untreated cells did not enhance IL-8, IL-6 or CCL5 gene expression (Figure 37 A, B 
and C).  
 
 
  
 
 
 
  
 
 
  
A. B. 
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Figure 37. LL-37 enhanced dsRNA –induced pro-inflammatory cytokine response in 
bronchial epithelial cells. 
Bronchial epithelial cells (16HBE14o-) were either left unstimulated (control) or were 
exposed to poly I:C (10 µg/ml) for 2 hours in serum-free media, washed with saline before 
incubating with LL-37 at concentrations indicated for 4 hours at 33oC. qPCR was conducted 
to determine levels of IL-8 (A), IL-6 (B) and CCL5 (C) mRNA transcripts. The GAPDH gene was 
used as a reference gene. Results are represented as the means +/- SEM from four 
independent experiments. Statistical analysis was performed using one-way ANOVA with 
Tukey’s multiple comparisons post-test (* p<0.05; **p<0.01; ***p< 0.001). 
 
Bronchial epithelial cells (16HBE14o-) were exposed to UV-inactivated HRV1B for 2h 
and washed before treating cells with LL-37 for 22h at 33oC. IL-8 (Figure 38 A), IL-6 
(Figure 38 B), and CCL5 (Figure 38 C) mRNA expression were determined by qPCR 
after a period of 24h. UV-inactivated virus did not induce IL-8, IL-6 or CCL5 mRNA 
expression above that of unstimulated cells. We observed no upregulation of IL-8, 
IL-6 and CCL5 mRNA expression by LL-37 treatment, although 30 µg/ml of LL-37 did 
induce a 2.7 –fold increase in IL-8 mRNA levels (A). Scrambled LL-37 had no effect 
on IL-8, IL-6 or CCL5 gene expression.   
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Figure 38. LL-37 treatment does not alter cytokine gene expression following host 
cell exposure to UV –inactivated HRV  
Bronchial epithelial cells (16HBE14o-) cells were exposed to UV-inactivated HRV1B (MOI 5) 
for 2H in serum-free media, washed with saline before incubating with LL-37 at 
concentrations indicated for 22 hours at 33oC. qPCR was conducted to determine levels of 
IL-8 (A), IL-6 (B) and CCL5 (C) mRNA transcripts. The GAPDH gene was used as a reference 
gene. Results are represented as the means +/- SEM from at least four independent 
experiments. Statistical analysis was performed using one-way ANOVA with Tukey’s 
multiple comparisons post-test. 
 
 
 
 
 
A. B. 
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5.3.4. Assessment of the inflammomodulatory effects of delayed LL-37 treatment 
in HRV-infected bronchial epithelial cells 
 
In order to determine the inflammomodulatory effects of LL-37 on later stages of 
HRV replication, 16HBE14o- cells were infected with HRV for 2h, washed and left in 
contact with maintenance media for 22h prior to LL-37 treatment, which consisted 
of 2h treatment, a wash step to remove non-internalised peptide and re-immersion 
of cells in fresh maintenance media for further 22h at 33oC. The mRNA transcript 
levels of IL-8 (Figure 39A), IL-6 (Figure 39B), and CCL5 (Figure 39C) were determined 
by qPCR after a period of 48h. Infection with rhinovirus induced the expression of 
genes for IL-8, IL-6 and CCL5. Addition of LL-37 to cells did not alter the expression 
of IL-8, IL-6 and CCL5 genes. Scrambled LL-37 enhanced HRV-induced IL-8 (to 6.5-
fold above unstimulated cells), but did not alter IL-6 or CCL5 mRNA levels compared 
to virus alone (Figure 39). LL-37 treatment of uninfected cells or Hela lysate 
treatment did not induce expression of IL-8, IL-6 or CCL5 above 2-fold (Figure 39).  
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Figure 39. LL-37 treatment did not alter the HRV-induced pro-inflammatory 
cytokine response in bronchial epithelial cells at later stages of infection. 
Bronchial epithelial cells (16HBE14o-) were infected with HRV1B (MOI 1) or left 
unstimulated in serum-free media for 2H, washed and re-immersed in fresh maintenance 
media for further 22h. Cells were treated with LL-37 for 2h, washed and re-immersed in 
fresh maintenance media for further 22h at 33oC.qPCR was conducted to determine IL-8 
(A), IL-6 (B) and CCL5 (C) gene expression. The GAPDH gene was used as a reference gene. 
Results are represented as the means +/- SEM from three independent experiments. 
Statistical analysis was performed using one-way ANOVA with Tukey’s multiple 
comparisons post-test. 
 
To confirm that the mRNA transcript levels were translated to changes at the 
protein level, we assessed cells supernatants for IL-8 protein release using ELISA 
(Figure 40). In agreement with mRNA data, rhinovirus infection considerably 
induced IL-8 release compared to uninfected cells (from 34.2pg/ml to 109.4pg/ml). 
Addition of LL-37 enhanced HRV-induced LL-37 (to 147.9pg/ml at 10µg/ml of LL-37 
and 230.6pg/ml at 30µg/ml of LL-37, *p<0.05). It is noteworthy that inflammatory 
concentrations of LL-37 (30µg/ml) increased IL-8 release in uninfected cells 
compared to negative control; however this was not statistically significant.  
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Figure 40. LL-37 enhances the HRV-induced inflammatory response in bronchial 
epithelial cells at later stages of viral infection. 
Bronchial epithelial cells (16HBE14o-) cells were infected with HRV1B (MOI 1) or left 
unstimulated in serum-free media for 2H, washed and re-immersed in fresh maintenance 
media for further 22h. Cells were treated with LL-37 for 2h, washed and re-immersed in 
fresh maintenance media for further 22h at 33oC. IL-8 protein levels were assessed by 
ELISA. Results are represented as the means +/- SEM from three independent experiments. 
Statistical analysis was performed using one-way ANOVA with Tukey’s multiple 
comparisons post-test to compare virus only to LL-37 treatment (* p<0.05). 
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5.3.5. Assessing the effects of low concentrations of LL-37 (1-10µg/ml) on the host 
cell inflammatory response to rhinovirus infection 
 
To determine the inflammomodulatory effects of low concentrations of LL-37 
during later stages of the rhinovirus replication cycle, 16HBE14o- cells were infected 
with HRV for 2h, washed and re-immersed in fresh maintenance media for 22h prior 
to LL-37 treatment for 24h at 33oC. The mRNA transcript levels of IL-8 (Figure 41A), 
IL-6 (Figure 41B), and CCL5 (Figure 41C) were determined by qPCR after a period of 
48h. Rhinovirus infection of 16HBE14o- cells strongly induced gene expression of all 
cytokines. The addition of LL-37 did not significantly alter the expression of HRV-
induced pro-inflammatory cytokines at any concentration tested. LL-37 treatment 
of uninfected cells did not induce the expression of pro-inflammatory cytokines 
above unstimulated cells. Poly I:C was used as a positive control and induced IL-8 
and IL-6 gene expression to a similar extent as HRV infection and strongly induced 
CCL5 above HRV infection (up to 1000-fold above unstimulated cells). 
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Figure 41. Low concentrations of LL-37 do not alter the pro-inflammatory cytokine 
response in HRV infection of bronchial epithelial cells. 
Bronchial epithelial cells (16HBE14o-) cells were infected with purified HRV1B (MOI 1) or left 
unstimulated in serum-free media for 2H, washed and re-immersed in fresh maintenance 
media for further 22h. Cells were washed and treated with LL-37 for 24h at 33oC. Poly I:C 
was used as a positive control for pro-inflammatory response and was incubated with 
16HBE cells for 48h in 5% FBS in IMDM. qPCR was conducted to determine IL-8 (A), IL-6 (B) 
and CCL5 (C) gene expression after 48h. The GAPDH and βActin genes were used as 
reference genes. Results are represented as the means +/- SEM from three independent 
experiments. Statistical analysis was performed using one-way ANOVA with Tukey’s 
multiple comparisons post-test. 
 
Again, to confirm that the mRNA transcript levels were correlated with protein 
release, we assessed cells supernatants for IL-8 (Figure 42A), IL-6 (Figure 42B) and 
CCL5 (Figure 42 C) protein release using ELISA assay. In agreement with mRNA data, 
infection with rhinovirus strongly induced all cytokines in comparison to uninfected 
cells, but addition of LL-37 did not significantly alter the release of HRV-induced pro-
inflammatory cytokines in comparison to virus alone.  
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Figure 42. Lower and physiologically relevant concentrations of LL-37 do not alter 
the pro-inflammatory cytokine response in HRV infection of bronchial epithelial 
cells. 
Bronchial epithelial cells (16HBE14o-) cells were infected with purified HRV1B (MOI 1) or left 
unstimulated in serum-free media for 2H, washed and re-immersed in fresh maintenance 
media for further 22h. Cells were washed and treated with LL-37 at concentrations 
indicated for 24h at 33oC. IL-8 (A), IL-6 (B) and CCL5 (C) protein levels were assessed by 
ELISA. Results are represented as the means +/- SEM from three independent experiments. 
Statistical analysis was performed using one-way ANOVA with Tukey’s multiple 
comparisons post-test. 
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5.4. Discussion 
 
The immunomodulatory activities of the sole human cathelicidin, LL-37, have been 
the subject of a number of studies demonstrating that the peptide can modulate 
immune and inflammatory pathways that may contribute to the resolution of viral 
infections. In this chapter, we investigated the ability of LL-37 to modulate the host 
inflammatory response to rhinovirus infection in the context of a range of LL-37 
concentrations and exposure regimens. hCAP18/ LL-37 is frequently expressed by 
cells in direct contact with the environment, and in the airways it is expressed in 
surface epithelia as well as serous and mucous cells of the bronchial airway (Bals et 
al. 1998). The expression of LL-37 in these cells is primarily controlled by 
inflammatory pathways, as well as by ER stress (Park et al. 2011) and 1, 25-
dihydroxyvitamin D3 concentrations (Gombart et al., 2005; Schauber and Gallo, 
2008). However, the involvement of host defence peptides in rhinovirus infection 
remains unclear, as only recently has it been identified that HDP are 
expressed/released during the innate response to this pathogen. A study by Rohde 
et al., (2014) analysed the endogenous expression levels of antimicrobial peptides 
in BAL fluid of subjects with HRV-induced experimental asthma exacerbations and 
demonstrated an increase in the levels of HNP1-3, however, no significant increase 
was seen in endogenous levels of LL-37. Nevertheless, a recent cohort study of 
hospitalised infants, which focused upon examining the role of LL-37 in 
bronchiolitis, revealed that infants with higher serum LL-37 levels were less likely to 
have RSV, but more likely to have HRV, indicating that elevated LL-37 levels were 
associated with rhinovirus infection (Mansbach et al., 2017).  
 
Infection of human airway epithelial cells with rhinovirus has been shown to induce 
the rapid production of several pro-inflammatory cytokines, including IL-8 (Kim et 
al, 2000; Subauste et al., 1995), IL-6 (Kim et al, 2000; Subauste et al., 1995), GM-CSF 
(Kim et al, 2000; Subauste et al., 1995) and CCL5 (Papadopoulos et al 2001). 
Increased levels of IL-6 (Zhu et al.1996), IL-8 (Zhu et al., 1997) and IL-1β (Proud et al. 
1994) were also detected in nasal washings taken from rhinovirus experimentally 
infected subjects. In this chapter, we focussed on the ability of LL-37 to modulate 
HRV-induced IL-8, IL6, and CCL5. These pro-inflammatory markers were chosen as 
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they are rapidly and strongly induced by rhinovirus infection both in vitro and in 
vivo, and have been implicated in the pathogenesis of rhinovirus infection. As 
markers of inflammation they have been extensively studied and associated with 
the severity of symptoms related to respiratory viral infections (Jacobs et al., 2013).  
 
To determine the impact of LL-37 treatment on rhinovirus-induced cytokine and 
chemokine responses in bronchial epithelial cells, HRV1B was pre-incubated with 
LL-37 prior to 16HBE14o- cell infection (“prophylactic treatment”) and expression 
levels of IL-8, IL-6 and CCL5 were determined after a total period of 24h. Our results 
indicated that LL-37 treatment in this exposure regimen was associated with 
reduced cytokine levels. Similarly, in RSV infection, the incubation of RSV with LL-37 
prior to infection of Calu-3 cells cultured at an air-liquid interface (ALI) resulted in a 
significant decrease in expression levels of IL-6, RANTES, CXCL10 and G-CSF 
(Harcourt et al., 2016). Similarly, in IAV-infected mice treated with LL-37 prior to, 
and during an IAV infection, the levels of IL-1β, GM-CSF, KC and RANTES determined 
in the BAL fluid were all significantly lower (Barlow et al., 2011). In Chapter 3, we 
demonstrate that incubation of HRV1B with LL-37 resulted in a significant drop in 
viral titer, indicating that the reduction in cytokine expression levels may be partly 
due to the reduced amount of viral RNA. 
We further evaluated our hypothesis by infecting cells for 2h prior to LL-37 
treatment for 22h at 33oC (“therapeutic treatment”) and determining the 
expression levels of the same cytokines after a total period of 24h. Exogenous LL-37 
treatment of infected cells did not alter IL-8, IL-6 and CCL5 gene expression. 
However, studies have shown that LL-37 used to therapeutically treat RSV-infected 
ALI calu-3 cells or Mycobacterium tuberculosis- infected macrophages resulted in a 
significant reduction in the expression levels of CCL5, IL-6, CXCL10 and G-CSF in RSV 
infection (Harcourt et al., 2016), and TNF-α and IL-17 in M. tuberculosis infection 
(Torres-Juarez et al., 2015). The differences observed between these studies and 
our own observations using similar treatment approaches, may be explained the 
use of different cells models and pathogens. 
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In this experimental regimen, rhinovirus infection induced IL-8, IL-6 and CCL5 gene 
expression to a greater extent when compared to the “prophylactic treatment” 
exposure regimen. The differences in gene expression levels observed between 
both exposures regimens could be explained by the use of different viral stocks. For 
the “therapeutic treatment” exposure regimen we used a purified virus stock and 
for the “prophylactic treatment” exposure regimen a crude virus stock. The use of a 
purified virus stock could potentially lead to an enhanced pro-inflammatory 
response in bronchial epithelial cells. 
In addition, our data indicates that LL-37 can be rapidly internalised and retained by 
16HBE14o- cells. Taken together this data indicates that LL-37 may be effective in 
part through the direct interaction with rhinovirus, and in part through uptake and 
interaction with16HBE14o- cells. In airway epithelial cells, HRV-induced IL-8 and IL-6 
production is primarily mediated by an NFkB-dependent transcription activation 
process (Zhu et al., 1997, 1996). The mechanism by which LL-37 modulates cell 
responses to infection is still unclear. Several cellular receptors have been 
identified, such as FPRL1 (De Yang et al., 2000), EGFR (Tjabringa et al., 2003), P2X7 
(Elssner et al., 2004), and GAPDH (Mookherjee et al., 2009). LL-37 has been shown 
to activate airway epithelial cells by transactivation of the EGFR via 
metalloproteinase-dependent processing of EGFR ligands (Tjabringa et al., 2003). 
Activation of these receptors by LL-37 may lead to downstream effects on 
inflammatory pathways. The ability of LL-37 to limit HRV-induced pro-inflammatory 
cytokine expression by bronchial epithelial cells may therefore also be partly due 
peptide-mediated effects on host cells. Previous studies showed that exogenous LL-
37 and mCRAMP inhibited NF-kB activity and TNF-α expression in response to 
Clostridium difficile toxin A and B in monocytes and mouse macrophages, 
respectively (Hing et al., 2013). It is therefore plausible that LL-37 reduces HRV-
associated inflammation by inhibiting NF-kB activity in response to rhinovirus 
infection of bronchial epithelial cells, however further studies are required to 
investigate this hypothesis.  
In previous studies utilising a BEAS-2B epithelial cell model, LL-37 was shown co-
localise with TLR3 in the endosome and the co-localization was increased in the 
presence of dsRNA – an intermediate in the replication cycle of rhinovirus (Singh et 
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al., 2013). LL-37 was also shown to enhance TLR3-mediated signalling and IL-6, 
CXCL10 and MCP-1 cytokine production in response to rhinovirus infection (Lai et 
al., 2011). This contrasts with our own data, in which LL-37 treatment was 
associated with reduced expression levels of IL-8, IL-6 and CCL5 in response to 
rhinovirus infection. TLR3 is an endosomal sensor involved in the recognition of 
rhinovirus infection in human airway epithelial cells and is responsible for 
modulating inflammatory responses to HRV infection (Slater et al., 2010). Previous 
studies have demonstrated that TLR3 is required for HRV-induced IL-8, CCL5 and 
CXCL10 (Slater et al., 2010), and while TLR3 has been associated with increased 
levels of pro-inflammatory mediators in response to rhinovirus infection, we believe 
the lower viral loads observed in LL-37 treated 16HBE14o- cells, may partly be 
responsible for the reduction in cytokine expression in this study.  
In order to further understand peptide-mediated effects on the bronchial epithelial 
cells during virus infection, we exposed cells to the TLR3 agonist, poly I:C, which 
mimics viral infection, and also to UV-inactivated HRV, which is able to enter cells 
but unable to replicate. Poly I:C is known to activate the antiviral pattern 
recognition receptors TLR3, RIG-I/MDA5 and PKR thus inducing signalling via 
multiple inflammatory pathways and triggering a strong inflammatory response in 
airway epithelial cells (Ritter et al., 2005; Slater et al., 2010). Bronchial epithelial 
cells were exposed to poly I:C for 2h, washed to remove non-internalised poly I:C, 
and treated with LL-37 for 4h. This experimental approach was designed to mimic 
rhinovirus infection in the context of the therapeutic treatment. A time-course 
experiment indicated that the expression levels of IFN1β and PKR induced by poly 
I:C peaked at 6h (Appendix 7), thus this time-point was chosen to investigate the 
poly I:C- induced pro-inflammatory cytokine response. Our observations revealed 
that poly I:C upregulated IL-8, IL-6 and CCL5 and the addition of LL-37, but not 
scrambled LL-37, significantly enhanced the poly I:C-induced IL-8, IL-6 and CCL5 
mRNA expression in a dose-dependent manner.  
In accordance with our own data, LL-37 was previously shown to enhance the poly 
I:C mediated induction of IL-6 and IL-8 cytokine production by BEAS2B cells (Lai et 
al., 2011). Due to its high affinity for nucleic acids, LL-37 has been shown to bind to 
DNA and facilitate its delivery across membranes (Zhang et al., 2010), and in 
155 
 
plasmacytoid dendritic cells, the LL-37-DNA/RNA complexes modulate the TLR9/7 
activation (Ganguly et al., 2009; Lande et al., 2007). Interestingly, studies have 
reported that poly I:C alone and poly I:C-LL-37 complexes can enter cells using a 
different endocytic mechanism, further demonstrating that trafficking of the poly 
I:C-LL-37 complex into endosomes was dependent on FPRL1 receptor in BEAS-2B 
cells (Singh et al., 2013). The experimental approach used in these reports (Lai et al., 
2011; Singh et al., 2013) consisted of the LL-37/poly I:C co-stimulation of BEAS-2B 
cells, which facilitated LL-37 binding to poly I:C forming LL-37-poly I:C complex 
before trafficking to the endosome. Our experimental approach exposed 16HBE14o- 
cells to poly I: C prior to LL-37 treatment. The differences in regimens used, and the 
similar results obtained in this study and those in the literature indicate that the 
formation of the complex prior to trafficking into the endosome may not be 
necessary for the enhanced TLR-3 signalling. However, the increased pro-
inflammatory response in the presence of LL-37 could be related to increased 
cytotoxicity, as poly I:C alone has been shown to be cytotoxic to bronchial epithelial 
cells and the combination of LL-37 was shown to increase the observed cytotoxic 
effects (Filewod et al., 2009). While the capacity of LL-37 to mediate TLR3-signalling 
during viral infections has been well documented, it would be interesting to further 
investigate the modulatory effects of the peptide on MDA-5 and RIG-I-signalling 
following rhinovirus infection. 
Our results showed that at 24h, UV-inactivated HRV infection of 16HBE14o- cells did 
not induce IL-8, IL-6 and CCL5 expression levels above uninfected cells. Previous 
studies have reported the ability of UV-inactivated rhinovirus to induce a significant 
IL-8 expression indicating that viral replication is not required for the IL-8 response 
(Newcomb et al., 2008). Early events before viral replication, such as viral 
attachment and internalisation may be sufficient for rhinovirus to induce an 
epithelial cell response (Newcomb et al., 2008). It is known that UV irradiation may 
partially inhibit viral attachment (Nuanualsuwan and Cliver, 2003), and therefore 
the lack of cellular response to UV-inactivated rhinovirus could be explained by an 
underestimation of the sufficient amount of virus to induce a host response, as well 
as, the 24h time-point chosen to perform the experiment. Our data also indicated 
that LL-37 treatment did not alter the expression levels of IL-8, IL-6 and CCL5 
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compared to UV-inactivated HRV alone, suggesting that when cells are infected with 
UV-inactivated rhinovirus, LL-37 did not exert measurable immunomodulatory 
effects. This suggests active viral replication is required to observe LL-37 mediated 
alteration of pro-inflammatory signalling although further studies will be needed to 
fully understand the mechanism through which LL-37 downregulates HRV-induced 
pro-inflammatory cytokine and chemokine production. Our data indicates that LL-
37 may be effective in part through the direct interaction with rhinovirus, and in 
part through uptake and interaction with airway epithelial cells. Previous studies 
showed that exogenous LL-37 and mCRAMP inhibited NF-kB activity and TNF-α 
expression in response to Clostridium difficile toxin A and B in monocytes and 
mouse macrophages, respectively (Hing et al., 2013). It is therefore plausible that 
LL-37 reduces HRV-associated inflammation by inhibiting NF-kB activity in response 
to rhinovirus infection of bronchial epithelial cells, however further studies are 
required to investigate this hypothesis.  
We investigated the effects of LL-37 on cytokine and chemokine expression induced 
in response to later stages of rhinovirus replicative cycle. Our data indicated that LL-
37 treatment at this point in the viral replication cycle enhanced the cytokine and 
chemokine responses of the cells. Statistical analysis showed that only LL-37 
(30µg/ml) + HRV co-stimulation exhibited a statistically significant increase in IL-8 
production in comparison to infected cells only (*p<0.05), indicating that co-
stimulation treatment synergistically increased IL-8 production in 16HBE14o- cells. 
The induction of an inflammatory cellular response by LL-37 at this stage may have 
a protective effect against an increased number of viral particles. LL-37 was shown 
to co-localise with TLR3 in the endosome and co-localization of LL-37 was increased 
in the presence of dsRNA (Singh et al., 2013). In 16HBE cells, TLR3 is primarily 
located in the endosomes, not at the cell surface, and is required for HRV29-
induced IL-8 expression in 16HBE airway cell (Sajjan, 2006). The airway epithelial 
cell line BEAS-2B displayed an increased expression of IL-6 when co-stimulated with 
HRV and LL-37 compared to HRV infection, and this was shown to be due to the 
activation of TLR3 (Lai et al., 2011). TLR3 and MDA-5, but not RIG-I, have been 
shown to be essential for maximal sensing of HRV dsRNA in BEAS-2B human 
bronchial epithelial cells. Both TLR3 and MDA5 signal through a common signalling 
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intermediate - IRF3 (Q. Wang et al., 2009). It appears that LL-37 may act to enhance 
the pro-inflammatory response of airway epithelial cells during viral infection by 
increasing the production of cytokines and chemokines. This could increase the 
number of recruited immune cells to the site of infection, ultimately leading to a 
more rapid and efficient clearance of the viral infection. 
In the respiratory tract, cathelicidin over-expression studies have shown improved 
clearance of pulmonary pathogens, which is consistent with the hypothesis that LL-
37 is an effector molecule of the airway immune responses (Bals et al., 1999a, 
1999b). In in vitro studies, LL-37 has been shown to induce IL-8 and IL-6 production 
in a dose- and time-dependent manner and to promote the activation of NF-kB, 
mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase 1/ 2 
(ERK1/2) and p38 in bronchial epithelial cells (Bowdish et al., 2004; Pistolic et al., 
2009; Tjabringa et al., 2003). In the context of the data in this study, LL-37 may act 
cooperatively to enhance the innate response to rhinovirus infection in bronchial 
epithelial cells in later stages of the infection.  
Finally, our data suggests that low concentrations of LL-37 did not alter the pro-
inflammatory response of airway epithelial cells to rhinovirus infection, although in 
contrast to our findings, previous studies have shown that the simultaneous 
exposure of bronchial epithelial cells to 3µg/ml of LL-37 and poly I:C or flagellin 
resulted in an increase production of IL-8 (Filewod et al., 2009). We believe, 
therefore, that in the context of an active replicating pathogen, higher 
concentrations of LL-37 may be required to elicit an effect. 
In summary, our data indicates that the capacity of LL-37 to modulate the pro-
inflammatory response of bronchial epithelial cells to HRV could have a strong 
influence on host cell responses to infection. In this chapter, we have shown that at 
early stages of rhinovirus infection, LL-37 reduces the HRV-induced expression of IL-
8, IL-6 and CCL5, but at later stages of infection, LL-37 enhances the HRV-induced 
expression of IL-8, IL-6 and CCL5. We suggest that at earliest stages of infection, LL-
37 modulates inflammation primarily by direct anti-viral mechanisms, as indicated 
by the reduction in viral load. However, at later stages of infection, LL-37 may act as 
stimulatory agent in order to increase the sensitivity to rhinovirus infection. 
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However, it is clear that further studies are required to determine the exact 
mechanisms and signalling pathways by which LL-37 modulates inflammatory 
responses to rhinovirus infection. 
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CHAPTER 6 
Investigating LL-37 ability to 
modulate cell death pathways in 
rhinovirus-infected airway 
epithelial cells 
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Chapter 6. Investigating LL-37 ability to modulate cell death 
pathways in rhinovirus-infected airway epithelial cells  
 
6.1. Introduction 
6.1.1. Apoptotic and necrotic cell death  
Apoptosis is a genetically programmed and tightly regulated form of cell death 
which is characterised by distinctive morphological changes including cell shrinkage, 
blebbing of the plasma membrane, chromatin condensation and nuclear 
fragmentation (Kerr et al., 1972). These morphological apoptotic characteristics are 
a strategic mechanism to contain damage associated molecular patterns (DAMPs) 
and avoid undesirable immune responses (Green et al., 2009). Apoptosis is induced 
by two main pathways: the extrinsic pathway which is initiated by binding of death 
ligands, such as TNF or Fas, to extracellular death receptors, resulting in the 
activation of caspase-8 followed by downstream caspase-7 and -3 activation; and 
the intrinsic pathway, which is initiated by internal signalling, resulting in 
mitochondrial outer membrane permeabilization with cytochrome c release into 
cytoplasm. This is followed by apoptosome formation, activation of caspase-9 and 
downstream activation of caspase-3 and caspase-7 (Shiozaki et al., 2002). Caspases 
are a family of cysteine proteinases which coordinate apoptotic cell death. They are 
generated by proteolytic cleavage of their inactive pro-forms, and are grouped into 
initiator caspases (caspase-2, -8, -9), executioner caspases (caspase-3, -6 and -7) and 
inflammatory caspases (caspase-1, -4, and -5).  
Necrosis has historically been considered a passive form of cell death induced by 
accidental injury of tissue with no activation of any specific cellular pathway. The 
typical morphological characteristics that define necrotic cells include early loss of 
plasma membrane integrity and cell swelling which culminate in the cell bursting 
and releasing the intracellular contents (Kögel and Prehn, 2013). However, in 
addition to passive necrosis, several studies have described that cells can undergo 
programmed necrosis (aka necroptosis), which occurs in the absence of chromatin 
condensation and caspase activation (Cho et al., 2009; Oberst et al., 2011 and 
Rodriguez et al., 2016).  
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In this chapter we assessed apoptosis and necrosis by flow cytometry quantification 
of FITC-labelled annexin V and propidium iodide (PI) staining. In healthy cells the 
plasma membrane is composed of lipids asymmetrically distributed in the inner and 
outer leaflets of the plasma membrane and one of these lipids, known as 
phosphatidylserine (PS), is located in the inner leaflet of the plasma membrane. 
Early events of apoptosis include the translocation of PS from the inner leaflet to 
the outer leaflet of the plasma membrane. AnnexinV is a 36 kDA Ca2+dependent 
phospholipid-binding protein with high affinity to PS, and can be fluorescently 
labelled in order to detect PS that is present in the surface of apoptotic cells by flow 
cytometry. Later stages of apoptosis and necrosis are accompanied by loss of 
membrane integrity, which can be stained with Annexin V used in combination with 
PI. Healthy cells with intact plasma membranes exclude PI; however, in damaged 
and dead cells the plasma membrane becomes permeable to PI. Consequently, 
healthy cells are negative for both annexin V and PI staining, early apoptotic cells 
are positive for annexin V and negative for PI staining, and late apoptotic or necrotic 
cells are positive for both annexin V and PI staining (Crowley et al., 2016). In 
addition we further assessed apoptosis by detecting caspase-3 activation through 
flow cytometry quantification of cleaved caspase-3.   
  
 
 
 
 
 
 
 
Figure 43.Representation of apoptotic and necrotic cell death. 
(A) Illustration showing cell death markers used for detection of apoptotic and necrotic cells 
death. (B) Representative dot blot of 16HBE14o- treated with camptothecin CPT (50 ng/ml) 
for 48h at 33oC. 
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The modulation of cell death pathways has been proposed as an important 
component of the pathogenesis of viral infections (Thomson, 2001) and most 
picornaviruses have been shown to induce cytopathic effects on host cells. Several 
studies have demonstrated, under certain conditions, that some of these viruses 
induce apoptotic cell death pathways  (Belov et al., 2003; Carthy et al., 2003; Girard 
et al., 1999). 
The dysregulation of apoptosis have been associated with the development of a 
wide diversity of diseases in humans, including cancer, autoimmune diseases, and 
neurodegenerative disorders (Bellamy et al., 1995). Nevertheless, apoptosis may be 
an important host defense mechanism for the clearance of viral infections. 
However, certain viruses have evolved to induce apoptosis as a mechanism of 
dissemination and to avoid the detection of the immune system. Poliovirus (PV) is 
an enterovirus part of the family Picornaviridae and is the etiological agent of 
paralytic poliomyelitis. The cytopathic effects of PV on the central nervous system 
(CNS) were shown to be associated with the induction of apoptosis during paralytic 
poliomyelitis. In vitro studies showed that PV infection activated an apoptotic 
pathway, involving mitochondrial damage, cytochrome c release, followed by 
activation of caspase-9 and caspase-3, which suggests that the major apoptotic 
pathway induced by PV infection is mitochondrial mediated (Belov et al., 2003). In 
vivo studies using transgenic mice expressing the human PV receptor demonstrated 
that PV infection induced apoptosis by displaying DNA fragmentation in CNS tissue 
from paralysed mice (Girard et al., 1999). Rhinoviruses have also been associated 
with apoptosis, a study by Taimen et al. (2004) demonstrated that HRV1B and HRV9 
infection of HeLa cells induced apoptosis. However, this study did not fully 
characterise the different apoptotic pathways induced by rhinovirus. A recent study 
revealed that following HRV14 infection, apoptotic cell death was observed in both 
HeLa cells and 16HBE14o- cells and this was accompanied by the release of 
cytochrome c and activation of caspase-9 and -3, but not caspase-8. This indicates 
that HRV14 induces apoptosis predominantly by the intrinsic pathway. The use of 
general caspase inhibitors resulted in the reduction of released virus, which 
indicates that apoptosis may be a key pathway for the release of newly synthesised 
viral particles (Deszcz, 2005).  
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The human cathelicidin, LL-37, has previously shown to have contrasting effects on 
apoptotic cell death pathways in different cells (Barlow et al., 2010, 2006; Lau et al., 
2006; Li et al., 2009; Suzuki et al., 2011). For example, it was shown that LL-37 
preferentially induced the apoptosis of Pseudomonas aeruginosa-infected bronchial 
epithelial cells, via induction of mitochondrial membrane depolarization, 
cytochrome c release and activation of caspase-9 and -3 (Barlow et al., 2010). In 
addition, although not in the context of infection, LL-37 was shown to induce 
apoptosis in primary epithelial cells possibly involving the activation of P2X7 
receptor, which has been shown to be a partial receptor for LL-37 –host cell 
interaction and signalling (Barlow et al., 2006). In contrast, in keratinocytes, LL-37 
was shown to supress camptothecin-mediated apoptosis via a COX-2/PGE-2 
antiapoptotic pathway (Chamorro et al., 2009).  
In this chapter we aim to investigate LL-37 ability to modulate apoptotic cell death 
in the context of rhinovirus infection of bronchial epithelial cells using different 
exposure regimens and different experimental methods to assess apoptotic and 
necrotic cell death. 
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6.2. Materials and Methods 
6.2.1. Annexin V/PI detection by flow cytometry 
To assess cell death pathways in infected cells, A549 and 16HBE14o- cells were used 
in in vitro models of infection and a number of treatment approaches were 
employed. Briefly, A549 and 16HBE14o- cells, were seeded at 1x105 and 5x104 in a 
12-well plate, respectively, and incubated at 37oC / 5% CO2. After 24h, A549 and 
16HBE14o-cells were infected with HRV (MOI 1 and MOI 5) for 2h in serum-free 
media, washed and treated with LL-37 (0-30µg/ml) for 22h in DMEM or IMDM 
supplemented with 1% (v/v) Utroser™ G Serum at 33oC, respectively (Figure 16). In 
other experimental approaches with longer infection periods, 16HBE14o- cells were 
infected with purified HRV (MOI 1) for 2 h in serum-free media, washed and re-
immersed in IMDM supplemented with 5% FBS for 22h at 33oC. Cells were washed 
prior to two different LL-37 exposure regimens which included (1) cells treated with 
LL-37 (10 and 30µg/ml) for 2h washed and re-immersed in IMDM supplemented 
with 5%FBS for 22h at 33oC (Figure 32) or (2) cells treated with low concentrations 
of LL-37 (1 and 10µg/ml) for 24h in IMDM supplemented with 1% (v/v) Utroser™ G 
Serum (Figure 33). Positive controls for apoptosis and necrosis were cells treated 
with camptothecin and scraped cells, respectively. After each treatment, media was 
collected; cells were washed and detached with 0.05% trypsin-EDTA. Trypsin was 
subsequently neutralised by the addition of cell media and cells were then placed in 
flow cytometry tubes and centrifuged at 230 x g for 5 minutes. Supernatant was 
discarded and cells were re-suspended in 2 ml of annexin V binding buffer (1x) and 
the wash step was repeated twice. Supernatant was discarded, leaving 
approximately 200µl in which 2.5 µl FITC-labeled annexin V (BD Pharmigen, Oxford, 
UK) was diluted. Cells were incubated for 20 minutes at room temperature in the 
dark, and once again centrifuged to remove FITC-Annexin V, and subsequently re-
suspended in binding buffer. Immediately prior to analysis by flow cytometry, 2.5 µl 
of propidium iodide (BD Pharmigen™, Oxford, UK) was added to cells.  
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6.2.2. Detection of cleaved caspase-3 and HRV1B by flow cytometry  
In order to detect HRV and activation of caspase-3 during viral replication, a pan-
enterovirus monoclonal antibody was used for HRV VP3 detection and anti-cleaved 
caspase 3 antibody was used to detect cleaved caspase-3. Briefly, 16HBE14o- cells 
were infected with purified HRV (MOI 1) for 2h in serum-free media, washed and re-
immersed in IMDM supplemented with 5%FBS for 4, 16, 22 and 46h at 33oC. Cells 
treated with camptothecin (6µM) were used as a positive control for caspase-3 
activation. After each time-point, supernatants were collected and cells were 
detached with 0.05% trypsin-EDTA (GIBCO, UK). Cells and supernatants were 
collected into a FACS tube and centrifuged at 300 x g for 5 minutes. Supernatants 
were discarded and re-suspended in 4% PFA for 15minutes at room temperature. 
PBS was added to dilute PFA and cells were centrifuged at 300 x g for 5 minutes. 
Supernatants were discarded and cells were permeabilised by adding ice cold 90% 
methanol while gently vortexing. Cells were incubated for 30 minutes on ice. 
Methanol was removed by washing cells with PBS and centrifuging cells at 400 x g 
for 4 minutes. Cells were re-suspended in 100µl of diluted primary antibodies in 
0.5% BSA in PBS (pan-enterovirus monoclonal antibody, mouse, 1:200 and cleaved 
caspase-3, rabbit, 1:800) and respective isotype controls (mouse and rabbit used at 
the same concentrations as the primary antibodies). Cells were incubated for 1h at 
room temperature and then washed with PBS before re-suspending cells in 100 µl 
of diluted goat PE anti-mouse (1:1000) and goat BV421-anti-rabbit (1:1000) in 0.5% 
BSA in PBS. Cells were incubated for 30 minutes at room temperature, and washed 
twice in 0.5% BSA in PBS before flow cytometry analysis in a BD FACS Celesta 
instrument (BD Biosciences, UK). In order to determine if LL-37 modulates caspase-
3 activation in HRV-infected cells, 16HBE14o- cells were infected with purified HRV 
(MOI1) for 2h in serum-free media, washed and re-immersed in IMDM 
supplemented with 5% FBS prior to treatment with LL-37 (1 and 10µg/ml) for 24h in 
IMDM supplemented with 1% v/v Ultroser G at 33oC (Figure 33). Cells treated with 
camptothecin (6µM) were used as a positive control for caspase-3 activation. 
Supernatants and trypsinised cells from each condition were collected in flow 
cytometry tubes and centrifuged at 300 x g for 5 minutes. Cells were washed with 
PBS and supernatants were discarded before incubation with 4% PFA for 15 minutes 
at room temperature. Cells were washed with PBS at 300 x g for 5 minutes and 
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supernatants were discarded. Cells were re-suspended in 0.05% saponin in PBS and 
centrifuged immediately at 400 x g for 4 minutes. Blocking was performed with 10% 
goat serum in 0.05% saponin in PBS for 20 minutes at room temperature and cells 
were subsequently centrifuged at 400 x g for 4 minutes. Cells were then re-
suspended in 100µl primary antibody (anti-cleaved caspase 3, rabbit, 1:800) and 
isotype control (rabbit isotype control, 1:800) diluted in 10% goat serum in 0.05% 
saponin in PBS and incubated overnight at 4oC. Cells were washed with PBS and re-
suspended in 100µl secondary antibody (BV421-anti-rabbit, 1:1000) diluted in 10% 
goat serum in 0.05% saponin in PBS. Cells were washed twice with PBS before flow 
cytometry analysis in a FACS Celesta instrument. 
6.2.2. Lactate dehydrogenase (LDH) quantification 
16HBE14o- cells were infected with HRV (MOI 5) for 2h in serum-free media, washed 
and treated with LL-37 (0-30µg/ml) in IMDM supplemented with 1% (v/v) Ultroser G 
for 22h at 33oC. After 24h, cell supernatants were aspirated and LDH activity was 
measured using LDH cytotoxicity detection kit (Promega, UK) according to 
manufacturer’s instructions. Controls included untreated cells as a negative control, 
and cells treated with lysis buffer (1x) 45 minutes before end of each treatment, as 
a positive control for maximum LDH release. The formula used to calculate the 
percent LDH release was: 
% LDH release (% cytotocity) = 100 × Experimental LDH Release (OD492) 
                                                                 Maximum LDH Release (OD492) 
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6.3. Results  
 
6.3.1. Assessment of the capacity of LL-37 to modulate cell death of HRV-infected 
airway epithelial cells 
In order to determine whether LL-37 modulated host cell apoptosis or necrosis of 
HRV-infected airway epithelium, the human alveolar epithelial cell line A549 was 
infected with HRV1B (MOI 1 or 5) for 2h prior to treatment with LL-37 (10 and 30 
µg/ml) for further 22h, or treated with camptothecin (30 µM) as a positive control 
for apoptosis. These cells were examined for apoptotic and necrotic cell death by 
flow cytometry. HRV alone did not induce cell death at this time-point (Figure 44. LL-
37 does not modulate apoptotic or necrotic cell death pathways in A549 cells infected with 
HRV1B. A, B), and this was also the case with LL-37 alone (Figure 44. LL-37 does not 
modulate apoptotic or necrotic cell death pathways in A549 cells infected with HRV1B. C, 
D). LL-37 treatment of infected cells did not increase induction of apoptosis or 
necrosis in this cell line (Figure 44. LL-37 does not modulate apoptotic or necrotic cell 
death pathways in A549 cells infected with HRV1B. A, B), and a scrambled LL-37 peptide 
also had no effect on apoptosis or necrosis (Figure 44A, B).  
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Figure 44. LL-37 does not modulate apoptotic or necrotic cell death pathways in 
A549 cells infected with HRV1B. 
A549 cells were left untreated or infected with HRV1B (MOI 1 or 5) for 2h in serum-free 
media at 33oC. Cells were washed and treated with LL-37 (10 and 30 µg/ml) for 22h at 33oC. 
After a period of 24h, cells were stained with Annexin V / PI and assessed by flow 
cytometry. (A, C) Graph of percentage of cell population that was AV+ / PI– (early 
apoptosis) and AV+ / PI+ (late apoptosis). (B, D) Graph of percentage of cell population that 
was AV– / PI+ (necrosis). (E) Representative scatter plot for each treatment. Results are 
represented as the means  SEM from three independent experiments. Statistical analysis 
was performed using one-way ANOVA with Tukey’s multiple comparisons post-test.   
 
The capacity of LL-37 to induce or suppress cell death in HRV-infected airway 
epithelial cells was also investigated in the 16HBE14o- bronchial epithelial cell line. 
16HBE14o- cells were infected with HRV1B (MOI 5) for 2h prior to treatment with LL-
37 (10 and 30 µg/ml) for further 22h, or with camptothecin as a positive control 
(30µM). Apoptotic and necrotic cell death was assessed by flow cytometry. In 
accordance with our observations in 16HBE14o- cells, HRV1B alone did not induce 
apoptotic or necrotic cell death in this cell line (Figure 45 A, B). However, LL-37 
peptide alone did induce necrosis at the highest treatment concentration (30 µg/ml, 
*p<0.05) compared to untreated cells (Figure 45B). LL-37 treatment of cells infected 
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with HRV did not have any effect on the basal rate of apoptosis in this cell line, 
however LL-37 treatment of infected cells also resulted in a significant increase in 
necrotic cell death at 30 µg/ml (*p<0.05) compared to infected control cells (Figure 
45 A,B). Assessment of the release of cytosolic lactate dehydrogenase indicated that 
LL-37 (30µg/ml) treatment of HRV infected cells resulted in a statistically significant 
increase in LDH detected in the supernatant(*p < 0.05), but that this did not occur 
when healthy cells were treated with LL-37 (Figure 45 D). A scrambled LL-37 peptide 
had no effect on cell death under any conditions (Figure 45 A,B,C and D).  
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Figure 45. Inflammatory concentrations of LL-37 induce necrotic cell death in HRV-
infected bronchial epithelial cells. 
16HBE140- cells were left untreated or infected with HRV1B (MOI 5) for 2h in serum-free 
media at 33oC. Cells were washed and treated with LL-37 (10 and 30µg/ml) for 22h at 33oC. 
After a period of 24h, cells were stained with Annexin V /PI and cell death was assessed by 
flow cytometry. (A) Graph of percentage of cell population that was AV+ / PI– (early 
apoptosis) and AV+ / PI+ (late apoptosis). (B) Graph of percentage of cell population that 
was AV– / PI+ (necrosis). (C) Representative scatter plot for each treatment. (D) Cytosolic 
release of LDH assessed by LDH assay. Results are represented as the means  SEM from 
three independent experiments. Statistical analysis was performed using one-way ANOVA 
with Tukey’s multiple comparisons post-test (* P 0.05). 
 
 
6.3.2. Assessment of LL-37 mediated modulation of cell death at later stages of 
HRV infection in bronchial epithelial cells 
In order to determine the ability of LL-37 to modulate cell death pathways at later 
stages of the HRV replication cycle, 16HBE14o- cells were infected with HRV1B (MOI 
1) for 2h, washed and re-immersed in fresh media for 22h prior to treatment with 
LL-37 (10 and 30µg/ml) for 2h before re-immersing cells in fresh media for further 
22h. Cells treated with camptothecin (50ng/ml) were used as a positive control for 
apoptosis and apoptotic and necrotic cell death was assessed by flow cytometry. At 
48h, cells infected with HRV showed significantly increased rates of apoptosis in 
comparison to uninfected cells (**p<0.01 and *p<0.05, respectively) [Figure 46A], 
but necrotic cell death rates were unaltered (Figure 46B). LL-37 treatment of 
infected cells reduced the rate of apoptosis in cells to levels that were no longer 
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significantly different from the negative control. The scrambled LL-37 peptide had 
no effect on the rate of HRV-mediated apoptosis (Figure 46 A). LL-37 alone had no 
effect on the basal levels of apoptosis and necrosis in this cell line (Figure 46A,B). LL-
37 treatment of HRV-infected cells did induce a small increase in levels of necrosis 
of infected cells but this effect was not statistically significant (Figure 46B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 46. LL-37 treatment of infected cells reduced the rate of apoptosis in cells 
to levels that were no longer significantly different from the negative control. 
Bronchial epithelial cells (16HBE14o-) were left untreated or infected with purified HRV1B 
(MOI 1) for 2h in serum-free media, washed and re-immersed in media supplemented with 
5% FBS for 22h at 33oC. Cells were washed and exposed to LL-37 for 2h, washed and re-
immersed in media supplemented with 5% FBS for 22h. After a total period of 48h, 
16HBE14o- cells were stained with Annexin V / PI and cell death was assessed by flow 
cytometry. (A) Graph of percentage of cell population that was AV+ / PI– (early apoptosis) 
A. 
B. 
Annexin V -FITC 
CPT 50ng/ml 
HRV+ LL-37 
(10) 
HRV+ LL-37 
(30) 
HRV+ sLL-37 
(30) 
HRV MOI 1 
LL-37 (10) LL-37 (30) Untreate
d P
ro
p
id
iu
m
 Io
d
id
e
  
C. 
172 
 
and AV+ / PI+ (late apoptosis). (B) Graph of percentage of cell population that was AV– / PI+ 
(necrosis). (C) Representative scatter plot for each treatment. Results are represented as 
the means  SEM from four independent experiments. Statistical analysis was performed 
using one-way ANOVA with Tukey’s multiple comparisons post-test (* P  0.05, **P  0.01). 
 
Respiratory epithelial cells, typically the first cells types to be infected, have an 
important role in limiting the virus and activating the immune system to respond to 
infection. Viral infection triggers the production and release of host defense 
peptides, such as cathelicidins, which initiate the host innate and adaptive immune 
responses. To determine the capacity of lower, physiologically relevant 
concentrations of LL-37 to modulate cell death in infected airway epithelial cells, 
the human bronchial epithelial cell line, 16HBE14o-, was infected for 2h with HRV 1B 
(MOI 1), washed and re-immersed in fresh media for 22h prior to treatment with LL-
37 (1 and 10µg/ml) for 24h. Cells treated with camptothecin (50 ng/ml) were used 
as a positive control for apoptosis, and apoptotic and necrotic cell death was 
assessed by flow cytometry. Infected cells showed significant levels of apoptosis in 
comparison to uninfected cells (*P<0.05) [Figure 47A], but necrotic cell death was 
not observed (Figure 47B). Similarly, infected cells treated with scrambled LL-37 also 
showed increased rates of apoptosis (Figure 47A). LL-37 treatment of healthy cells 
did not alter apoptosis and necrosis (Figure 47A,B). Interestingly, LL-37 treatment of 
infected cells reduced the rate of apoptosis in cells to levels that were no longer 
significantly different from the negative control (Figure 47A). In addition, treatment 
of infected cells with LL-37 (10µg/ml) induced a significant increase in necrosis 
compared to uninfected cells at this time point, although only 3.5% of cells were 
found to be necrotic (**p<0.01) [Figure 47B].   
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Figure 47. Lower and physiologically relevant concentrations of LL-37 suppress 
HRV-induced apoptosis, but enhance necrosis in bronchial epithelial cells 
Bronchial epithelial cells (16HBE14o-) cells were left untreated or infected with purified 
HRV1B (MOI 1) for 2h in serum-free media, washed and re-immersed in media 
supplemented with 5% FBS for 22h at 33oC. Cells were washed and treated with LL-37 (1 
and 10µg/ml) for 24h in media supplemented with 1% Ultroser G. After a total period of 
48h. 16HBE14o cells were stained with Annexin V / PI and cell death was assessed by flow 
cytometry. (A) Graph of percentage of cell population that was AV+ / PI– (early apoptosis) 
and AV+ / PI+ (late apoptosis). (B) Graph of percentage of cell population that was AV– / PI+ 
(necrosis) (C) Representative scatter plot for each treatment. Results are represented as the 
means  SEM from five independent experiments. Statistical analysis was performed using 
one-way ANOVA with Tukey’s multiple comparisons post-test (* p≤0.05, **P≤0.01). 
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6.3.3. Assessment of HRV and LL-37 mediated effects on activation of caspase 3 
 
To establish if LL-37 modulated apoptosis in rhinovirus-infected cells, we assessed 
caspase-3 activation by flow cytometry. Our initial approach was to assess the 
ability of HRV1B to induce caspase-3 activation in 16HBE14o- cells during viral 
replication. A pan-enterovirus monoclonal antibody was used to detect rhinovirus 
and anti-cleaved caspase-3 was used to detect cleaved caspase-3 by flow cytometry 
at 6, 18, 24 and 48h post-HRV1B infection (Figure 48). Camptothecin was used a 
positive control. The data showed a substantial increase in cleaved caspase-3 at 24h 
post-infection compared to uninfected cells (from 4.8% to 13.94%). From those 
13.94% cells positive for cleaved caspase-3, human rhinovirus was detected in 
2.54% of this population. Similar results were seen at 48h after infection (12.13% 
positive cells for cleaved caspase-3); however, there was a reduction in the number 
of cells positive for HRV (from 2.54% at 24h to 1.53% at 48h) [Figure 48].  
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Figure 48. Rhinovirus activates caspase 3 in bronchial epithelial cells. 
16HBE14o- cells were left unstimulated or infected with purified HRV1B (MOI 1) for 2h, 
washed and re-immersed in media supplemented with 5% FBS in IMDM for 4, 16, 22 or 46h 
at 33oC. As a positive control cells were treated with camptothecin (6µM) in 5% FBS in 
IMDM. Cleaved caspase-3 was detected using primary anti-cleaved caspase 3 (rabbit) 
antibody and secondary BV421 Goat Anti-Rabbit antibody. HRV1B VP3 protein was 
detected using primary pan-enterovirus monoclonal antibody (mouse) and secondary PE 
Goat anti-mouse antibody. Representative dot blots at each time point for uninfected, HRV-
1B infected and CPT-treated 16HBE14o- cells.  
 
To determine if LL-37 exposure modulated caspase-3 activation in HRV-infected 
cells, 16HBE14o- cells were infected with purified HRV (MOI 1) for 2h, washed and 
re-immersed in fresh media for 22h prior to treatment with low concentrations of 
LL-37 (1 and 10µg/ml) for 24h. Flow cytometry analysis indicated that rhinovirus 
infection alone increased cleaved caspase-3 in comparison to uninfected cells but 
this increase was not significant (Figure 49). LL-37 treatment of healthy cells also 
increased cleaved caspase-3 levels to a comparable extent as HRV only. Infected 
cells treated with 1µg/ml of LL-37 showed a reduction in cleaved-caspase-3 levels, 
in comparison to HRV alone, similar to levels observed in uninfected cells. The 
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scrambled LL-37 control did not have any effects on the levels of cleaved caspase-3 
in any of the conditions tested (Figure 49). However, the isotype control used for 
detection of background cell staining did also show positive events for cleaved 
caspase-3 staining, which indicates that the observed staining for cleaved caspase-3 
in the other samples may be partly due to background staining.  
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Figure 49. LL-37 does not alter caspase 3 activation in HRV-infected 16HBE cells. 
16HBE14o cells were left unstimulated or infected with purified HRV1B (MOI 1) for 2h, 
washed and left in contact with 5% FBS in IMDM for 22h. Cells were washed and LL-37 (1-10 
µg/ml) was added to cells for 24h in 1%UltraGserum in IMDM. Cleaved caspase-3 was 
detected by flow cytometry. Cleaved caspase-3 was detected using primary anti-cleaved 
caspase 3 (rabbit) antibody and secondary BV421 Goat Anti-Rabbit. (A) Representative dot 
blots for each treatment. (B) Representative graph for % of positive events for cleaved 
caspase-3. Results are represented as the means +/- SEM from two independent 
experiments. 
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6.4. Discussion 
 
The sole human cathelicidin, LL-37, is a pleiotropic peptide with the ability to 
modulate host immunity and inflammation, but the underlying mechanisms of 
action by which LL-37 contributes to host defense against infections is still unclear. 
Previously, LL-37 was shown to preferably promote the apoptosis of Pseudomonas 
aeruginosa-infected human bronchial epithelial cells (Barlow et al., 2010); and thus 
the modulation of apoptotic pathways in rhinovirus-infected airway epithelial cells 
could represent a novel peptide-mediated host cell mechanism to reduce viral 
infection. In this chapter, we investigated the potential for LL-37 to modulate cell 
death pathways in rhinovirus-infected airway epithelial cells in the context of 
varying peptide concentrations and exposure regimens using different experimental 
methods to assess apoptotic and necrotic cell death.  
 
In this study we found that treating HRV-infected cells with physiological 
concentrations of LL-37 (10-30µg/ml) did not result in increased rates of apoptotic 
cell death, when cells were infected for 2h (MOI 1 and MOI 5) prior to LL-37 
treatment for 22h. This was in contrast to previous studies using bacterial infection 
models (Barlow et al., 2010), although differences in experimental approach and 
treatment regimens should be noted. This indicates that, at this stage of viral 
infection and replication (24h post infection) alteration of apoptotic cell death may 
not represent a mechanism by which LL-37 reduces viral replication in epithelial 
cells. However, treatment of uninfected and HRV-infected 16HBE14o- cells with 
physiological inflammatory concentrations of LL-37 (30µg/ml) did lead to a 
significant increase in necrosis (*p≤0.05) which was further confirmed by 
measurement of the cytosolic release of lactate dehydrogenase into cell 
supernatants.  
 
In chapter 3 we observed a significant decrease in virus titer, measured by TCID50 
assay, in HRV-infected 16HBE14o- cells treated with 30µg/ml LL-37 (Figure 21). 
Furthermore, we observed statistically significant increase in the release of the pro-
inflammatory IL-8 chemokine in uninfected and HRV-infected cells treated with 
30µg/ml LL-37. The prolonged exposure time utilised here (22h) and the relatively 
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high concentrations of LL-37, while still within physiological estimates, may 
therefore contribute to the cytopathic effects we observed in the 16HBE14o- cells 
(Appendix 12). This indicates that LL-37 may have differential roles in the innate 
immune system depending on the concentration found at the site of infection.  
 
In accordance with our findings, high concentrations of LL-37 (≥30µg/ml) have been 
shown to be cytotoxic to eukaryotic cells (Aarbiou et al., 2006; Barlow et al., 2006; 
Johansson et al., 1998; Thomas et al., 2017). In human primary nasal epithelial cells 
and in mouse macrophages, LL-37 was shown to cause cellular death through the 
pro-inflammatory necrotic and/or pyroptosis pathways (Thomas et al., 2017). 
Pyroptosis, also known as caspase-1-dependent cell death, has been described 
morphologically by the loss of plasma membrane integrity and the extracellular 
release of cytoplasmic content, followed by plasma membrane “re-seal” and 
swelling, DNA fragmentation and nuclear condensation (Labbé and Saleh, 2008). 
Caspase-1, also known as interleukin-1β converting enzyme, does not play a role in 
the classical apoptotic pathways and is required for the cleavage of pro-IL-1β, -IL-18 
and, -IL-33 into their active cytokine forms, which have been shown to play an 
important role in inflammatory response to infection (Fantuzzi and Dinarello, 1999). 
Contrary to apoptotic cell death, the production of IL-1β and IL-18 during pyroptosis 
results in a highly inflammatory state (Rock and Kono, 2008). This further reveals 
the role of LL-37 in modulating alternative cell death pathways, such as pyroptosis. 
Future work would involve investigating the role of LL-37 in modulating pryroptosis 
in the context of viral infection.  
 
By inducing necrotic cell death, LL-37 appears to damage both infected and non-
infected cells inducing a pro-inflammatory response and impairing viral replication. 
However, it remains unclear if LL-37 induces cell death universally through a 
necrotic pathway or an apoptotic cell death pathway. Nevertheless, in in vitro 
experiments, apoptotic cells are not cleared by alveolar macrophages as they are in 
vivo. Therefore, cells will eventually lyse and gain a necrotic appearance, which is 
known as secondary necrosis (Arandjelovic and Ravichandran, 2015). Therefore, the 
increase in necrotic cell death observed in LL-37-treated 16HBE14o- cells measured 
at 24h could be in fact secondary necrotic cell death.  
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Apoptosis and necrosis were evaluated by flow cytometry quantification of FITC-
labelled annexin V and propidium iodide (PI) staining, and it is worth noting that this 
approach does not necessarily distinguish between cells that have undergone 
apoptosis and subsequently become necrotic from those that have died as a result 
of a necrotic cell death because cells can stain for both annexin V and PI. Therefore, 
different results may be obtained utilising an in vivo model of rhinovirus infection 
and this should be considered for future investigation in this area.  
 
We further assessed apoptotic cell death by detecting cleaved-caspase 3 by flow 
cytometry. The cleavage of caspase-3 is generally considered a universal marker for 
cells undergoing apoptosis because caspase-3 activity is required for the 
morphological and biochemical changes that occur during apoptosis (Elmore, 2007; 
Poręba et al., 2013). Caspases, a family of cysteine proteases, are generally present 
in healthy cells as inactive zymogens, however when stimulated they undergo 
autolytic cleavage becoming active. Caspase-3 is cleaved in two sites, resulting in 
three fragments: the pro-domain, the large and small subunit. The first cleavage 
only partially activates caspase-3 and the second autolytic cleavage results in full 
activation (Martin et al., 1996). The cleaved fragments remain intact during 
apoptosis and can be detected using fragment-specific antibodies (Crowley and 
Waterhouse, 2016). The cleaved caspase-3 antibody used in our experiments 
detects endogenous levels of the large fragment (17/19kDa) of activated caspase-3, 
and does not recognise full length caspase-3 or other cleaved caspases. This 
antibody can then be used to specifically label cells in which caspase cleavage has 
occurred, therefore allowing for the quantification of apoptosis by flow cytometric 
detection of the cleaved caspase-3.  
 
Interestingly, we found that physiologically relevant concentrations of LL-37 
protected bronchial epithelial cells from HRV-induced apoptosis at later stages of 
rhinovirus infection. This was observed using two distinct exposure regimens: cells 
infected with HRV1B for 2h, washed and re-immersed in fresh maintenance media 
for 22 h prior to (1) treatment with LL-37 (10, 30 µg/ml) for 2h, and then washed 
and re-immersed in fresh media for 22h or (2) treatment with lower concentrations 
of LL-37 (1 and 10 µg/ml) for a period of 24h. Furthermore, we demonstrated that 
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HRV induced apoptosis via caspase-3 activation; however the protective effects of 
LL-37 were not associated with a decrease in caspase-3 activity, demonstrated by 
the quantification of apoptosis by flow cytometric detection of the cleaved caspase-
3. 
LL-37 has previously been shown to mediate contrasting effects on apoptotic cell 
death pathways (Alalwani et al., 2010; Barlow et al., 2010, 2006; Li et al., 2009). In 
agreement with our findings, LL-37 has been proposed to inhibit neutrophil 
apoptosis via activation of P2X7 receptors and G-protein-coupled receptor FPRL1 
with subsequent downstream activation of ERK 1/1 MAPK pathway (Nagaoka et al., 
2006). In contrast to this study, Barlow et al. (2006) demonstrated that LL-37 acted 
as a potent inhibitor of spontaneous neutrophil apoptosis via P2X7 receptors and G-
protein coupled receptors other than FPRL1 with subsequent downstream 
activation of PI3K pathway. Despite the contrasting results, this indicates that LL-37 
signalling involves the combination of receptors types, which is in accordance with a 
previous study which argued against a highly structure-specific interaction between 
LL-37 and cell surface receptors (Braff et al., 2005). It was further demonstrated 
that LL-37 modulated the expression of the anti-apoptotic protein Mcl-1, and 
inhibited the cleavage of pro-apoptotic protein BID and pro-caspase 3, suggesting 
that LL-37 suppresses neutrophil apoptosis by acting on the intrinsic and extrinsic 
apoptotic pathways (Barlow et al., 2006). Furthermore, LL-37 was shown to protect 
keratinocytes from camptothecin-induced apoptosis by induction of COX-2, which 
catalyses the production of PGE2 which subsequently induces the expression of 
inhibitor of apoptosis protein (IAP-2) genes (Chamorro et al., 2009). IAP-2 is known 
as a main regulator of apoptosis which acts through the direct inhibition of caspase-
3 (Roy et al., 1997). In addition, LL-37 was shown to supress LPS-induced apoptosis 
of endothelial cells through LPS neutralization (Suzuki et al., 2011) as well as 
preventing RSV-induced cell death in Hep-2 cells when cells were simultaneously 
incubated with RSV and LL-37 or continuously exposed to LL-37 for up to 5 days 
correlating with a significant reduction in viral load (Currie et al., 2013). 
 
While we have explored the ability of LL-37 to suppress HRV-induced apoptotic cell 
death in 16HBE14o- cells, this did not translate to a corresponding reduction in viral 
load. Strikingly, we did not observe a reduction in detectable viral copies in cells 
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treated with LL-37 (1, 10 or 30µg/ml) compared to virus alone (see Appendix 8 and 
9) using the two peptide exposure regimens (2h LL-37 treatment, wash and 22h in 
fresh media or 24h continuous LL-37 treatment) described previously. However, our 
findings should be considered in the context of other work which has shown that 
treating host cells with the pan-caspase inhibitor Z-VAD-FMK did not affect HRV14 
replication in a HeLa cell model. Specifically, no drop in virus titer, determined in 
cell pellets, was observed in HRV14-infected HeLa cells treated with Z-VAD-FMK in 
comparison to virus alone. Nonetheless, the caspase inhibitor did reduce the 
amount of released virus, while unreleased virus appeared to accumulate inside of 
cells. This therefore indicates that apoptosis may be a critical mechanism to 
facilitate the release of intact rhinovirus from cells (Deszcz, 2005). We therefore 
suggest that, in similarity to what was shown for the major group strain HRV14, the 
minor group strain, HRV1B, might also modulate the induction of apoptosis to 
facilitate viral dissemination.  
 
Several cells have been shown to undergo apoptosis in response to viral infections. 
There is evidence that some viruses induce apoptosis and utilise the cell remnants 
as vehicle for viral dissemination and as a measure to escape the immune system 
detection (Thomson, 2001). Influenza A virus has been shown to induce apoptosis in 
many cell types (Fesq et al., 1994; Stray and Air, 2001). Apoptosis was initially 
thought to be an anti-viral host defence mechanism, however later research 
showed that the overexpression of the anti-apoptotic protein Bcl-2 lead to a 
reduction in the viral load (Olsen et al., 1996). An in vivo study showed that IAV- 
induced apoptosis by modulating the expression of Annexin A1 (Arora et al., 2016). 
Annexin A1 (ANX1), an immune-modulatory protein, has been described as a pro-
apoptotic protein, where the transfection of ANX1 in monocytic cells induced 
spontaneous apoptosis (Solito et al., 2001). ANX1 is shown to mediate caspase-3 
activation and the translocation of the pro-apoptotic protein BAD to the 
mitochondria (Petrella et al., 2005; Solito et al., 2001). While our results 
demonstrated that HRV1B induced apoptosis at later stages of viral infection, 
leading to a time-dependent increase in the levels of cleaved caspase-3, we did not 
observe an increase in the levels of necrosis above those in uninfected cells. 
Apoptosis has been demonstrated in HeLa cells and 16HBE14o- cells infected with 
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HRV1B, -9 and 14 (Deszcz, 2005; Taimen et al., 2004). This was predominantly 
triggered via the intrinsic pathway and involved translocation of cytochrome c into 
cytoplasm, DNA fragmentation and caspase-9 and -3 activation and cleavage of 
caspase substrates (Deszcz, 2005). 
 
As previously described, LL-37 appears to inhibit caspase-3 activity via the activation 
of a number of different cellular receptors. Thus we proposed that LL-37 could also 
inhibit HRV-induced apoptosis by reducing caspase-3 activity, which in turn could 
result in the accumulation of viral particles inside the cells. This is consistent with 
our data which demonstrated no significant reduction in intracellular viral copies 
(Appendix 8 and 9), but a decrease in virus release following LL-37 exposure 
(Appendix 10). However, while our results indicated that rhinovirus induced 
caspase-3 activation in a time-dependent manner, we observed that treatment of 
HRV-infected 16HBE14o- cells with LL-37 did not result in a significant reduction of 
caspase-3 activity. However, we would note that immuno-based detection of 
cleaved caspase-3 was challenging, reflected by isotype controls showing high 
background. Therefore, we believe that this data has to be viewed critically, and 
would propose that further studies are required to determine the exact pathway 
and mechanism by which LL-37 acts in this context.  
 
In contrast to our own observations, several studies have convincingly shown the 
ability of LL-37 to induce apoptotic cell death in a variety of models. Higher 
concentrations of LL-37 (≥30 µg/ml) induced apoptosis in A549 and 16HBE14o- cells 
in the absence of serum (Lau et al., 2006) and in primary bronchial epithelial cells at 
concentrations ≥10 µg/ml (Barlow et al., 2006). The mechanism by which LL-37 
induced apoptotic cell death in these cells has not been fully elucidated, however, 
in human cervical epithelial cells the activation of P2X7 receptors have been 
implicated in apoptosis induction (Q. Wang et al., 2004) which contrasts with the 
apoptosis-inhibitory role of P2X7 receptors in neutrophils (Barlow et al., 2006; 
Nagaoka et al., 2006). While LL-37 preferentially promoted the apoptosis of 
Pseudomonas aeruginosa-infected 16HBE14o- cells, this required specific pathogen-
epithelial cell interaction with live bacteria, capable of airway epithelium invasion. 
Several other studies have reported LL-37 capability to induce apoptosis in the 
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context of the anti-tumorigenic activity of the peptide. A study by Mader et al. 
(2009) demonstrated that LL-37 induced apoptosis of Jurkat human T leukaemia 
cells in a caspase-independent manner. The pro-apoptotic mechanism of LL-37 
resulted in the activation of Ca2+/Calpain-dependent pathway which resulted in a 
calpain-dependent Bax translocation to mitochondria, causing the dissipation of 
mitochondrial membrane potential (ΔψM). The dissipation of ΔψM resulted in 
Apoptosis-Inducing Factor (AIF) release into the cytoplasm and subsequent 
migration to the nucleus, where AIF triggers DNA fragmentation and chromatin 
condensation. An interesting study looked at the potential anticancer effect of FK-
16, a fragment of LL-37 corresponding to residues 17 to 32, and revealed that this 
fragment induced a distinctive pattern of cell death associated with the activation 
of caspase-independent apoptosis and autophagy. FK-16 induced apoptosis in colon 
cancer cells by promoting the nuclear translocation of AIF and Endonuclease G 
(EndoG) to the nucleus (Ren et al., 2013). EndoG is a key modulator protein of 
caspase-independent apoptosis via DNA fragmentation(Zhdanov et al., 2015). This 
suggests that LL-37 induces apoptotic cell death via different pathways in different 
cells. 
 
In summary, our results indicate that LL-37 can protect airway epithelial cells from 
apoptosis induced by rhinovirus infection, which may represent a novel role for LL-
37 in innate immune defence against viral infections. Apoptosis may play an 
important role by facilitating the release of newly synthesised viral particles and 
thus increasing the pathogenicity of rhinovirus infection by promoting the virus 
spread. Therefore, LL-37 represents a promising therapeutic target for the 
treatment of rhinovirus infections, by suppressing the apoptosis of infected cells 
thus inhibiting viral spread. However, the accumulation of viral particles inside cells 
may lead to an increase in the pro-inflammatory response that could be damaging 
to the airway environment. Nevertheless, in the natural physiological context, 
infected cells would be targeted by phagocytes (i.e. alveolar macrophages) which 
would ingest the infected epithelial cells, clearing these cells and avoiding tissue 
inflammation. Hence, we propose that the role of LL-37 in host innate immunity 
against viral infections represents a balancing act between the elimination of the 
virus and immune-mediated damage of the airway epithelium. The mechanism by 
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which LL-37 suppresses HRV-induced apoptosis remains to be established and we 
suggest that the use of air-liquid interface culture of differentiated bronchial 
epithelial cell monolayers in contact with immune cells (i.e. macrophages and 
dendritic cells) would be of value in this context. In addition, LL-37 has been shown 
to have the ability to modulate alternative cell death pathways, such as pyroptosis 
(Hu et al., 2016, 2014) as well as pro-survival pathways including autophagy (Yuk et 
al., 2009) and thus, these pathways should also be characterised in the context of 
viral infection.  
  
186 
 
 
 
 
 
CHAPTER 7 
General Discussion and 
Future Considerations 
  
187 
 
Chapter 7. General Discussion and Future Considerations 
 
This thesis has investigated the antiviral activity of the sole human cathelicidin LL-37 
against human rhinovirus 1B and assessed the immunomodulatory properties of 
this peptide, including the modulation of inflammation and cell death, in the 
context of rhinovirus infection of airway epithelial cells  
 
Rhinovirus replicates in the upper and lower respiratory tract, and with the 
development of more sensitive molecular techniques HRV was associated with 
severe respiratory tract infections, including bronchiolitis, pneumonia and 
exacerbations of COPD and asthma in younger children, immunocompromised 
individuals and elderly (Ghosh et al., 1999; Louie et al., 2009, 2005). In healthy 
individuals, rhinoviruses are the main etiological agent for the development of the 
common cold. The annual healthcare burden of human rhinovirus infections costs 
billions of dollars (Arden and Mackay, 2009). To date there are more than 140 
serotypes identified which make the development of vaccines extremely 
challenging. Several antiviral drugs against rhinovirus have reached different phases 
of clinical trials; however, to date no anti-HRV drug has been approved by the EMEA 
or FDA. Consequently, there are no specific and effective therapies for rhinovirus 
infections. The development of alternative antiviral therapeutics is urgently 
required and in this thesis we provide evidence of the potential therapeutic role of 
the human cathelicidin LL-37 in protecting from and treating human rhinovirus 
infections.  
 
Previous studies provided strong evidence for the antimicrobial, antiviral and 
immunomodulatory properties of LL-37 (Barlow et al., 2014; Kahlenberg and 
Kaplan, 2013; Putsep et al., 2002). Using different exposure regimens, peptide 
concentrations and different experimental techniques we demonstrated the potent 
antiviral activity of LL-37 against HRV1B. The concept exploited in this project is that 
exogenous LL-37, or derivatives could be potentially used as a prophylactic and/or 
as a therapeutic measure for rhinovirus infection and therefore we developed 
several different exposure regimens representing the use of exogenous LL-37 to 
prevent and protect cells from infection and to treat infected cells. 
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In this thesis, we demonstrate that LL-37 displays direct antiviral activity against 
rhinovirus 1B in vitro, and this effect was observed when the virus was exposed to 
the peptide prior to cell infection, and when cells were infected prior to the peptide 
treatment. In our study, the virus exposure to LL-37 prior to cell infection was more 
efficient than the LL-37 treatment of already infected cells at reducing viral load and 
chemokine expression in HRV-infected bronchial epithelial cells. These observations 
were consistent with previous studies, in which LL-37 reduced RSV infection of Hep-
2 cells in similar experimental context, indicating that LL-37 may be effective partly 
by directly interacting with the virus, and in part through interaction with and 
uptake by host cells (Currie et al., 2013; Harcourt et al., 2016).  
 
The interaction of LL-37 with airway epithelial cells was characterised by using 
DANSLY-labelled LL-37 and confocal microscopy. It was demonstrated that LL-37 
was taken up into A549 and 16HBE14o- cells revealing that the intracellular 
localization of the peptide was relatively diffuse although notably some peptide did 
localise around the perinuclear region of the cell. This was consistent with previous 
studies which demonstrated that LL-37 was actively taken up into A549 cells via a 
clathrin-mediated endocytosis and that trafficking into the perinuclear region was 
dependent on microtubules (Lau et al., 2005). This study further demonstrated that 
LL-37 itself is able to permeabilize the eukaryotic membrane without disturbing the 
integrity of the membrane. The porcine antimicrobial peptide, PR-39, in contrast to 
LL-37 is able to rapidly enter human microvascular endothelial cells without plasma 
membrane permeabilization (Chan and Gallo, 1998). Interestingly, a well-
characterised antiviral and antimicrobial activity of the human LL-37 relates to its 
ability to target and disrupt the bacterial cell wall (Henzler Wildman et al., 2003; J. 
Turner et al., 1998; Zasloff, 2002)and the viral envelop (reviewed in Barlow et al.( 
2014)). In fact, it has been well documented that LL-37 can also be cytotoxic to 
certain eukaryotic cell lines (Oren et al., 1999). Nevertheless, we have shown that 
LL-37 is not cytotoxic to the respiratory epithelial cell lines (A549 and 16HBE14o-) 
utilised in this study, at concentrations of ≤30µg/ml, unless cells were exposed to 
longer periods of time (around 24h) at inflammatory concentrations of LL-37 
(i.e.30µg/ml). Importantly, LL-37 was shown to inhibit rhinovirus replication at the 
concentrations used without exhibiting cytotoxicity towards the airway epithelial 
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cells. A study by Sandgren et al., (2004) showed that LL-37 was not cytotoxic to 
eukaryotic cells in concentrations up to 10µM, whereas E.coli cells were killed at 
concentrations below 3 µM. The ability of the peptide to differentially target 
prokaryotic and eukaryotic cells is related to the peptides preferential binding to 
negatively charged outer leaflet of bacteria plasma membrane as compared to the 
predominantly zwitterionic outer leaflet (i.e. the phospholipids present in the outer 
leaflet have their head groups with a perfectly balanced positive and negative 
charge –essentially a neutral charge) as well as the presence of cholesterol in the 
eukaryotic plasma membrane (Zasloff, 2002). However, viral envelops have a very 
similar phospholipid profile to the host cellular lipid membrane (Aloia et al., 1993). 
In fact, viral envelopes lack the high negative charge that is the basis of the HDP 
interaction and disruption of bacterial cells (Chazal and Gerlier, 2003). Several 
studies of viral envelopes have identified a higher cholesterol-to-phospholipid ratio 
in comparison to host cell lipid membrane from which they are derived (Aloia et al., 
1993; Cordero et al., 2014; Scheiffele et al., 1999). The selectivity of HDPs, 
therefore, relies on differences between the host cell and viral lipid membranes.  
Host defense peptides have also revealed the ability to target non-enveloped virus; 
LL-37 was shown to inhibit adenovirus replication in A549 cells (Barlow et al., 2014), 
and HBD5 was shown to induce AdV aggregation (Gounder et al., 2012), which 
could impact viral infectivity by impeding cell binding. The mechanisms of action of 
host defense peptides are numerous and in addition to their positive charge, the 
structural diversity of theses peptides may account for the multiple mechanisms of 
action, including their role in modulating immune responses. Specifically regarding 
the antiviral mechanism of action of cathelicidins, several studies have provided 
evidence on their ability to inhibit viral replication and different mechanism of 
action have been proposed, including the ability of LL-37 to bind to the envelop E 
protein of dengue virus type 2 inhibiting entry into the cells (Alagarasu et al, 2018), 
the ability to inhibit the replication of HIV-1 in peripheral blood mononuclear cells 
by supressing HIV reverse transcriptase (Bergman et al., 2007), as well as, disrupting 
IAV membrane, preventing viral replication (Tripathi et al., 2013). 
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In addition to its direct antiviral activity, LL-37 has an active role in modulating the 
immune responses in the lung, displaying both pro- and anti-inflammatory 
properties, chemotactic activity, inducing the production of several chemokines 
and cytokines, and modulating dendritic cell maturation (Hiemstra et al., 2016; 
Mansour et al., 2014). In fact there is increasing evidence pointing towards LL-37 
as a major player in local innate immunity, demonstrating that this may be its 
primary role in vivo at mucosal surfaces (Diamond et al., 2009; Scott et al., 2002). 
Cathelicidins have apparently paradoxical functions in regulating or modulating 
immune responses. In this study we assessed the cathelicidin immunomodulatory 
activity during rhinovirus infection of bronchial epithelial cells. Our data revealed 
that at early stages of rhinovirus infection, LL-37 reduced HRV-induced expression 
of IL-8, IL-6 and CCL5, but at later stages of infection, LL-37 enhanced HRV-induced 
expression of pro-inflammatory cytokines. Therefore, suggesting that at early stages 
of infection, LL-37 modulates inflammation primarily by direct anti-viral 
mechanisms, as indicated by the reduction in viral load and, at later stages of 
infection LL-37 may act as stimulatory agent in order to increase the sensitivity to 
rhinovirus infection. However a prolonged increase in pro-inflammatory cytokines 
can mediate the harmful inflammatory response which is often observed in diseases 
such as cystic fibrosis (Stecenko et al., 2001). During infection, the inflammatory 
response increases the local LL-37 concentration which could potentially lead to an 
even higher production of pro-inflammatory mediators (Pistolic et al., 2009; 
Tjabringa et al., 2003), which could disrupt the carefully regulated immune 
response and lead to excessive inflammation. The mechanism by which LL-37 
modulates cell responses to infection is still unclear. These effects derive from the 
capacity to activate or transactivate host cell receptors. Several cellular receptors 
have been identified, such as FPRL1 (De Yang et al., 2000), EGFR (Tjabringa et al., 
2003), P2X7 (Elssner et al., 2004), and GAPDH (Mookherjee et al., 2009) and EGFR. 
The peptides ability to interact and utilise several different receptors may lead to 
different outcomes, and depending on the cell type and microenvironment this 
could be an anti- or a pro-inflammatory response. Inhibition studies, using specific 
toxins, for example pertussis toxin to inhibit Gi-coupled receptors, or CRISPR 
technology to knockdown the cell receptor genes activated by LL-37, could be 
applied to better understand the role of LL-37 in the regulation of the host cell 
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response to viral infections. The downstream signalling pathways activated by LL-37 
should also be investigated and again knockdown of specific genes involved in these 
pathways could provide a more accurate idea of the mechanism behind LL-37 
regulatory effects. Extensive studies, in different experimental settings, are required 
to fully understand the underlying mechanism by which LL-37 modulates the airway 
epithelial cell inflammation. 
 
We further demonstrated that LL-37 was able to protect airway epithelial cells from 
apoptosis induced by rhinovirus infection, which could represent a novel role for LL-
37 in innate immune defence against viral infections. Apoptosis may play an 
important role by facilitating the release of newly synthesised viral particles and 
thus increasing the pathogenicity of rhinovirus infection by promoting the virus 
spread. Therefore, LL-37 represents a promising therapeutic target for the 
treatment of rhinovirus infections, by suppressing the apoptosis of infected cells 
thus inhibiting viral spread. However, the accumulation of viral particles inside cells 
may lead to an increase in the pro-inflammatory response that could be damaging 
to the airway environment. Hence, we propose that the role of LL-37 in host innate 
immunity against viral infections represents a balancing act between the 
elimination of the virus and immune-mediated damage of the airway epithelium. 
The mechanism by which LL-37 suppresses HRV-induced apoptosis remains to be 
established and we suggest that the use of air-liquid interface culture of 
differentiated bronchial epithelial cell monolayers in contact with immune cells 
would be of value in this context. In addition, LL-37 has been shown to have the 
ability to modulate alternative cell death pathways, such as pyroptosis (Hu et al., 
2016, 2014) as well as pro-survival pathways including autophagy (Yuk et al., 2009) 
and thus these pathways should also be characterised in the context of viral 
infection.  
 
Chronic respiratory diseases are a growing global epidemic and a prominent cause 
of death and disability, and their prevalence is expected to increase significantly in 
the coming years (Mathers and Loncar, 2006). Rhinovirus infections are the most 
common cause of exacerbations in individuals with chronic respiratory diseases, 
such as asthma, cystic fibrosis and COPD. In these patients, during exacerbations, 
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bacterial colonization is commonly found and it is linked to severity and duration of 
these exacerbations (Arnason et al., 2014; Mallia et al., 2012). Co-infections with 
virus and bacteria are very common but are poorly understood phenomena in 
individuals with chronic lung diseases. Several studies have attempted to 
understand the mechanisms by which virus predispose the airways to secondary 
bacterial infections. Rhinovirus infection of the airways has been associated with a 
dysregulation of the innate host defense mechanisms, such as an impaired cationic 
host defense peptide expression in the lungs. Arnason et al., (2014) demonstrated 
that primary human bronchial epithelial cells infected with HRV16 and then 
subsequently bacteria (H.influenzae/P.aeruginosa) showed increased levels of β-
defensins when compared to HRV and bacteria alone. A study by Mallia et al. (2012) 
showed that experimental rhinovirus infection was followed by secondary bacterial 
infections in subjects with moderate COPD but not in smokers and non-smokers 
with normal lung function. In addition, the sputum LL-37and α-defensins levels 
were increased significantly from baseline in the COPD group but this was not 
verified in either of the control groups; however only sputum LL-37 levels in 
subjects with COPD correlated with peak sputum viral load, inflammatory cells, 
neutrophils and bacterial load. Of note, the increased HDPs expression could be a 
secondary phenomenon of neutrophil activation and that other mechanisms, such 
as the activation of reactive oxygen species and the release of other pro-
inflammatory mediators, may at least contribute to the exacerbations of chronic 
respiratory illnesses.  
 
Patients frequently report cold-like symptoms before exacerbations (Hutchinson et 
al., 2007; Seemungal et al., 2001) and several in vitro studies have linked rhinovirus 
to increase susceptibility to bacterial infection. Primary human airway epithelia cells 
grown in ALI and bronchial epithelial cells (16HBE14o-) infected with rhinovirus 
showed a significant increase in bound bacteria when compared to sham-infected 
cultures, as well as a decrease in transepithelial resistance and loss of zona 
occludins (ZO)-1 from tight junctions (Sajjan et al., 2008). Rhinovirus was also shown 
to induce the expression of fibronectin, platelet-activating factor receptor, and 
carcinoembryonic antigen-related cell adhesion molecule in nasal epithelial cells 
which significantly increased the adhesion of S.aureus, S.pneumoniea and 
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H.influenzae(Wang et al., 2009). Keeping this in mind, the development of effective 
anti-HRV therapies is highly required for this population group. The development of 
antiviral therapies as an early intervention at the onset of cold symptoms in 
subjects with chronic airway diseases could therefore raise the prospect that they 
not only decrease the severity and possibly prevent the virus-induced COPD 
exacerbations, and in addition they also have the potential to prevent secondary 
bacterial infections. This thesis provides relevant in vitro data on the direct antiviral 
activity of LL-37 against HRV1B, as well as, demonstrating the ability of LL-37 
peptide to modulate innate immune responses to viral infection, by down-
modulating pro-inflammatory mediators (e.g. IL-8, IL-6 and CCL5), and by protecting 
airway epithelial cells from virus-induced apoptosis. In vivo studies further 
demonstrated that influenza-infected mice treated with LL-37 had lower 
concentrations of pro-inflammatory cytokines detected in the BAL in comparison to 
infected mice that had not been treated with the human cathelicidin (Barlow et al., 
2011). Patients with chronic lung diseases which are a risk population for rhinovirus 
infections require an effective and specific antiviral therapy, and the administration 
of exogenous cathelicidins, or their derivatives, could represent a promising novel 
therapy for this specific population group. However, it seems contradictory to 
administer a cathelicidin-based therapy, when studies have shown a dysregulation 
in the expression of these cationic host defense peptides, in particular a significant 
increase expression of LL-37 during viral and bacterial co-infection. Impaired HDP 
expression was only observed during co-infection of virus and bacteria, and not 
during viral infection only (Arnason et al., 2014; Mallia et al., 2012), and as 
previously mentioned, this could be an epiphenomenon of neutrophil activation 
and other mechanisms. However, it is important to fully understand the role of LL-
37 in inflammation, because an increase in LL-37 concentration could potentially 
lead to an even higher cytokine/chemokine release, leading to excessive 
inflammation that could prolong the disease state. These observations further 
emphasise the importance of an early intervention at the onset of cold symptoms in 
subjects with chronic airway diseases.  
 
An important factor to consider for the development of potential therapeutics 
based on administration of exogenous LL-37 is the proteolytic degradation of the 
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peptide. Peptides are susceptible to many host proteases, such as the digestive 
enzyme trypsin and chymotrypsin, which cleave proteins and peptides at basic 
and hydrophobic residues respectively, all of which are important for the 
structure and function of LL-37 (Kim et al., 2014). Several strategies have been 
proposed to block proteolytic degradation, such as incorporating non-natural D-
isomers of amino acids, altering the stereochemistry of the peptide and making 
the peptides protease-resistance (Barlow et al., 2011; Molhoek et al., 2011). D-LL-
37 and D-mCRAMP were shown to retain their potent antiviral activity against IAV 
in vitro and in vivo (Barlow et al., 2011). However, in the context of 
immunomodulation, little is known about the interaction of D-peptides with 
target host cells and whether the substitute of D-amino acids would compromise 
the receptor-ligand interactions (Mansour et al., 2014). Another strategy consists 
in incorporating unnatural amino acids into the peptide sequences providing an 
improved metabolic stability and preserving the positive charges, such as the 
replacement of one arginine residue by L-ornithine or L-homoarginine. The 
substitution for L-homoarginine was shown to increase the peptides stability in 
serum without affecting the anti-bacterial activity against E.coli (Berthold et al., 
2013). A recent study demonstrated that LL-37 with Arg residues substituted by 
homoarginine, displayed full activity of native LL-37 despite peptidyl-arginine 
deiminases (PADs) treatment. PAD enzymes are responsible for the citrullination 
of cathelicidins/LL-37 which render the peptides inactive (Wong et al., 2018). 
Interesting future work would involve investigating the antiviral activity of 
homoarginine-LL-37/D-LL37 against rhinovirus infection, as well as, assessing the 
immunomodulatory properties of these peptides in the context of viral infections.  
 
The differences in the ability of the peptides to modulate the pro-inflammatory 
response of bronchial epithelial cells to HRV infection were seen in the different 
exposure regimens.  This indicates that the context of LL-37 exposure is a key 
determinant in the effect of the peptide and will likely determine the direction of 
cellular responses to viral infection. An important observation related to the 
immunomodulatory activity of LL-37, is that in healthy non-infected cells, none of 
the immunomodulatory effects were seen; LL-37 did not have any effects on 
cytokine and chemokine expression, or on cell death. This could suggest that some 
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aspects of immunoregulation mediated by the peptide are dependent upon 
infection, which should be considered when developing therapeutics relying up on 
exogenous peptide treatment, potentially allowing for preferential targeting of 
the viral infection.  
 
The immunomodulatory activity of cathelicidins is very complex and mechanistic 
studies have proposed the involvement of several signalling pathways (i.e. NFkB, 
p38 and JNK, MAPK, and PI3K) which are activated depending on the intracellular 
uptake, endocytic mobilization and the interaction with several receptors (De Yang 
et al., 2000; Lau et al., 2005; Mookherjee et al., 2009; Nagaoka et al., 2006). Despite 
all the information on the immunomodulatory properties of cathelicidins, the role 
of LL-37 in protecting against viral infections is still far from being completely 
understood. This thesis provides a characterisation of the role of LL-37 against 
rhinovirus infection, investigating the antiviral activity, the inflammomodulatory 
properties and the modulation of cell death in a bronchial epithelial cell model of 
infection. In the context of these findings, and taking into account the limitations of 
our experimental approaches, we propose the use of a more physiological relevant 
model of infection, such as the development of air-liquid interface cell model using 
bronchial epithelial cells which could be co-cultured with alveolar macrophages and 
dendritic cells. An alternative to this would be through the use of a lung organoid 
model of infection, to better mimic the in vivo environment. In addition it would be 
relevant to evaluate the antiviral activity of LL-37 against a number of different 
serotypes of rhinovirus.   
 
The data in this thesis indicates that LL-37 is able to inhibit rhinovirus 1B infection 
in bronchial epithelial cells. The possible mechanisms involved in the peptides-
mediated antiviral activity are depicted in the figures 40 and 41. This thesis 
therefore provides strong evidence for the potential of LL-37 to inform the 
development of alternative antiviral therapies for rhinovirus infection.   
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Figure 50. Proposed mechanisms of LL-37-mediated antiviral activity against 
human rhinovirus 1B at earlier stages of viral infection. 
This figure highlights the possible mechanisms involved in LL-37-mediated antiviral activity 
against HRV1B during earlier stages of infection of 16HBE14o- bronchial epithelial cells. LL-
37 may be effective in part through direct interactions with HRV (1), and in part through 
interaction with and uptake by 16HBE14o- cells. LL-37 may modulate the expression of HRV-
targeted receptors (i.e ICAM-1 and LDLr) therefore limiting viral spread (2). In addition LL-
37 may interact with airway epithelial cells through different cell receptors (i.e. EGFR, 
FPRL1, P2X7) and may limit HRV-associated inflammation by inhibiting NF-kB activity (3).  
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Figure 51. Proposed mechanisms of LL-37 mediated-antiviral activity against 
human rhinovirus 1B at later stages of viral infection. 
This figure highlights the possible mechanisms involved in LL-37-mediated antiviral activity 
against HRV1B during later stages of infection of 16HBE14o- bronchial epithelial cells. In 
later stages of infection, rhinovirus infection induces apoptotic cell death of bronchial 
epithelial cells which may facilitate the release of newly synthesised viral particles. LL-37 
was shown to supresses the apoptosis of HRV-infected cells, which may represent a novel 
role for LL-37 in innate immune defence against viral infections (2). LL-37 increases the 
production of pro-inflammatory cytokines and chemokines in response to HRV infection 
possibly by mediating cellular signalling through the activation of host cell receptors (i.e. 
EGFR, FPRL1 and/or P2X7) which could then lead to an increase in immune cell recruitment 
and likely aid in a more rapid and efficient infection clearance from airway epithelial cells 
(1). 
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APPENDIX 
 
1. Intracellular localization of DANSYL-labelled LL-37 in A549 cells (Z-stack 
analysis) 
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2. Intracellular localization of DANSYL-labelled LL-37 in 16HBE14o- cells (Z-
stack analysis) 
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3. Fluorescence intensity of DANSYL-LL-37 through time. 
 
A549 cells were treated with DANSYL-labelled LL-37 (10µg/ml) for 30 minutes, 
washed with saline and left in contact with 5% FBS DMEM for further 16h. Live-cell 
imaging was set up using confocal microscopy immediately after the addition of 
fresh media (5% FBS DMEM) and images were taken every 2 minutes for 16 hours. 
The graph represents the DANSYL intensity mean value of images taken every 0.5 h 
up to 16h.  
 
4. SDS-PAGE performed with virus samples obtained after the first sucrose 
gradient purification  
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5. Second sucrose gradient purification  
 
 
 
 
 
 
 
  
6. UV inactivation of HRV1B 
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7. Time-course analysis of IFN1β (A) and PKR (B)gene expression in 16HBE14o- 
treated with poly I:C (10µg/ml) 
 
 
Bronchial 16HBE cells were exposed to poly I:C (10µg/ml) for 2h washed and re-
immersed in IMDM supplemented with 5%FBS for 1, 4, 16,22,46 or 70h at 33oC. 
Total RNA was extracted from 16HBE cell lysates and qPCR was performed to determine the 
relative expression of INF1β (A), and PKR (B). The GAPDH and β-actin genes were used as 
reference genes. Results represent one independent experiment. 
 
 
A. 
B. 
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8. Viral RNA copies extracted from 16HBE14o- cell lysates 
 
 
 
 
 
 
 
Bronchial epithelial cells (16HBE14o-) were infected with HRV1B (MOI 1) or left 
unstimulated in serum-free media for 2H, washed and re-immersed in fresh maintenance 
media for further 22h. Cells were treated with LL-37 for 2h, washed and re-immersed in 
fresh maintenance media for further 22h at 33oC. After 48h, cells were lysed and viral RNA 
copies were determined by qPCR. Statistical analysis was performed using one-way ANOVA 
with Tukey’s multiple comparisons post-test to compare virus only to LL-37 treated cells. 
 
 
9. Viral RNA copies extracted from 16HBE14o- cell lysates 
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Bronchial epithelial cells (16HBE14o-) cells were left untreated or infected with purified 
HRV1B (MOI 1) for 2h in serum-free media, washed and re-immersed in media 
supplemented with 5% FBS for 22h at 33oC. Cells were washed and treated with LL-37 (1 
and 10µg/ml) for 24h in media supplemented with 1% Ultroser G. After 48h, cells were 
lysed and viral RNA copies were determined by qPCR.  Statistical analysis was performed 
using one-way ANOVA with Tukey’s multiple comparisons post-test to compare virus only 
to LL-37 treated cells. 
 
10. Virus infectious titer determined by TCID50 assay in 16HBE14
o- cells 
 
 
 
 
 
 
 
 
 
 
Bronchial epithelial cells (16HBE14o-) were infected with HRV1B (MOI 1) or left 
unstimulated in serum-free media for 2H, washed and re-immersed in fresh maintenance 
media for further 22h. Cells were treated with LL-37 for 2h, washed and re-immersed in 
fresh maintenance media for further 22h at 33oC. After 48h, cell supernatants were used to 
determine the infectious titer by TCID50 assay. Statistical analysis was performed using one-
way ANOVA with Tukey’s multiple comparisons post-test to compare virus only to LL-37 
treated cells (* p≤0.05). 
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11. Inflammatory concentrations of LL-37 significantly enhance IL-8-release 
from rhinovirus-infected 16HBE14o- cells. 
 
 
 
 
 
 
 
 
 
16HBE14o- cells were left unstimulated (control) or were exposed to HRV (MOI 5) 
for 2 hours at 33oC in serum-free media, washed with saline before incubating with 
LL-37 at concentrations indicated for 22 hours at 33oC. IL-8 protein levels released 
into cell supernatants were assessed by ELISA. Results are represented as the 
means +/- SEM from four independent experiments. Statistical analysis was 
performed using one-way ANOVA with Tukey’s multiple comparisons post-test 
(**p<0.01; ***p<0.001). 
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12. Time-course analysis of IL-8 (A), IL-6 (B), CCL5 (C) and IFN1β (C) gene 
expression in A549 cells treated with HeLa Lysates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. 
B. 
C. 
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A549 cells were exposed to HeLa lysates for 2h, washed and re-immersed in fresh 
maintenance media for 4h, 16h, 22h, 46h or 72h prior to determination of gene 
expression by qPCR.  
 
13. Time-course analysis of IL-8 (A), IL-6 (B), CCL5 (C) and IFN1β (C) gene 
expression in 16HBE14o- cells treated with HeLa Lysates 
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16HBE14o- cells were exposed to HeLa lysates for 2h, washed and re-immersed in 
fresh maintenance media for 4h, 16h, 22h, 46h or 72h prior to determination of 
gene expression by qPCR.  
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